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ABSTRACT 
 
Laboratory studies, epidemiological investigations and human clinical trials indicate 
that flavonoids have important effects on cancer chemoprevention and therapy.   
Flavonoids may interfere in several steps that lead to cancer development but may 
also lead to toxicity as the inhibition of carcinogen-activating enzymes may also cause 
potential toxic flavonoid-drug interactions. However, the potential toxicity of these 
dietary components has not been well studied. The use of polyphenol-enriched 
supplements prepared from South African herbal teas, rooibos (Aspalathus linearis) 
and honeybush (Cyclopia spp.) are being marketed to alleviate symptoms that are 
known to be “cured” by the herbal teas. However, there is a lack of information 
regarding the possible health promoting effects of these polyphenol-enriched extracts 
on xenobiotic metabolism. In the present study, the modulating effects of aspalathin-
enriched rooibos and mangiferin-enriched C. genistoides and C. subternata extracts on 
the gene expression of xenobiotic metabolising enzymes (XMEs) were investigated in 
vivo in the rat liver and kidneys. An in vitro study, utilising a primary rat hepatocyte cell 
model, was included to further evaluate changes in the expression of selected XMEs 
by the herbal tea extracts, including their major polyphenolic constituents, aspalathin 
and mangiferin. The use of the in vitro primary hepatocytes assay as a predictive cell 
model for the modulation of the expression of XMEs genes by the herbal tea extracts 
in vivo was critically evaluated.  
 
In the liver and kidneys, the C. subternata polyphenol-enriched herbal tea extract 
effected the majority of changes regarding the expression of XMEs genes when  
compared to the rooibos and C. genistoides. Variations in the modulation of gene 
expression of the XMEs by the herbal tea extracts were related to differences in their 
polyphenol constituents, although non-polyphenolic constituent could also be involved.  
Overall the herbal teas regulated alcohol, energy, drug and steroid metabolism in the 
liver, whereas in the kidneys the gene expression of phase I, phase II, steroid 
metabolising enzymes, as well as drug transporters were modulated.  It would appear 
that the herbal teas are likely to exhibit both beneficial and adverse effects in vivo, 
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depending on the specific organ, the xenobiotic and/or drug that are involved. The 
primary rat hepatocytes model display varying effects with respect to modulating gene 
expression of specific XMEs by the polyphenol-enriched herbal tea extracts. Apart 
from the reduction in 17β-hydroxysteroid dehydrogenase gene expression care should 
be taken to directly extrapolate the in vitro findings to changes that prevail in vivo. 
However, interesting results regarding the masking effect of complex mixture on the 
modulation of XME gene expression of individual polyphenols were encountered. In 
addition differences in the dose and duration of exposure between the in vitro and in 
vivo studies were not comparable and should be further explored to validate the in vitro 
primary hepatocytes model to predict changes in vivo. Future studies should 
investigate the effects of the herbal tea extracts, its polyphenols and metabolites on 
XME induction at a protein level as well as varying herb-drug-enzyme interactions. 
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GENERAL INTRODUCTION 
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GENERAL INTRODUCTION 
 
Medicinal herbs and pharmaceutical drugs are therapeutic at one dose and toxic at 
another (Fugh-Berman, 2000). 
 
For centuries, people have been using herbs as medicine for longevity and essential 
well being. Decoctions and mixtures are used to treat many illnesses such as 
respiratory and cardiac problems (Bocek, 1984). The World Health Organisation 
(WHO) estimates that 4 billion people, 80 percent of the world population, presently 
use herbal medicine for some aspect of primary health care (Farnsworth et al., 1985). 
Many patients use herbal products in combination with prescribed drugs, however, 
concurrent use of herbs may mimic, magnify, or oppose the effect of drugs (Fugh-
Berman, 2000).  
  
Pharmaceutical drugs and herbal preparations, amongst others, are considered 
foreign to the body, where it elicits various responses. These xenobiotics are 
metabolised by specific enzymes known as xenobiotic metabolising enzymes (XMEs), 
including cytochrome P450, which are present predominantly in the liver, but are also 
found in extrahepatic tissues such as the kidneys. Some xenobiotics are substrates to 
the same enzymes and thus compete for the same binding sites. Therefore, one 
xenobiotic may inhibit or enhance the metabolism of the other due to overlapping 
substrate specificity (Nebert, 1991). However, some metabolites or so-called reactive 
intermediates are known to be toxic, interact with cellular constituents such as the 
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DNA resulted in genotoxic effects and eventually carcinogenesis (reviewed in Nebert, 
1991). 
The most common means of regulating XMEs is transcriptional (Porter and Coon, 
1991). The genes that code for XMEs are regulated by nuclear hormone receptors 
(Savas et al., 1999) which are turned on when there are elevated intracellular levels 
of exogenous ligands. An explanation for this is that XMEs could be responsible for 
controlling the steady state levels of xenobiotics (Nebert, 1991). However, xenobiotic 
metabolism is not the primary function of the XMEs as it also metabolises 
endogenous substrates such as steroids, due to the structural similarity between 
foreign chemicals and endogenous ligands. It is therefore important to study the 
effects on XMEs when exploring the health benefits of herbal preparations and/or its 
constituents. South African herbal teas, rooibos (Aspalathus linearis) and honeybush 
(Cyclopia spp.) are popular beverages worldwide (Snyman, 2000; De Villiers, 2004). 
The increase in the herbal tea market is due to the known beneficial health properties 
of the teas, which is mainly anecdotal. Although scientific evidence is minimal with 
respect to the health benefits and effects of the herbal teas in humans, animal and in 
vitro studies have shown anti-oxidant, anti-mutagenic, anti-inflammatory and anti-
carcinogenic properties (Marnewick et al., 2000; Marnewick et al., 2004; Joubert et 
al., 2008; Sissing et al., 2010). It is believed that these properties are attributed to the 
rich polyphenolic content of the herbal teas, with special reference to the major 
constituents, aspalathin in rooibos and mangiferin in honeybush tea. Polyphenol-
enriched extracts have thus been introduced as supplements in an attempt to magnify 
the health beneficial effects observed after consumption of the herbal teas. However, 
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since polyphenols are known to interact with XMEs (Pirmohamed, 2008), it is 
imperative to investigate the effects of the polyphenol-enriched extracts on XME 
regulation, in order to deem it safe for consumption. The present thesis discusses the 
effects of aspalathin-enriched rooibos and mangiferin-enriched extracts of two 
species of Cyclopia, C. genistoides and C. subternata, on the gene expression of 
XMEs in the liver and kidneys of male Fisher rats. The effect of the tea extracts on the 
gene expression of selected genes was also investigated in rat primary hepatocytes 
in order to validate differences between in vivo and in vitro effects. 
 
A review on the fate of xenobiotics within the cell and the ability of cells to combat 
their effects are highlighted in Chapter 2.  A short introduction into the history of the 
herbal teas and there chemopreventive properties is also included.  Evidence on the 
role of polyphenol-enriched extracts of rooibos and two honeybush species on the 
expression of XME’s are presented in Chapter 3, highlighting differences in the 
responses between the liver and kidneys.  The validation of the primary hepatocyte 
cell culture system as an in vitro test model to further predict in vivo changes are 
investigated and differences outlined in Chapter 4. Findings of the thesis are critically 
reviewed and contextualised with respect to the outcome of the present findings in the 
General Discussion section (Chapter 5).  Experimental details of the primary 
hepatocyte culture technique utilised, ethical approval of animal experiments 
conducted, as well as results to validate certain experimental parameters are 
summarised in the Addendum section. Abstracts of conference attendance and 
awards received are attached.    
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Xenobiotics 
Introduction to xenobiotics 
Interactions between foreign compounds, i.e. xenobiotics, and cells have been 
extensively studied in both humans and animals (Wang et al., 1994; Hu et al., 
2010; Le Bail et al., 1998; Michalopoulos et al., 1976; Guo et al., 2009). All life 
forms are constantly being exposed to xenobiotics, beneficial or harmful 
depending on the dose, which may originate from both naturally occurring and 
synthetic compounds and are often lipophilic in nature.  
Some of these xenobiotics may prove to be advantageous to a cell and can be 
utilised in normal biological processes to provide energy or act as precursors in 
the synthesis of macromolecules such as steroids (Wetzel et al., 1994). 
However, xenobiotics such as  many environmental chemicals are harmful and 
may interact with the cell’s metabolic pathways and basic cellular constituents 
such as RNA, DNA (Boyland and Green, 1962) and proteins, leading to the 
disruption of normal cellular functions (by inducing cell damage and cell death) 
and ultimately diverse toxic effects.   
 
(i) Environmental carcinogens 
It is estimated that the majority of human cancers results from exposure to 
environmental carcinogens associated with certain life style factors such as diet 
and tobacco use (Miller, 1978; Wogan et al., 2004).  These environmental 
carcinogens are diverse in nature regarding their chemical structures and mode 
of action which has been studied extensively to evaluate their risk in cancer 
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development in humans.  Depending on their chemical structures these 
carcinogens can broadly be divided in different categories such as the poly 
aromatic hydrocarbons (PAH), aromatic and heterocyclic amines, nitrosamines, 
alkylating agents and certain fungal toxins.   
 
Tobacco carcinogens 
 
Extensive prospective epidemiologic studies clearly establish cigarette smoking 
as the major cause of lung cancer (Blot and Fraumeni, 1996). Tobacco smoke 
contains carcinogenic polycyclic aromatic hydrocarbons (PAHs) (Hecht, 1999) 
and tobacco-specific nitrosamines 4-(methylnitrosamino)-1-(3-pyridyl)-1-
butanone (NNK), N’-Nitrosonornicotine (NNN), N’-Nitrosoanabasine (NAB) and 
N’-Nitrosanatabine (NAT) (Figure 1), which are formed from natural 
components of the tobacco plant. Carcinogens such as NNK and PAHs require 
metabolic activation to exert their carcinogenic effects; there are competing 
detoxification pathways, and the balance between metabolic activation and 
detoxification differs among individuals and will affect cancer risk. 
 
            
 
Figure 1 Representation of tobacco-specific nitrosamines. 
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Diet related carcinogens 
 
Diet has long been recognised as one of the major factors that can influence 
the development of cancer (Doll and Peto, 1981; WCRF, 1997). Some 
carcinogens occur naturally on food, such as nuts and grains that are 
contaminated by mycotoxin-producing fungi. Other carcinogens are formed 
during food preparation and preservation; polycyclic hydrocarbons, such as 
benzo[a]pyrene (B[a]P), are formed during cooking of meat on an open flame, 
and the meat preservative, sodium nitrite, can be converted to nitrosamines. 
  
 
(ii) Pharmaceutical drugs   
 
Pharmaceutical drugs are considered to be xenobiotics, since it is not produced 
by the organism neither is it part of its normal diet. These drugs include 
analgesics (acetaminophen), chemotherapeutics (rifampicin) and 
antidepressants, amongst others. Drugs share the same metabolic enzymes as 
other xenobiotics (Block and Gyllenhaal, 2002), therefore interactions between 
xenobiotics as well as certain cellular processes may occur. 
 
 
 
(iii) Plant polyphenols 
 
Polyphenols are essential secondary metabolites produced by plants for 
protection, pigmentation, growth and pollination (Gould and Lister, 2006) and 
are considered a xenobiotic if ingested by animals or humans.  
Plant polyphenols possess an aromatic ring bearing one or more hydroxyl 
substituents. The structure of the natural polyphenols varies from simple 
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molecules, such as phenolic acids, to highly polymerised compounds, such as 
condensed tannins (Harborne, 1980). Flavonoids represent the most common 
and widely distributed group of plant phenolics. Their common structure 
consists of two aromatic rings linked through three carbons that usually form an 
oxygenated heterocycle (Harborne, 1980; Heim et al., 2002) (Figure 2).  
 
 
                   
O
B
CA
 
 
 
Figure 2  The nuclear structure of flavonoids. 
 
 
 
Flavonoids are a large class of naturally occurring secondary metabolites 
(Huffman, 2003). With more than 6500 different compounds described, these 
polyphenols are widely present in green plants such as vegetables, fruits and 
teas (Hollman and Katan, 1997; Harborne and Williams, 2000). Based on 
different substitutions and oxidation status of the chromane ring (C-ring), 
flavonoids can be classified into subclasses flavones, flavonols, flavonones, 
flavanols, isoflavones, chalcones, dihydrochalcones and anthocyanidins (Figure 
3). Studies suggest that these flavonoids are metabolised by the same 
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enzymes (phase I and II) that metabolise the majority of the known 
pharmaceutical drugs (Zhou et al., 2004).  
The effect of xenobiotics on cellular metabolic pathways will be discussed. 
 
Metabolism   
 
Metabolism can be described as the breakdown (catabolism) and/or build up 
(anabolism) of molecules in a cell in order to protect it against foreign 
compounds, or to synthesise macromolecules required for basic biological 
processes. Metabolic enzymes are crucial to metabolism since it regulates 
metabolic pathways in response to changes in the cell's environment or signals 
from other cells. These enzymes are able to metabolise a variety of substrates, 
which in turn compete for the binding sites of the enzymes. Therefore one 
substrate can alter the kinetics of the other. Chemicals, such as prescribed 
pharmaceutical drugs to treat many disease conditions in humans, also interact 
with the same metabolic pathways which eventually may affect their 
pharmacological mode of action (Manzi and Shannon, 2005). Several non-
nutrient hydrophilic xenobiotic constituents from plant origin that are widely 
distributed in food also undergo numerous endogenous metabolic events (Galli, 
2007).  As similar metabolic pathways exist between the different xenobiotics in 
the cell, several interactions are known to exist which could result in beneficial 
and/ or adverse cellular effects (Huang and Lesko, 2004).
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Figure 3 Basic structures of dietary flavonoids (Joubert et al., 2008). 
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The biological basis for xenobiotic metabolism is to decrease the period during 
which a foreign substance is retained in the body. Essentially the xenobiotic is 
converted to a water-soluble form (a process known as biotransformation), 
making it less soluble in the lipid-based membranes facilitating excretion from 
the cell (Kalra, 2007).  
When xenobiotics enter the organism, it is subjected to phase I oxidation, 
reduction, hydrolysis and hydration reactions which results in a functional group 
being added or unveiled. Phase II enzymes then conjugate endogenous 
molecules (glutathione, amino acids, sulfates, acetyl groups, etc) to the 
functional groups and the product are excreted via the urine, faeces, breath or 
sweat. Conversely, the metabolism of these compounds can sometimes lead to 
more reactive intermediary compounds that may exhibit adverse biological 
effects that exceed that of the parent compound (Lin and Lu, 1997; Guengerich, 
2003). 
Over centuries, organisms have evolved a complex enzyme system to eliminate 
foreign/toxic compounds. The enzymes that play a role in xenobiotic 
metabolism are located in specific cell types in various organs, but are more 
prominent in the liver (Yamada et al., 1997). The sites for biotransformation are 
summarised in the Table 1.  
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Table1 Enzyme localisation within the various organs that play a role in the 
biotransformation of xenobiotics. 
 
 
Morphology and function of the liver: Adaptation to xenobiotic 
metabolism 
 
The liver is the largest gland in the body which constitutes 2-5% of the body 
weight of an adult male and is the first organ that comes into contact with 
nutrients and xenobiotics absorbed by enterocytes via the portal vein. Its unique 
metabolism and relationship to the gastro intestinal tract (GIT) makes it an 
important site for biotransformation of xenobiotics. The main function of the liver 
is the production of bile, regulation of plasma proteins and glucose, 
biotransformation of drugs and toxins, and to detoxify endogenous compounds 
(Pineiro-Carrero and Pineiro, 2004). 
The liver consists of four main types of cells; hepatocytes, endothelial cells, 
Kupffer cells and stellate cells (Figure 4). The hepatocytes are the biosynthetic 
engines of the liver. Their prominent golgi system and rough endoplasmic 
reticulum enable them to synthesise and secrete a variety of enzymes. 
Organ Location of enzymes 
Liver Parenchymal cells (hepatocytes) 
Kidney Proximal tubular cells (S3 segment) 
Lung Clara cells, Type II alveolar cells 
Intestine Mucosa lining cells 
Skin Epithelial cells 
Testes Seminiferous tubules, Sertoli cells 
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Endothelial cells line the sinusoids and serve as a barrier between the blood 
and hepatocytes. The Kupffer cells function as macrophages and the stellate 
cells store fat and vitamin A. The hepatocytes are arranged in lobules which are 
divided into three zones according to its proximity to the portal vein, hepatic 
artery and hepatic vein (Pineiro-Carrero and Pineiro, 2004). Zone 1 hepatocytes 
are closest to the portal vein and receive the richest oxygen and nutrient supply 
and have a high concentration of enzymes involved in cellular respiration; they 
mostly synthesise glycogen and other proteins. Since zone 3 is located closest 
to the hepatic veins, little oxygen is available and the hepatocytes are involved 
in the glycolytic energy production and contain cytochrome P450 (CYP) 
enzymes. Therefore, the hepatocytes in zone 3 are more specialised in 
biotransformation reactions. Zone 2 is the intermediate area of hepatocytes 
between zones 1 and 3; its function depends on how close it is to the portal 
vein. 
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Morphology and function of the kidneys: Adaptation to xenobiotic 
metabolism 
 
The kidneys play a very important physiological role in maintaining water and 
electrolyte homeostasis, synthesis, metabolism and secretion of hormones, and 
excretion of the waste products of metabolism. Additionally, the kidneys play a 
major role in the metabolism and excretion of drugs and other xenobiotics 
(Anders, 1980; Bock et al., 1990).  
The kidney is divided into two main areas: the outer renal cortex and the inner 
renal medulla. Within the medulla there are cone-shaped renal pyramids 
separated by renal columns. Each kidney consists of about one million 
Figure 4 Internal structure of the liver lobule (Pineiro-Carrero and 
Pineiro, 2004). 
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microscopic nephrons, the most basic structures of the kidneys. Nephrons are 
composed of the glomerulus inside the Bowman’s capsule, the Malpighian 
corpuscle, proximal and distal convoluted tubules, and the loop of Henlé. Using 
an isolated tubule preparation in rats and rabbits, Endou (1983) found that 
CYP450 was localised to the proximal tubule with the highest concentration in 
the microsomes of the S2 and S3 segments (Figure 5). Cytochrome P450 
enzyme activities have been found in the kidneys.  
 
 
 
Figure 5 Regional (A), tubular (B), and subcellular (C) localisation of  
xenobiotic-metabolising enzyme systems in the kidney (Lohr et 
al., 1998). 
 
 
 
S2 
S3 
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Phases of xenobiotic metabolism 
The detoxification enzymes are classified according to phase of action: (i) 
phase I (cytochrome P450 monooxygenases), (ii) phase II (UDP-
glucuronosyltransferases, glutathione-S-transferases and sulfotransferases) 
and (iii) phase III (ABC transporters). These detoxification systems are highly 
complex and responsive to the individual’s environment, lifestyle and genetic 
uniqueness.  
 
(i) Phase I metabolism 
Phase I reactions involve the chemical modification of xenobiotics by 
introducing or unveiling polar functional groups that provide sites for phase II 
metabolism. These include oxidation, reduction and hydrolysis reactions. Phase 
I enzymes are responsible for adding, or exposing, a functional group to 
xenobiotic molecules by adding one oxygen atom leading to the availability of a 
polar functional group such as -OH, -SH, -NH2, or –COOH in the molecule 
undergoing biotransformation. At this stage, the molecule is slightly more 
hydrophilic, but not yet ready for excretion. Further metabolism occurs via 
phase II reactions.  
 
The principal phase I enzymes include the superfamily of haem-protein mixed-
function oxidases (cytochrome P450), flavin monooxygenases, monoamine 
oxidases, esterases, amidases, hydrolases, reductases, dehydrogenases and 
oxidases. The cytochrome P450 supergene family of enzymes is generally the 
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first enzymatic defense against foreign compounds. They also play a pivotal 
role in the biosynthesis and catabolism of endogenous substrates such as bile 
salts, vitamins, fatty acids, prostaglandins and steroids. 
 
Discovery, evolution and nomenclature of cytochrome P450 
Cytochrome P450 was first isolated in the 1950s. A cellular pigment in rat and 
pig microsomes was discovered when an unusual, red-shifted, visible 
absorption maximum at about 450nm was observed (Klingenberg, 1957; 
Garfinkel, 1958). This pigment at 450nm was observed when the reduced form 
of the enzyme formed a complex with carbon monoxide. This absorption 
maximum was quite different from that displayed by typical haemproteins such 
as myoglobin (435nm). The name cytochrome P450 can be explained as “cyto” 
meaning microsomal vesicle, “chrome” for coloured, “P” for pigmented and 
“450” for the 450nm spectrophometric absorption peak (Ortiz de Montellano, 
1995). In 1958 it was found to be labile to detergents, low pH and enzymatic 
digestion. It was further characterised and purified by Omura and Sato (1964) 
and was shown to be a b-type cytochrome (Omura and Sato, 1962). In 1965 
cytochrome P450 was established as being the terminal oxidase of the liver 
microsomal drug-metabolising enzyme system (Cooper et al., 1965). The 
discovery that high concentrations of glycerol stabilise CYPs against detergent 
treatment was made by Ichikawa and Yamano (1967). This was a major 
breakthrough in the purification of membrane-bound P450s. 
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Various forms of cytochrome P450 were successfully identified in the late 
1970s, followed by the cloning of their cDNAs in the 1980s. This showed the 
presence of different molecular species in animals, plants and fungi where each 
cytochrome P450 enzyme exhibit very distinct but broad substrate specificity. 
The highly conserved amino acid sequence motifs of those isoforms were 
indicative of their evolutional divergence from a single ancestral form (Nelson 
and Strobel, 1987; Gotoh, 1989). Individual forms are important in the 
metabolism of foreign hydrophobic compounds which may include dietary 
components, xenobiotics, therapeutic drugs (eg. phenobarbital, PB) or chemical 
carcinogens (Nebert and Gonzales, 1987). Many isoforms play vital roles in 
some tightly regulated pathways, such as developmental regulation and 
modulation by steroid or polypeptide hormones. The classification system of all 
P450s was based on the degree of similarity in their amino acid sequences. In 
1987 isoforms were divided into “families” and “subfamilies”. Members within 
the same family typically have >40% identity in their amino acid sequence, 
whilst members of the same subfamily are at least >55% identical (Nebert, 
1989, 1991; Nelson, 1993; Guengerich, 1997). It is estimated that mammals 
have about 50-80 P450 genes in its genome and plants might have even more. 
However, no P450 genes have been found in the genome of Escherichia coli 
(Nelson, 1999). In humans 57 functional CYP genes and 58 pseudogenes have 
been sequenced (Nelson, 2002; Purnapatre et al., 2008). These comprise 18 
families and 44 subfamilies. Families CYP1-4 are mainly involved in xenobiotic 
metabolism. The contribution of the major isoforms to overall drug metabolism 
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is as follows: 1A2 (4%), 2A6 (2%), 2C9 (10%), 2C19 (2%), 2E1 (2%), 2D6 
(30%) and 3A4 (50%) (Purnapatre et al., 2008). Others are typically not 
involved in xenobiotic metabolism, but rather metabolise physiological 
endogenous substances e.g. CYPs 11, 17, 19 and 21 catalyse the 
hydroxylation required for steroid hormone biosynthesis from cholesterol 
(Nelson et al., 1996). In rats, however, 60 genes and 4 pseudogenes have been 
sequenced.   
The isolation and characterisation of the cytochrome P450 system led to the 
current understanding of their mechanism of action (Estabrook, 2003).  
 
Cytochrome P450 isoforms 
The CYP families 1-3 are responsible for 70-80% of all phase I dependent drug 
metabolism (Wijnen et al., 2007).  
 
CYP1 
 
The CYP1 family includes two sub-families, CYP1A and CYP1B, which consists 
of isoforms 1A1, 1A2 and 1B1, respectively (Nebert and McKinnon, 1994). 
CYP1A is linked to the aryl hydrocarbon receptor (AhR) as inducible genes 
(Gonzales et al., 1993; Dogra et al., 1998; Waxman, 1999) and the enzyme is 
capable of bioactivating several procarcinogens (Heidel et al., 2000). CYP1A1 
activates B[a]P and other polyaromatic hydrocarbons while CYP1A2 activates 
aromatic amines, such as 2-acetylaminofluorene, heterocyclic amines and 
aflatoxin B1 (Eaton et al., 1995; Gallagher et al., 1996; Pelkonen and Raunio, 
1997; Rendic and Di-Carlo, 1997). CYP1A1 is expressed in many tissues, but 
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typically only after induction with TCDD or other AhR ligands. CYP1A2 is found 
exclusively in the liver (Dogra et al., 1998) and is primarily involved in the 
hydroxylation and demethylation of compounds through oxidative metabolism. 
Its substrates include caffeine (Miners and Birkett, 1996), PAH (Castorena-
Torres et al., 2005), theophylline (Rasmussen and Brosen, 1997) and naproxen 
(Miners et al., 1996). Grapefruit juice (GFJ) (Fuhr et al., 1993; Tassaneeyakul et 
al., 2000) and drugs like fluvoxamine (Becquemont, et al., 1998) and 
ciprofloxacin (Fuhr et al., 1990) are potent inhibitors of CYP1A2. This inhibiting 
action increases serum levels of substrates resulting in toxicity. Examples of 
enzyme inducers are cruciferous vegetables, charbroiled meat (Wijnen et al., 
2007) and tobacco smoke (Wardlaw et al., 1998; Schrenk, et al., 1998; Zevin 
and Benowitz, 1999). CYP1A2 also metabolises PAHs into carcinogenic 
compounds and has a higher activity in Chinese men (Ou Yang et al., 2000).  
CYP1B1 is a more recently characterised member of the CYP1 family. It is 
constitutively expressed in most tissues, but is also inducible through the Ah 
receptor pathway (Cheung et al., 1999). However, the protein is undetectable in 
normal human liver (McFadyen et al., 2004). CYP1B1 typically metabolises 
endogenous estrogens (Hayes et al., 1996), as well as activating the 
biotransformation of heterocyclic amines found in charcoal-broiled meat (Crofts 
et al., 1997). The presence of CYP1B1 has been proven to decrease the 
sensitivity of cancer cells to the cytotoxic effects of a specific anticancer drug 
(docetaxel) making it less cytotoxic (McFadyen et al., 2001). Polymorphisms of 
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CYP1B1 gene at codons 119 and 432 has been found to be a risk factor for 
renal cell cancer (Sasaki et al., 2004). 
CYP2 
The CYP2E1 gene is constitutively expressed in the liver and the enzyme 
accounts for 7% of total CYP content. It catalyses highly conserved functions, 
including the oxidation of the fatty acid, arachidonic acid (Capdevila et al., 1992; 
Laetham et al., 1993). The enzyme is also involved in gluconeogenesis through 
its ability to metabolise acetone to acetol (Lieber, 1997). However, its primary 
functions are to metabolise ethanol and acetaminophen (paracetamol), and to 
metabolically activate many low molecular weight compounds such as N-
nitrosamines, aniline, vinyl chloride, and urethane (Bartsch and Montesano, 
1984; Guengerich et al., 1991) in an attempt to eliminate it. Polymorphism of 
CYP2E1 is very common, resulting in serious complications such as cancer and 
toxicity.  
 
CYP3A 
The CYP3A family is the most abundant cytochrome P450 enzymes in the liver, 
accounting for 30% of total hepatic content and 70% of intestinal wall content 
(Chang and Kam, 1999). The expression of CYP3A seems to be regulated by 
pregnane X receptor (PXR), a nuclear receptor belonging to the family of 
ligand-activated (Kliewer et al., 1998) transcription factors. PXR binds as a 
heterodimer with 9-cis retinoic acid receptor (NR2B) to DNA response elements 
in the regulatory regions of CYP3A gene (Kliewer et al., 2002). CYP3A does not 
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exhibit genetic polymorphism, but its isoforms are expressed differently across 
species; the rat isoform is CYP3A1/23. The human isoform CYP3A4 is known 
to metabolise approximately 60% of prescribed drugs (Guengerich, 1999). The 
enzyme is induced by rifampicin (Li and Chiang, 2006) and the coding gene has 
been shown to be down-regulated by grapefruit juice (Garteiz et al., 1982). 
Although metabolism of exogenous compounds is the major function of this 
isoform, it is also able to metabolise endogenous compounds such as 
progesterone, estradiol, testosterone and cortisol (Waxman, 1996).  
 
CYP structure and mechanism of action 
The microsomal cytochrome P450 system is composed of two enzymes i.e. the 
haem-containing enzyme CYP450 and NADPH-cytochrome P450 reductase 
(Lu and Coon, 1968; Masters et al., 1971). These enzymes are present in all 
organs, but predominantly in the liver, entrenched in the phospholipid matrix of 
the endoplasmic reticulum and the mitochondria (Omura, 1999). It is the 
phospholipid layer that facilitates the interaction between the two enzymes. The 
active site is deep within the enzyme, next to a catalytic iron atom held at the 
center of a haem group. It can accommodate a variety of different carbon-rich 
molecules, pressing them tightly against the active oxygen atom (Goodsell, 
2001). The reaction begins with the introduction of a single atom of molecular 
oxygen derived from O2, into the substrate, with the simultaneous reduction of 
the accompanying oxygen atom to water.  
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The general equation for CYP catalysis is shown below: 
 
 
RH* + O2 + H+ + NADPH ROH + H2O + NADP+  
*RH represents the substrate and ROH represents the oxidised product. 
 
This equation only represents a very general and simple mechanism. The 
reaction is best represented as a cyclic reaction showing the interactions that 
occur between cytochrome P450 and the NADPH-cytochrome P450 reductase 
(Figure 6) (Porter and Coon, 1991; Guengerich 1991; Guengerich et al., 1998).   
The reaction is initiated when the substrate binds to the active site of the 
cytochrome P450, close to the haem bound region of the molecule. It involves 
the reduction of molecular oxygen by the stepwise addition of two electrons. 
These electrons are donated by the reducing co-factor NADPH. NADPH is a 
two-electron donor but cytochrome P450 can only accept one electron at a 
time. Therefore an accessory enzyme is required such as NADPH-cytochrome 
P450 reductase which possesses two flavin prosthetic groups (Suzuki, 1965). 
This catalyses the transfer of two electrons from NADPH to the P450 (Omura et 
al., 1966). The ratio of NADPH-cytochrome P450 reductase to CYP molecules 
present in liver microsomes is about 2:1. It is during the first electron donation 
that the iron atom present in the CYP is reduced to the ferrous state (Fe2+) and 
molecular oxygen binds to the CYP complex. A second electron is then donated 
CYP450 
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to the CYP from the NADPH-cytochrome P450 reductase (Iyanagi, 2005). This 
is followed by electron arrangement, insertion of an oxygen atom and product 
release with the generation of water or hydrogen peroxide 
 
Figure 6 Generalised catalytic cycle for P450 reactions (Guengerich,  
1991 and Guengerich et al., 1998). 
 
CYP1 family members are under the transcriptional regulation of the AhR 
(Dogra et al., 1998; Tredger et al., 2002; Baumgart et al., 2005). AhR binds 
exogenous molecules such as PAHs present in air pollution and cigarette 
smoke (Song et al., 2002; Denison et al., 2003). Upon binding, AhR 
translocates to the nucleus where it binds aryl hydrocarbon nuclear translocator 
(ARNT). The AhR/ARNT dimer regulates transcription of target genes (Denison 
et al., 2003).   
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The regulation of drug metabolism is highly complex, being affected by both 
genetic and non-genetic host factors. Genetic factors may cause variability in 
an enzyme’s activity, function, stability and responsiveness to an inducer or 
regulator (Kalow, 2001). These variations in the metabolism of a drug may 
affect the responsiveness of a patient to a drug and even predispose the patient 
to adverse effects (Park and Pirmohamed, 2001). A single base change can 
have dramatic effects on specificity. A study on mutagenesis showed that a 
substitution of a single amino acid, S473V, allows CYP2C2 to accept 
progesterone as a substrate, whereas CYP2C2 is normally a lauric acid 
hydroxylase (Ramarao and Kemper, 1995). This change in substrate specificity 
is very important because it now allows this enzyme to be involved in steroid 
metabolism.   
 
Non-genetic factors such as sex, age, xenobiotics and disease state can also 
affect the expression of CYPs. Cytochrome P450 is important to our species 
individuality because no two species will have the same complementary P450 
genes (Nelson, 1999). 
  
Xenobiotic induction/inhibition of cytochrome P450  
 
Xenobiotics metabolising enzymes can either be induced or inhibited by 
concomitantly administered drugs, food substances or pollutants, which can 
result in clinically significant interactions (Pirmohamed and Orme, 1998). 
Enzyme induction results in an increased level and activity of the enzyme 
(reviewed by Berthou, 2001). The most commonly prescribed enzyme inducers 
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are listed in Table 1 (Addendum I), together with drugs that can be affected 
(Pirmohamed, 2008). An example of an enzyme induction interaction is 
warfarin, an anticoagulant, and carbamazepine, an anticonvulsant. Co-
administration of these two drugs will lead to an increase in metabolism of 
warfarin, which could lead to a failure of anticoagulation. Enzyme induction has 
also been observed with the herbal medicine St John’s wort (SJW), which 
affects the metabolism of warfarin as well as immunosuppressant and anti-viral 
drugs (Mannel, 2004). 
 
Inhibition of CYP enzymes lead to a decrease in the metabolic rate, resulting in 
an increase in drug concentration and consequent toxicity. A list of CYP 
enzyme inhibitors is shown in Table 2 in the addendum I (Pirmohamed, 2008). 
An example of an inhibitor is grapefruit juice (GFJ) which inhibits CYP3A4. 
Grapefruit juice interacts with a number of drugs including terfenadine, 
ciclosporin and simvastatin (Ameer et al., 1997). Knowledge of the interaction 
potential of herbs and drugs may prevent adverse drug interactions.  
 
Steroidogenesis: the role of cytochrome P450  
The role of CYPs in steroid hydroxylation was first elucidated by Estabrook et 
al., (1963). Six forms of cytochrome P450 and two hydroxysteroid 
dehydrogenases are the main enzymes involved in steroid biosynthesis (Omura 
and Morohashi, 1995) from cholesterol in animal tissues (Nelson et al., 1996). 
The very first steroidogenic cytochrome P450 purified was P450scc in 1973 
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(Shikita et al., 1973). This was followed by five more (P45011β, P450aldo, 
P45017α, P450c21 and P450arom). P450scc, P45011β, P450aldo, are located in the 
inner membrane of the mitochondria, whereas P45017α, P450c21 and P450arom 
are in the membrane of the endoplasmic reticulum. The two hydroxysteroid 
dehydrogenases (HSD), 3β-HSD and 17β-HSD, are also associated with the 
endoplasmic reticulum membrane (Omura and Morahashi, 1995). These CYPs 
together with the two HSDs regulate the biosynthesis of steroids (Figure 7).  
 
 
 
Figure 7 Enzymes involved in steroid biosynthesis. 
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The relationship between cytochrome P450 and cancer  
 
The natural chemical environment contains many toxic compounds, such as 
procarcinogens and direct carcinogens that may require metabolism to exert an 
effect. Procarcinogens are parent compounds that cause cancer following 
activation via normal metabolism, e.g. benzo(a)pyrene. Direct carcinogens refer 
to the reactive metabolite that covalently binds to and modify DNA. Cytochrome 
P450 plays an important role in the aetiology of cancer diseases (Oyama et al., 
2004; Rooseboom et al., 2004) by bioactivating carcinogens e.g.  aflatoxin B1, a 
hepato carcinogenic mycotoxin. Aflatoxin B1 is metabolised by CYP1A1 to an 
exo epoxide, which binds and intercalate into the DNA resulting in DNA adducts 
and mutations (Guengerich, 2006). 
 
Cytochrome P450 as a target for anticancer therapy 
The CYP superfamily plays a central role in influencing the response of tumors 
to anticancer drugs. They can either activate or deactivate it. Drug activation 
(resulting in cytotoxicity) and deactivation (resulting in potential resistance) 
depend on the relative amount and activity of specific CYPs in individual tumor 
cells (McFadyen and Murray, 2005). CYP1B1 has been identified as the main 
CYP present in a variety of human cancers, in various tissue types e.g. prostate 
cancer cells (Beuten et al., 2000) and lung carcinoma cells (Wenzlaff et al., 
2005). Although CYP1B1 mRNA appears to be expressed in a wide variety of 
normal tissues, the 1B1 protein has not yet been detected (Church et al., 2010). 
CYP1B1, along with 1A1, has the ability to metabolise anticancer-drugs, a 
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reaction that might help tumors to avoid chemotherapeutic induced cytotoxicity 
(McFadyen et al., 2001; Stiborova et al., 2001; Patterson and Murray, 2002). In 
addition to this, CYP1B1 also activates several carcinogens in chemical classes 
of polycyclic aromatic hydrocarbons, heterocyclic amines, aromatic amines, and 
nitropolycyclic hydrocarbons. Of importance, however, is the role of CYP1B1, 
as well as that of CYP19A1, in estradiol metabolism. CYP1B1 catalyses the 
hydroxylation of estradiol primarily at the C4-position, which plays an important 
role in estrogen-related tumorigenesis, whilst CYP19A1 (aromatase) catalyses 
the rate limiting step in the conversion of androgens to estrogens (Bruno and 
Njar, 2007). A study using CYP1B1 knockout mice showed strong resistance to 
7,12-dimethylbenz[a]anthracene (DMBA) induced tumor formation. Another 
study by Heidel et al., showed that CYP1B1 deletion prevents profound 
cytotoxicity in bone marrow, produced by DMBA (Heidel et al., 2000; Galvan et 
al., 2003). A possible strategy for chemoprevention would therefore be to inhibit 
transcription or translation of these genes or enzymes. 
 
 
(ii) Phase II metabolism 
 
Phase II of biotransformation involves conjugation reactions that result in 
inactivation or detoxification of xenobiotics. However, it can also result in 
bioactivation or reactive species generation (Cantelli-Forti et al., 1998). Studies 
have shown that glutathione-S-transferase (GST) activates halogenated 
hydrocarbons and epoxide hydrolases while sulfotransferases activates PAHs 
(Wood et al., 1976; Kasper and Henion, 1980; Wolf et al., 1984; Hanna et al., 
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1992). Phase II reactions typically occur much faster than phase I reactions, 
making the latter the rate limiting step of biotransformation. Most phase II 
enzymes are located in the cytosol, except UDP-glucuronyltransferases 
(UGTs), which are microsomal. Their substrates are typically lipophilic and 
access the intracellular space by diffusion (Zamek-Gliszczynski et al., 2006). 
Phase II enzymes conjugate large molecules onto chemical substrates, such as 
carcinogens that contain free amine, hydroxyl or carboxyl groups. The 
conjugated moieties makes the carcinogen-conjugate charged and thus more 
water soluble, easy to excrete and less likely to be reabsorbed. It is important to 
note that phase I and II xenobiotic metabolising enzymes are able to activate or 
detoxify xenobiotics simultaneously, depending on the catalysed chemical 
reaction (Guengerich, 1985). 
 
Glucuronidation       
Glucuronidation, catalyzed by a family of membrane-bound UGT enzymes, is a 
metabolic reaction converting lipophilic xeno- and endobiotics to more water 
soluble metabolites, the glucuronides (Burchell and Coughtrie, 1989; Miners 
and Mackenzie, 1991). The reaction occurs primarily in the liver, intestinal 
mucosa and kidneys. UGTs transfer glucuronic acid from UDP-glucuronic acid 
to the aglycone substrate which includes compounds containing nucleophilic 
functional groups such as alcohols, phenols and primary and secondary 
amines. The clearance of some endogenous substances, such as bilirubin, 
steroid hormones, and bile acids, is largely dependent on UGT-mediated 
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metabolism. In addition, a large variety of drugs, such as the carboxylic acid 
drug naproxen, are metabolised primarily by glucuronidation (Kaivosaari, 2010). 
Aspirin, menthol, synthetic vanilla, flavonoids (Otake et al., 2002), food 
additives such as benzoate, and some hormones are also metabolised by 
UGTs.    
 
Sulfation 
Sulfation increases molecular hydrophilicity of xenobiotics in preparation for 
biliary excretion or efflux across the hepatic basolateral membrane for 
subsequent renal clearance (Zamek-Gliszczynski, 2006). Intracellular inorganic 
sulfate originates from hydrolysis of sulfoconjugates, oxidation of reduced 
organic sulfur, or uptake of sulfate from blood across the basolateral membrane 
(Markovich, 2001). The following reaction occurs in the cytosol:  
 
Si + AMP                                     Adenosine 5’– phosphosulphate (APS) 
 
APS                                            3’- phosphoadenosine-5’- phosphosulphate       
                                                          (PAPS) 
Si= inorganic sulfur; AMP= Adenosine monophosphate. PAPS is the donor of sulfate 
groups (SO4-) in all sulfate conjugation reactions (Low, 1998; Klaassen and Boles, 
1997). 
 
Sulfotransferases (SULTs) are most abundant in the liver, but are found in a 
variety of tissues. They are generally high-affinity, low- capacity 
biotransformation enzymes that operate effectively at low substrate 
concentrations (Sacco and James, 2005). 
ATP 
sulfurylase 
APS kinase 
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The general reaction of SULT can be represented by the equation below: 
 
PAPS  + Carcinogen – OH    SULT     
   Carcinogen – NH2    Carcinogen-sulfate 
   
Carcinogen – SH 
 
PAPS - 3’- phosphoadenosine-5’-phosphosulphate; SULT -Sulfotransferases  
 
Soluble or cytosolic SULT enzymes are subdivided into three families: SULT1 
(phenol sulfotransferase family), SULT2 (hydroxysteroid sulfotransferase family) 
and brain-specific SULT4 (Weinshilbaum et al., 1997; Falany et al., 2000). The 
SULT1 family is further subdivided into four subfamilies: SULT1A (phenol-type 
xenobiotics), SULT1B (dopa/tyrosine and thyroid hormones), SULT1C 
(hydroxyarylamines) and SULT1E (estrogens). Although individual SULT 
isoenzymes have substrate preference, there is evidence of substrate overlap 
(Nagata et al., 1993; Doerge et al., 2000). SULT plays an important role in the 
metabolism of steroids, thyroid hormones and bile acids (Gamage, 2006). 
However, it may also result in bioactivation of xenobiotics (Glatt, 2000).  
   
Glutathione conjugation 
Glutathione (GSH), a major nucleophile in the cell, is composed of three amino 
acids (cysteine, glutamic acid and glycine). GSH is specifically directed to 
scavenge toxic electrophiles and they are also important antioxidants. This 
combination of detoxification and free radical protection results in glutathione 
being one of the most important anticarcinogens and antioxidants. Therefore, a 
deficiency can result in serious liver dysfunction and damage. Although 
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glutathione is able to spontaneously react with electrophiles, this reaction 
requires a catalyst. Glutathione-S-transferases (GSTs) are a series of cytosolic 
enzymes (Ryle and Mantle, 1984; Strange et al., 2001) able to catalyse these 
reactions. GSTs are expressed in all life forms (Strange et al., 2000). 
Conjugation of GSH typically occurs in the cytoplasm of the liver and the 
conjugates can be excreted intact into bile, or converted to mercapturic acids by 
the kidney (Anders, 1980) and excreted in the urine (Barnes et al., 1959; 
Boyland and Chasseaud, 1969).  
 
Methylation 
Methylation involves conjugating methyl groups to toxins. Most of these methyl 
groups originate from s-adenosylmethionine (SAM) (Axelrod and Tomchick, 
1958). SAM is synthesized from the amino acid methionine, a process which 
requires the nutrients choline, vitamin B12 and folic acid. With the exception of 
nicotine methylation that produces quaternary ammonium ions, methylation 
decreases water solubility of drugs. This is mediated by three groups of 
enzymes: O, N, and S- methyltransferases. O-methylation via catechol-O-
methyltransferase (COMT) is important in the metabolism of (1) catecholamines 
that serve as neurotransmitters (epinephrine, norepinephrin and dopamine) and 
(2) plant flavonoids containing catechol groups (Manach et al., 1999; Nagai et 
al., 2004).  
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Acetylation 
N-acetylation is a major route of biotransformation of drugs containing an 
aromatic amine (R-NH2) or a hydrazine group (R-NH-NH2) (Payton et al., 1999; 
Grant et al., 1992). It is dependent on thiamine, panthothenic acid and vitamin 
C and is catalysed by N-acetyltransferases and requires acetylcoenzyme A 
(acetyl-CoA) as a cofactor (King and Glowinski, 1983). Humans express only 
two acetyltransferases, NAT1 and NAT2 (Grant et al., 1992). 
 
Amino acid conjugation 
Several amino acids (glycine, taurine, glutamine, arginine and ornithine) are 
used to conjugate toxins. Of these, glycine is the most commonly utilised in 
phase II amino acid detoxification (Liska, 1998). There are two pathways by 
which drugs can be conjugated with amino acids. One involves carboxylic acid 
groups; the other requires an aromatic hydroxylamine group. 
 
(iii) Phase III metabolism 
Since some conjugates are generally too large and too polar to diffuse 
passively to bile or urine, specific transporters are required to aid their 
movement across cell membranes. The ATP-binding cassette (ABC) 
transporter superfamily genes represent the largest family of transmembrane 
proteins. These proteins bind ATP and use energy to drive the translocation of 
a wide variety of substrates across the extra- and intracellular membranes, 
including metabolic products, lipids and sterols, and drugs. Transporters 
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specifically recognise organic acids (glucuronides, sulfates, etc) or organic 
bases (amines) and pump them from the cell. 
Phase III drug transporters play an important role in reducing drug absorption 
and enhancing drug elimination back to the gut lumen.  
Phylogenetic analysis places the 48 known human ABC transporters into seven 
distinct subfamilies of proteins. A list of ABC transporters and their functions are 
summarised in Table 2. 
 
Herb-drug interactions  
It is imperative to note that many medicinal herbs and pharmaceutical drugs are 
therapeutic at one dose and toxic at another. All ingested substances have the 
potential to interact with one another, the same transporter and the same 
metabolising enzymes. Concurrent use of herbs may mimic, magnify or oppose 
the effect of drugs (Fugh-Berman, 2000). Herb-drug interactions may occur 
through two major mechanistic routes; inhibition of enzyme action or activation 
of gene transcription (Plant, 2007). Many studies focus on their effects on 
xenobiotic metabolising enzymes alone however, Interference at the level of 
ABC transporters could also play a role. P-glycoprotein (P-gp), an ABC 
transporter (ABCB1), plays a physiological role in detoxification of toxic 
metabolites. It secretes these toxic compounds into bile, urine and the intestinal 
lumen. This function can either be beneficial in the intact organism by 
preventing substances from being absorbed into the body or negative in the 
case of the treatment of malignant tumours with cytotoxic anticancer drugs, 
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which need to enter the cells for their pharmacological effect. P-gp is expressed 
in natural barriers such as the intestinal epithelium, the blood-brain barrier, liver, 
and kidney for excretion of xenobiotics. P-gp presents high transport capacity 
and broad substrate specificity. It generally transports hydrophobic, amphipathic 
molecules. Some P-gp substrates are able to either inhibit or induce P-gp-
mediated transport of other substrates. Herbal constituents have been reported 
to modulate P-gp expression and/or activity (Romiti et al., 1998; Sadzuka et al., 
2000; Anuchapreeda et al., 2002; Bhardwaj et al., 2002; Jodoin et al., 2002; 
Kim et al., 2003; Choi et al., 2003; Zhang and Morris, 2003; Limtrakul et al., 
2004; Mei et al., 2004; Nabekura et al., 2005). Constituents of grapefruit and 
orange juice were also found to block P-gp function (Takanaga et al., 2000; Xu 
et al., 2003; Zhou et al., 2004). Expression levels of P-gp and xenobiotic 
metabolising enzymes appear to be regulated by nuclear receptors like 
pregnane X receptor (PXR) (Savas et al., 1999), constitutive androstane 
receptor and vitamin D binding receptor (Xu et al., 2005).  
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Table 2       List of human ABC genes and their function (Dean, 2002). 
    
Symbol Alias  Function 
    
ABCA1 ABC1 Cholesterol efflux onto HDL 
ABCA2  ABC2 Drug resistance 
ABCA3 ABC3/ABCC Surfactant secretion? 
ABCA4 ABCR N-Retinylidiene-PE efflux 
ABCA5    
ABCA6    
ABCA7    
ABCA8    
ABCA9    
ABCA10    
ABCA12    
ABCA13    
ABCB1 PGY1/ MDR  Multidrug resistance 
ABCB2 TAP1 Peptide transport 
ABCB3 TAP2 Peptide transport 
ABCB4 PGY3 PC transport 
ABCB5    
ABCB6 MTABC3 Iron transport 
ABCB7 ABC7 Fe/S cluster transport 
ABCB8 MABC1   
ABCB9    
ABCB10 MTABC2   
ABCB11 SPGP Bile salt transport 
ABCC1 MRP1 Drug resistance 
ABCC2 MRP2 Organic anion efflux 
ABCC3 MRP3 Drug resistance 
ABCC4 MRP4 Nucleoside transport 
ABCC5 MRP5 Nucleoside transport 
ABCC6 MRP6   
ABCC7  CFTR Chloride ion channel 
ABCC8 SUR  Sulfonylurea receptor 
ABCC9 SUR2 K(ATP) channel regulation 
ABCC10 MRP7   
ABCC11    
ABCC12    
ABCD1 ALD VLCFA transport regulation 
ABCD2 ALDL1/ALDR   
ABCD3 PXMP1/PMP70   
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Symbol Alias  Function  
ABCE1 OABP/RNS4I Oligoadenylate binding protein 
ABCF1 ABC50   
ABCF2    
ABCF3    
ABCG1 ABC8, White  Cholesterol transport? 
ABCG2 ABCP, MXR, BCRP  Toxin efflux, drug resistance 
ABCG4 White2   
ABCG5 White3 Sterol transport 
ABCG8  Sterol transport 
    
    
Effect of flavonoids on xenobiotic metabolisers 
A number of studies have shown that flavonoids modulate the CYP450 system, 
in vitro and in vivo (Wattenberg et al., 1968; Wood et al., 1986; Ho and Saville, 
2001). Genistein, the soy isoflavone, is metabolised by and decreases the 
activity of CYP1A1, 1A2, 2E1 and SULT1E1 (Helsby et al., 1998; Chan and 
Leung, 2003; Chen et al., 2004; Ohkimoto et al., 2004) and increases the 
activity of UGT (Sun et al., 1998) and GST (Ansell et al., 2004). Quercetin 
increases the activity of CYP1A1 (Ciolino et al., 1999), UGT (Sun et al., 1998; 
van der Logt et al., 2003) and quinone reductase (QR) (Uda et al., 1997) and it 
decreases the activity of CYP1A2 (Tsyrlov et al., 1994), 3A4 (Obach, 2000), 
UGT1A1 (van der Logt et al., 2003; Sun et al., 1998), GSTP1-1 (van Zanden et 
al., 2003), SULT1A1 (Eaton et al., 1996; Ghazali and Waring, 1999; Harris et 
al., 2004) and SULT1E1 (Otake et al., 2000; Ohkimoto et al., 2004). Additional 
reactions are summarised in Table 3 in the addendum I.  
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Effect of herb-drug interactions on chemoprevention and protection 
Up to 90% of all cancers are thought to be due to environmental carcinogens 
(Kwak et al., 2001) such as those found in cigarette smoke, food, water and air. 
High levels of exposure to carcinogens, coupled with slow or absent detoxifying 
enzymes, significantly increase susceptibility to cancer. Many chemicals require 
metabolic activation to electrophilic intermediates to exert carcinogenic activity 
(Miller and Miller, 1983). If not detoxified, these reactive species target 
nucleophilic groups in DNA, causing point mutations and other genetic lesions. 
This may result in activation of pro-oncogenes and inactivation or loss of tumour 
suppressor genes (Kwak et al., 2001). 
 
The ability of a carcinogen to interact with its target depends on the balance 
between competing activating and detoxifying reactions. While this balance is 
under genetic control, it is readily modulated by a variety of factors including 
nutritional status, age, hormones and exposure to drugs or other xenobiotics 
(Conney, 1982). If these factors, especially xenobiotics such as flavonoids, 
interact with these enzymes (Block and Gyllenhaal, 2002) and favour the 
activation reaction above the detoxification, it could result in reactive 
carcinogenic intermediate generation. In addition to this, herb-drug interactions 
can lead to toxicity, where the herb inhibits the metabolism of the drug, 
increasing the drug levels in the plasma. Conversely, it may increase the 
elimination process of the drug, rendering it ineffective. The latter may result in 
inability of the drug to suppress the tumour growth. 
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An increasing number of cancer patients are using complementary and 
alternative medicines (CAM) in combination with their conventional 
chemotherapeutic treatment. Therefore herb-drug interactions are becoming 
increasingly important. St John’s wort (SJW) is very popular among cancer 
patients because of its supposed activity in depression (Mathijssen et al., 2002; 
Pal and Mitra, 2006). SJW has been found to interact with the anticancer drugs 
irinotecan (Mathijssen et al., 2002; Huang and Lesko, 2004) and imatinib (Frye 
et al., 2004).  
 
Hyperforin, the active constituent of St. John’s wort, binds to and activates the 
pregnane X receptor (PXR) (Figure 8). Upon activation, PXR forms a 
heterodimer with the 9-cis retinoic acid receptor (RXR), and this complex binds 
to the xenobiotic response elements (PXRE) in the cytochrome P450 3A4 
 
 
Figure 8 The effect of hyperforin on irinotecan therapy (Meijerman et al., 
2006). 
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 (CYP3A4) gene. The transcription of the gene is increased, and more CYP3A4 
is formed, thereby increasing the metabolism of irinotecan into an inactive 
metabolite, SN-38 (oxidised irinotecan). The amount of irinotecan left to be 
metabolised into SN-38 decreases, leaving less active SN-38 and a lower 
therapeutic efficacy of irinotecan (Meijerman et al., 2006) 
 
South African herbal teas 
Tea has been consumed in China to promote health and longevity since 3000 
BC. In South Africa only two Cape fynbos plants, Aspalathus linearis, better 
known as rooibos and various species of Cyclopia, commonly known as 
honeybush, have been successfully commercialised.  
 
Aspalathus linearis (rooibos tea) is a member of the legume family of plants. It 
is only grown in a small area in the Cederberg region of the Western Cape 
Province. Rooibos was initially used by the Khoi-San for medicinal use before it 
was rediscovered by Dutch botanist Carl Thunberg in 1772 (Thunberg, 1795). 
Generally, the leaves are oxidized or fermented to produce the distinctive 
reddish-brown colour, but unfermented "green" rooibos is also produced. 
Rooibos flavonoids predominantly consist of dihydrochalcones, flavonols and 
flavones.  Its flavonoid composition uniquely contains aspalathin (Rabe et al., 
1994), nothofagin and a rare β-hydroxydihydrochalcone (Joubert, 1996). It has 
been found that fermentation of rooibos leaves decrease the aspalathin and 
nothofagin content (Joubert, 1996).  
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Cyclopia spp. (honeybush tea) is generally found on sandy soils of the coastal 
areas from Yzerfontein to the Cape peninsula. Honeybush is indigenous to the 
Cape of South Africa where it is used to make beverages and medicinal tea that 
has a pleasant, mildly sweet taste and aroma, somewhat like honey. The 
honeybush plant was noted in botanical literature by 1705. The bushes can 
grow up to 2m tall; however the leaf shape and size differ among the species, 
but most are thin, needle-like to elongated leaves. All the species are easily 
recognised in the field as they are covered with the distinctive, deep-yellow 
flowers, which have a characteristic sweet honey scent. Traditionally, the tea is 
harvested during flowering; either in early autumn or late spring, depending on 
the flowering period of the species. Three major phenolic constituents were 
identified in the leaves of Cyclopia species namely, mangiferin (a xanthone C-
glycoside) and O-glycosides of flavonones hesperitin and isokuranetin (De 
Nysschen et al., 1996). However, Joubert et al., (2003) showed that the relative 
quantities of these phenolics vary between the different Cyclopia species and 
within a geographical area. 
Both rooibos and honeybush herbal tea is caffeine-free and has very low tannin 
content (Greenish, 1881; Blommaert and Steenkamp, 1978; Terblanche, 1982; 
Morton, 1983; Yoshikawa et al., 1990; Hubbe and Joubert, 2000). Research 
has shown that rooibos and honeybush exhibit a vast array of health benefits. A 
study by Sasaki et al., (1993) in hamster ovary cells and male ICR mice showed 
that extracts of fermented rooibos tea decreased the number of chromosome 
aberrations and micronucleated reticulocytes, respectively, after exposure to 
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benzo(a)pyrene and mitomycin. Furthermore, fermented rooibos protected male 
Wistar rats against CCl4–induced hepatic injury and showed histological 
regression of steatosis and cirrhosis in the liver tissue (Ulicna et al., 2003). 
Unfermented rooibos and honeybush (C. intermedia) also have a protective 
effect against methylbenzylnitrosamine-induced oesophageal papillomas in 
rats, decreasing it in size and number (Sissing, 2008). A study, conducted in the 
Salmonella mutagenicity assay, showed that hot water extracts of rooibos and 
honeybush exhibited protection against carcinogens requiring metabolic 
activation (Marnewick et al., 2000). Unfermented rooibos and honeybush 
significantly reduced the activation of aflatoxin B1 and protected against 2-AAF-
induced mutagenesis in cytosolic liver fractions of rats (Marnewick et al., 2004). 
Matsuda et al., (2007) showed that rooibos causes an increase in intestinal 1’- 
and 4-hydroxylation activities of CYP3A4 in rats as well as an increase in 
intestinal CYP3A4 content; although rooibos did not affect the concentration of 
microsomal liver CYP450. Both teas significantly increased the cytosolic 
glutathione-s-transferase α and microsomal UDP-glucuronosyl transferase 
activities, as well as the glutathione content (Marnewick et al., 2003), resulting 
in an increase in GSH/GSSG ratio. 
 
CONCLUSIONS 
Xenobiotic metabolising enzymes (cytochrome P450 and phase II and III) are 
responsible for activating or deactivating any foreign chemical an organism is 
exposed to. The fate of the xenobiotic depends on its chemical composition or 
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structure and its enzyme affinity. Some xenobiotics are metabolised by the 
same enzymes and thus compete for the same binding sites. Therefore, one 
xenobiotic can inhibit or enhance the metabolism of the other. This is known as 
herb-herb or herb-drug interactions. It is imperative to investigate these 
interactions, especially when studying the health properties of herbs. Herb-drug 
interactions can result in toxicity or ineffectiveness of pharmaceutical drugs. 
Many carcinogens are also metabolised by CYPs, which may enhance the 
formation of DNA-reactive metabolites, leading to an increased risk of tumor 
formation. The induction of certain phase II enzymes, however, can protect 
against the adverse effects by enhancing the deactivation and excretion of 
these DNA-reactive metabolites. Studies have shown that rooibos and 
honeybush herbal teas modulate hepatic phase II xenobiotic metabolising 
enzymes in rats, however, it has not previously been established whether the 
teas or their respective polyphenols affect xenobiotic metabolising enzymes at 
transcriptional level. 
.  
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CHAPTER 3 
Effect of polyphenol-enriched herbal teas on the expression of genes 
encoding xenobiotic metabolising enzymes, in rat liver and kidneys 
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ABSTRACT 
The use of polyphenol-enriched extracts by the nutraceutical and pharmaceutical 
industries has been controversial with respect to their potential health beneficial 
effects. At present very little information is available on the effect of polyphenol-
enriched extracts of rooibos (Aspalathus linearis) and honeybush (Cyclopia spp.) 
herbal teas on different cellular processes and their safety when used in dietary 
supplements. In the present study qPCR array analyses were used to investigate the 
effect of polyphenol-enriched extracts of rooibos and two honeybush species (C. 
genistoides and C. subternata) on the expression of hepatic and renal genes encoding 
the xenobiotic metabolising enzymes. Rats receiving the rooibos extract had the 
highest total polyphenol intake with the dihydrochalcone, aspalathin, as the major 
polyphenol. The major polyphenols consumed by the rats receiving the honeybush 
extracts were the xanthones, mangiferin and  isomangiferin. The flavanone and 
flavone intake of the rats receiving the C. subternata extract was higher (P≤0.05) when 
compared to C. genistoides treated rats while the latter extract provided a higher 
xanthone intake.  
 
In the liver both rooibos and honeybush up-regulated the genes encoding aldehyde 
dehydrogenase, glucose phosphate isomerase, while down-regulating the gene for 
17β-hydroxysteroid dehydrogenase 2 (Hsd17β2). Cytochrome P450 (Cyp) 19a1 was 
selectively increased by rooibos while honeybush (C. genistoides) up-regulated 
alcohol dehydrogenase and down-regulated Hsd17β1. The effect of C. subternata was 
different, up-regulating carboxyl esterases 1 and 2, Cyp2e1, while down-regulating 
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Cyp’s 2b6 and 2c13.  In the kidneys the genes encoding the phase II enzymes, 
glutathione–S-transferase (Gstm1) and microsomal Gst1, were up-regulated by 
rooibos, whereas the ATP binding cassette transporter (Abcb1), Cyp4b1, gamma 
glutamyltransferase 1 (Ggt1) and N-acetyltransferase 1 (Nat1) were down-regulated. 
Cyclopia genistoides up-regulated the Cyp19a1, Cyp1a1 and Hsd17β3 encoded 
genes, but down-regulated the genes of Gstm3 and 5 and hexokinase 2 (Hk2). 
Cyclopia subternata, on the other hand,  up-regulated the genes encoding 
arachidonate 15-lipoxygenase (Alox15), aryl hydrocarbon receptor nuclear translocator 
(Arnt), Cyp1b1, fatty acid amide hydrolase (Faah), Gstm1 and 4, Mgst2 and 
myeloperoxidase (Mpo), but down-regulated the esterase 22 (Es22), Gstm5 and Hk2 
encoded genes. The results indicated that differences exist in the modulation of 
xenobiotic metabolism at the transcriptional level, depending on the tissue type and 
the herbal tea utilised, presumably related to specific polyphenol constituents.   
 
Keywords:  Aspalathus linearis, Cyclopia spp, xenobiotic metabolising enzymes, 
qPCR array. 
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INTRODUCTION 
Xenobiotics are foreign substances entering the body and can either be beneficial or 
harmful depending on the dose and/or metabolic fate. Examples of xenobiotics include 
environmental carcinogens such as the polyaromatic hydrocarbons (PAH) and 
tobacco-related nitrosamines and pharmaceutical drugs, as well as a vast array of 
naturally occurring plant polyphenols. These xenobiotics may interact with the cell’s 
metabolic pathways and basic cellular constituents such as RNA, DNA and proteins 
(Boyland and Green, 1962), often leading to the modulation of normal cellular 
functions. 
 
Upon entering an organism most xenobiotics undergo metabolism that is catalysed by 
the xenobiotic metabolising enzymes (XMEs) which play a central role in the 
detoxification and/or elimination of the chemicals from the body (Meyer, 1996). These 
cellular processes include the phase I and phase II metabolising enzymes and phase 
III transporters, which are present in abundance either at the basal and/or at induced 
levels after exposure to xenobiotics (Meyer, 1996; Rushmore and Kong, 2002; Wang 
and LeCluyse, 2003). In general, it appears that exposure to xenobiotics and the 
interaction with metabolising enzymes (phase I and phase II) and phase III 
transporters may trigger cellular “stress” responses leading to an increase in gene 
expression  (Plant, 2007; Wahli and Martinez, 1991), which ultimately enhances the 
elimination and clearance of xenobiotics (Xu et al., 2005). Consequently, these 
homeostatic responses play a central role in the protection of cells against 
“environmental” insults such as those elicited by exposure to xenobiotics. 
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Indigenous to South Africa, the herbal teas Aspalathus linearis (rooibos herbal tea) 
and Cyclopia spp. (honeybush herbal tea) have become increasingly popular for their 
unique flavour, as well as anecdotal health properties. Traditional medicinal uses of 
rooibos in South Africa include alleviation of infantile colic, allergies, asthma and 
dermatological problems, while a decoction of honeybush was used as a restorative 
and as an expectorant in chronic catarrh and pulmonary tuberculosis (Bowie, 1830; 
Morton, 1983; Rood, 1994; Joubert et al., 2008). Since their global commercialisation, 
researchers have been investigating the health properties of the herbal teas and 
postulate their protective role against several human diseases. A study has shown that 
fermented rooibos herbal tea protected male Wistar rats against carbon tetrachloride 
(CCl4)–induced hepatic injury and caused histological regression of steatosis and 
cirrhosis in the liver tissue (Ulicna et al., 2003). Both herbal teas also significantly 
reduced the metabolic activation of aflatoxin B1 and protected against 2-
acetylaminofluorene (2-AAF)-induced mutagenesis (Marnewick et al., 2000 and 2004). 
Unfermented rooibos and honeybush herbal teas enhanced the activity of glutathione-
S-transferase and UDP-glucuronosyltransferase in rat liver (Marnewick et al., 2003).   
 
Although rooibos and honeybush herbal teas exhibit beneficial health properties, it is 
not known whether extracts of these herbal teas, in particular enriched in polyphenol 
content could modify the expression of the xenobiotic metabolising enzymes. In the 
present study polyphenol-enriched rooibos and honeybush herbal tea extracts were 
investigated for their in vivo effect on the expression of genes encoding xenobiotic 
metabolising enzymes in rat liver and kidney.  The extracts were used to further 
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elucidate their potential beneficial and/or adverse effects when used as antioxidant 
supplements. 
 
MATERIALS AND METHODS 
 
Chemicals 
Analytical grade methanol, ethanol, hydrochloric acid, and sodium carbonate (Na2CO3) 
were purchased from Merck Chemicals (Germiston, South Africa). Gallic acid (GA), 
dimethyl-sulfoxide (DMSO), and Folin-Ciocalteau (F-C) reagent were obtained from 
Sigma-Aldrich (South Africa) as was the molecular biology grade β-mercaptoethanol 
(β-ME).  Orientin and iso-orientin were obtained from Carl Roth GmbH & Co. KG 
(Karlsruhe, Germany), mangiferin and hesperidin from Sigma-Aldrich (St Louis, MO, 
USA) and vitexin, isovitexin, hyperoside, luteolin, chrysoeriol, rutin, narirutin and 
hesperetin from Extrasynthese (Genay, France). The HPLC Far UV gradient grade 
acetonitrile was obtained from BDH (VWR International, Poole, UK) and acetic acid 
from Riedel-de Haën (Seelze, Germany).  Aspalathin and nothofagin were purified 
from unfermented rooibos at the PROMEC Unit of the Medical Research Council, 
Tygerberg, South Africa to a purity of >95%. 
 
Chemical analysis of herbal tea samples  
The polyphenol-enriched herbal tea extracts (Aspalathus linearis, Cyclopia genistoides 
and C. subternata) were supplied by the RAPS Foundation (Germany). The 
preparation was according to US patent application US2008/0247974 A1.  
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The total polyphenol (TP) content of the enriched extracts was determined by using 
the scaled-down Folin-Ciocalteau (F-C) method with gallic acid as standard. Six gallic 
acid standard solutions, ranging from 50-500 µl, and extract stock solutions, prepared 
in distilled water, were diluted in triplicate in distilled water to a final volume of 5 ml. F-
C reagent (10%) (5 ml) and 7.5% Na2CO3 (4 ml) were then added to either a 1 ml 
standard, extract solution or distilled water as a blank, to a final volume of 10 ml, 
vortex mixed and incubated for 2 hrs at 37°C. The absorbance was determined at 765 
nm and the TP content expressed as gram (g) gallic acid equivalents (GAE) per 100 g 
extract. 
 
 
Analyses of monomeric polyphenols by high performance liquid 
chromatography (HPLC) 
 
An Agilent 1200 HPLC system consisting of a quaternary pump, autosampler, in-line 
degasser, column oven and diode-array detector (Agilent Technologies Inc., Santa 
Clara, USA) with Chemstation 3D LC software was used for HPLC-DAD analysis. 
Stock solutions of all standards were prepared in DMSO and aliquots frozen at -20°C. 
Extracts were dissolved in deionised water (ca 6 mg/mL). Standard calibration 
mixtures were prepared in a range of concentrations by dilution in HPLC grade water. 
Ascorbic acid was added to the standard calibration mixtures and samples (final 
concentration ca 10 mg/mL) before filtering with 0.45 µm pore-size Millex-HV syringe 
filter devices (Millipore) prior to HPLC analysis. UV-Vis spectra from 220 to 400 nm 
were recorded for all analyses. Peaks were identified by comparing retention times 
and UV-Vis spectra with those of authentic standards.  
 
 
 
 
83 
 
 
 
Rooibos herbal tea: Separation, according to a modified version of the method 
by Joubert (1996), was achieved on a Gemini C18 (150 × 4.6 mm, 5 µm particle size, 
110 Å pore size; Phenomenex,  Torrance, USA) column protected by a guard column 
with the same stationary phase at 38°C and a flow rate of 0.4 mL/min. Solvent A, 2% 
acetic acid (v/v), and B, methanol, were used in the following solvent gradient: 0–3 min 
(20% B); 15 min (30% B); 18 min (30% B); 27 min (35% B); 29 min (35% B); 35 min 
(40% B); 54 min (60% B); 62 min (80% B); 68 min (60% B); 81 min (20% B); 90 min 
(20% B at 1.2 mL/min). Aspalathin and nothofagin were quantified at 288 nm, while 
350 nm was used for quantification of the other compounds. 
Honeybush herbal teas: Separation was carried out according to the method of 
De Beer and Joubert (2010) on a Zorbax Eclipse XDB-C18 (150 × 4.6 mm, 5 µm 
particle size, 80 Å pore size; Agilent Technologies) column protected by a guard 
column with the same stationary phase at 30°C. Solvent A, 0.1% formic acid (v/v), and 
B, acetonitrile, were used in the following solvent gradient at a flow rate of 1 mL/min: 
0–6 min (12% B); 7 min (18% B); 14 min (25% B); 19 min (40% B); 24 min (50% B); 29 
min (12% B); and 40 min (12% B). The xanthones were quantified at 320 nm, the 
flavanones at 288 nm and the flavones at 350 nm. Scolymoside and the eriodictyol-
glycoside were quantified as luteolin and hesperidin equivalents, respectively. 
 
Animals, treatment and clinical biochemical parameters  
The animal study was conducted by Ms J.D. van der Merwe of the Department of Food 
Science, University of Stellenbosch as part of her PhD degree. The use of 
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experimental animals was approved by the Ethics Committee for Research on Animals 
(ECRA) of the Medical Research Council (MRC) (Letter attached in Addendum II). 
Seven to eight weeks old male Fischer rats (n=10) weighing between 150-200 g were 
obtained from the Primate Unit of the Medical Research Council (Tygerberg, South 
Africa). The animals were housed individually in stainless steel wire-bottomed cages 
fitted with Perspex houses in a room illuminated for 12 hr photoperiods at 50% 
humidity and a constant room temperature of 24-25°C.  Freeze-dried extracts of 
aspalathin-enriched green rooibos (18% aspalathin), mangiferin-enriched green C. 
subternata (3.8% mangiferin) and C. genistoides (9.3% mangiferin) were mixed into 
mash, prepared from feed cubes  (Epol Ltd, Cape Town, South Africa), by milling, 
respectively, using a food mixer. Rats had free access to food and water. 
The different herbal tea diets were fed for 28 days, whereas the control rats (n=10) 
received only the feed. The feed intake was monitored every second day while the 
body weight was recorded once weekly (Tables 1 and 2, Addendum II). Following the 
28 day feeding period, rats were fasted overnight and terminated by cervical 
dislocation. Blood was collected in SST sterile  tubes (BD Vacutainer Systems, 
Preanalytical Solutions, Plymouth, UK) and  serum  prepared by centrifugation at 
2,000 xg for 10 minutes at 4 ºC.    
 
Serum clinical biochemical parameters were determined on a Technikon RA 1000 
automated analyzer (NIRS, MRC of South Africa) and included creatinine, alkaline 
phosphatase (ALP), total cholesterol, total iron, aspartate transaminase (AST), alanine 
transaminase (ALT) and total (TBili) and unconjugated (DBili) bilirubin. The liver and 
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kidney tissues were harvested and weighed, and sections (200 – 400 mg) of each 
tissue type were immediately snap frozen in liquid nitrogen and stored at -80°C for 
investigating changes in the gene expression patterns.  
 
Gene expression analyses 
Extraction of ribonucleic acid (RNA)  
Total RNA was isolated from the liver and kidney tissue of rats in each group using the 
RNeasy mini kit* (Qiagen, Valencia, CA, USA). This technology combines the selective 
binding properties of a silica-gel-based membrane with the speed of micro-spin 
technology to extract RNA in the presence of a specialised high-salt buffer system. In 
short, liver and kidneys tissue (20-25 mg) were lysed in 600 µl of a highly denaturing 
guanidine isothiocyanate (GITC)-containing lyses buffer (RLT) and homogenised in a 
Tissuelyser II (Qiagen, Valencia, CA, USA) for 40 sec.  
 
Beta-mercaptoethanol (β-ME) (14.3 M) was added to the RLT buffer (10 µl/ml) prior to 
use. The lysate was centrifuged at 10,000 ×g for 3 min and the supernatant transferred 
to a clean micro-centrifuge tube. Ethanol (75%; 600 µl) was added and the mixture 
fractionated on an RNeasy spin column by centrifugation at 8,000 ×g for 2x15 sec. The 
RNeasy spin column membrane was washed with RW1 buffer (700 µl) by 
centrifugation at 8,000 ×g for 15 sec. A final wash step, using RPE buffer (500 µl), was 
performed by a two-step centrifugation, first for 15 sec and then again for 2 min at 
8,000 ×g. The RNA was eluted from the spin column membrane with RNase-free 
water (50 µl) and centrifugation at 8,000 ×g for 1 min.  
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*The description, concentrations and pH of the buffers are not defined in the RNA 
extraction kit user manual.  
 
RNA cleanup and quality assessment 
Genomic DNA in the RNA samples was digested using the Ambion® Turbo DNA-
free™ kit (Applied Biosystems, South Africa) according to the manufacturer’s 
recommendations. Once again the buffer strength and pH were not available.  Briefly, 
RNA (20 µg), DNase buffer, DNAse I (4 units) and nuclease-free water were mixed 
and incubated for 90 min at 37°C in a final volume of 20 µl. The DNAse enzyme was 
then deactivated by incubating the mixture with 10 µl DNAse inactivation reagent for 2 
min at room temperature. In order to collect the RNA-containing supernatant, the 
mixture was centrifuged at 8,000 ×g for 15 min.  
 
The RNA was quantified spectrophometrically by placing 2 µl RNA on the pedestal of a 
Nanodrop 1000 (Thermo Scientific, Wilmington, DE, USA) (Table 4, Addendum II) and 
the RNA quality was analysed on an Agilent Bioanalyzer 2100 (Agilent Technologies, 
Waldbron, Germany). The Agilent Bioanalyzer provides a platform that uses a 
fluorescent assay involving electrophoretic separation to evaluate RNA samples 
qualitatively. The software creates an electrogram, which diagrams the fluorescence 
over time. Briefly, a gel-dye mixture (9 µl) was transferred to a RNA 6000 Nano 
Labchip and spread across by plunging 1 ml of air, using a syringe, into the chip for 30 
sec. The gel-dye mix (9 µl) was also transferred to two additional wells for quality 
control purposes. A Nano marker buffer was added to all sample wells and the RNA 
ladder well. The RNA samples (400 ng in 1 µl) and RNA 6000 ladder (1 µl) (Ambion) 
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were denatured at 70°C for 2 min before loading into their respective wells. The chip 
was vortexed at 240 rpm for 1 min, developed and analysed on the Bioanalyzer using 
an Agilent software program. The small (18S) and large (28S) ribosomal RNA (rRNA) 
subunits were recorded as bands and peaks on an electrogram. RINs (RNA integrity 
numbers), displayed as numbers from 1 to 10, were determined from the ratio between 
the size of the 28S band to the 18S band.   
 
Following the RNA quality assessment, the RNA samples were stored at -80°C prior to 
gene analyses. Of the 10 liver and kidney samples available for each treatment group, 
three samples were selected for qPCR array analyses while four liver samples per 
treatment group were selected for the gene validation assay. The sample selection 
was based on the best RNA integrity parameters (Figures 1 and 2, Addendum II).  
 
 
Reverse transcription (RT) 
First strand complimentary deoxyribonucleic acid (cDNA) synthesis was carried out 
using the isolated RNA (three samples per group) and RT2 First Strand Kit (SA 
Biosciences, Frederick, Maryland, USA) according to the manufacturer’s protocol. 
Briefly, contaminating genomic DNA was eliminated from total RNA (1 µg) with a five 
times concentrated genomic DNA elimination buffer (2 µl) and nuclease-free water to a 
final volume of 10 µl and incubated at 42°C for 5 min. The sample was subsequently 
mixed with oligo-dT primers, a five times concentrated reverse transcription buffer and 
reverse transcriptase to a final volume of 20 µl and incubated 42°C for 15 min. The RT 
reaction was terminated by heating at 95°C for 5 min and stored at -20°C until use. 
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qPCR array analyses in the liver and kidneys 
The resultant cDNA (20 µl) was further diluted in nuclease-free water to a final volume 
of 111 µl.  A subsample (102 µl) was mixed with a twice concentrated RT2 qPCR 
SYBR green I master mix (550 µl) (SA Biosciences), containing HotStart DNA 
polymerase, and nuclease-free water (448 µl) to a final volume of 1100 µl. The cDNA 
mixture (10 µl)  was transferred  to  a polymerase chain reaction (PCR) profiler array 
(SA Biosciences) containing 84 genes, coded for xenobiotic metabolising enzymes 
and transporters, five reference genes and quality control parameters (Table 3, 
Addendum II). Data were generated in real time from a ABI 7900HT real time PCR 
apparatus (Applied Biosystems, South Africa) with a two-step cycling program (1 cycle 
at 95°C for 10 min; 40 cycles at 95°C for 15 sec and then at 60°C for 1 min). All 
samples were analysed in triplicate. The data were analysed on the Microsoft Excel-
based PCR array data analysis template from the SA Biosciences website.  
(http://www.superarray.com/pcrarraydataanalysis.php)  
 
Genomic DNA and reverse transcription controls 
The cycle threshold (Ct) reflects the cycle number at which the fluorescence generated 
within a reaction exceeds the background noise and this inversely correlates to the 
initial amount of target template. The mean Ct for each sample’s genomic DNA control 
(GDC) parameter was determined (Table 5, Addendum II). A value greater than 35 
indicates that the genomic DNA contamination is too low to affect the gene expression 
profiling results. For the samples that were between 30 and 35, a gene-by-gene 
analysis for each gene of interest (GOI) was done using the equation ∆Ct(GOI) = Ct 
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(GDC) – Ct (GOI). If the value is six or greater, the results may still be used without 
further validation. However, if the value is less than six, the results should be validated 
with individual gene-specific primer assays that include a no reverse transcription 
(NRT) control. 
The reverse transcription control (RTC) indicates whether the concentrations of 
impurities in the RNA sample are enough to inhibit the reverse transcription reaction. 
RTC signifies the difference between the average Ct of the RTC and the positive PCR 
control (PPC). A value below 5 is evidence of no RT inhibition. 
 
Data normalisation and analysis 
Five reference (housekeeping) genes [ribosomal protein large P1 (Rplp1), 
hypoxanthine guanine phosphoribosyl transferase (Hprt), ribosomal protein L13A 
(Rpl13a), lactate dehydrogenase A (Ldha) and β-actin (Actb)] were used for 
normalisation. The mean Ct of each cDNA sample for each target gene and all 
reference genes were determined.  ∆Ct(GOI) is the difference in Ct between the target 
gene and reference gene. For example, if the target gene (Cyp1a1) has an average Ct 
value of 25 and the average Ct value of the reference gene 10, then the ∆Ct(Cyp1a1) will 
be equal to 15.  
 The comparative Ct (∆∆Ct) method was used to calculate the relative amount of 
transcripts in the treated and untreated samples (control): ∆∆Ct = ∆Ct (treated) – ∆Ct 
(control). The fold-change for each treated sample relative to the control sample was 
calculated using the formula 2-∆∆Ct. Statistical calculations were done based on the ∆Ct 
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values using a two-tailed t-test. A P-value equal to and/or less than 0.05 was 
designated as significant.  
 
Validation of selected genes in the liver using qPCR 
Current publication guidelines require that all microarray results be confirmed by an 
independent gene expression profiling method. Although it is not necessary for PCR 
arrays (Gaj et al., 2008), quantitative real time PCR was used to validate the PCR 
array results in this study to confirm that the results are accurate. The first step in 
confirming array results by real-time PCR is the selection of gene-specific primer pairs. 
The following were selected from the list of genes that were analysed on the 
microarrays: Aldehyde dehydrogenase 1a1 (Ald1a1), because it was affected by all 
three extracts, catechol-O-methyltransferase (Comt), since its enzyme is known to be 
associated with polyphenol metabolism, cytochrome P450 1a1 (Cyp1a1), is one of the 
major CYPs, cytochrome P450 2e1 (Cyp2e1) had a fold difference of less than 1.5, 
17β- hydroxysteroid dehydrogenase 2 (Hsd17β2) was affected by all extracts, 
sulfotransferase 1e1 (Sult1e1) because of its known association with polyphenol 
metabolism and Hprt1 as a reference gene for data normalisation (Table 1).  
 
Reverse transcription 
Four RNA samples per group were used for the validation of selected genes. Total 
RNA (10 µg), in a volume of 10 µl, was reversed transcribed into cDNA using the High 
capacity cDNA reverse transcription kit (Applied Biosystems, South Africa) according 
to the manufacturer’s protocol. Briefly, RNA was mixed with 25 times concentrated 
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deoxyribonucleotide triphosphate (dNTP) mix (100 mM), 10 times concentrated RT 
Random primers, MultiScribe reverse transcriptase, 10 times concentrated reverse 
transcription buffer and nuclease-free water to a final volume of 20 µl. The thermal 
cycler (Eppendorf, Germiston, South Arica) conditions were as follows: 25°C for 10 
min, 37°C for 120 min and 85°C for 5 sec. The cDNA was then stored at -20°C until 
further use. 
Primer design and optimisation 
Gene-specific qPCR primers (Table 1) were designed using the Primer Express® 
software v2.5 (Applied Biosystems, South Africa) and synthesised by Integrated DNA 
technologies (IDT, Whitehead Scientific, South Africa). 
 
Table 1 Primer sequences of selected genes for qPCR analyses. 
Gene Genebank Sense Antisense 
5’→3’ 5’→3’ 
Ald1a1 NM_022407 CAAGGCAGATGTTGACAAAGCT GGGAGCCAATCTGGAAAGC 
Comt NM_012531 CCATGGAGATGAACCCTGACTAC TAGGCCTGCAAAGTTCAGCATT 
Cyp1a1 NM_012540 GCCCCGGCTTTCTGACA CGGAAGGTCTCCAGGATGAAG 
Cyp2e1 NM_031543 TTGGCCGACCTGTTCTTTG TTTCTGGGTATTTCATGAGGATCA 
Hprt1 NM_012583 TCAAGCAGTACAGCCCCAAAAT CAACACTTCGAGAGGTCCTTTTC 
 
Hsd17β2 NM_024391 CGCAGAGAAGATACAAGACAAAGG AAAGTGCAAGACCCCAGCAT 
Sult1e1 NM_012883 TCCAGGAGATGAAGAACAATCCA AGGGCTTCAGGGAAGTGGTT 
Aldehyde dehydrogenase 1a1 (Ald1a1), catechol-O-methyltransferase (Comt), cytochrome P450 1a1 (Cyp1a1), 
cytochrome P450 2e1 (Cyp2e1), 17β- hydroxysteroid dehydrogenase 2 (Hsd17β2), sulfotransferase 1e1 (Sult1e1) 
and hypoxanthine guanine phosphoribosyl transferase 1 (Hprt1). 
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Quantitative real-time PCR (qPCR) of liver samples 
Real-time PCR was carried out in duplicate in a 25 µl amplification mixture containing 
2 µl of template cDNA, 12.5 µl of two times concentrated SYBR Green I Master Mix 
(Applied Biosystems, South Africa), and 1.25 µl each of 22.5 µM sense and antisense 
primers. The PCR conditions included a polymerase activation step at 95°C for 10 min 
followed by 40 cycles of 95°C for 15 sec and 60°C for 60 sec and developed on an ABI 
Real-time PCR 7500 system (Applied Biosystems, South Africa). A non-template 
control was included for all of the primer pairs to eliminate the possibility of significant 
DNA contamination. Messenger RNA (mRNA) levels from each treated and untreated 
rat were normalised to the corresponding reference gene, Hprt’s mRNA levels. The 
gene expression levels from the control were set as 1 to compare the relative amounts 
of gene expression levels in the experimental groups. Statistical analysis (Anova) of 
the results was performed in Microsoft Excel. Significant difference was determined 
with P ≤ 0.05 by the Student t test. 
 
RESULTS  
Analyses of monomeric polyphenols by HPLC 
The dihydrochalcone C-glucoside, aspalathin, was found to be the most abundant 
flavonoid in the rooibos extract followed by the flavonols, rutin+isoquercitrin+quercetin-
3-robinobioside, the dihydrochalcone, nothofagin and the flavone oxidation products of 
aspalathin, isoorientin and orientin (Table 2). Only small amounts of vitexin, isovitexin, 
hyperoside, luteolin-7-glucoside, luteolin and chrysoeriol were recorded, as well as 
traces of quercetin. 
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Of the honeybush polyphenolic constituents, the xanthones, mangiferin and 
isomangiferin, were found to be the most abundant. Cyclopia genistoides had a higher 
xanthone content, whereas C. subternata had either similar or higher flavanone and 
flavone levels. Of interest is the high eriocitrin content of C. subternata and the 
presence of scolymoside. The chemical structures of these polyphenols are presented 
in Figure 1. 
 
Feed, herbal tea extract and polyphenol intake  
The feed intake of the rats between the different dietary treatments and control was 
not significantly different (Table 3). Rats receiving the rooibos extract, containing 
almost twice the total polyphenol content of the honeybush extracts, have the highest 
total polyphenol intake followed by C. subternata with C. genistoides having the lowest 
intake.     
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Table 2 Monomeric rooibos and honeybush polyphenolic constituents of the 
enriched extracts incorporated in the rat diets. 
Aspalathus linearis (Rooibos) 
 
Polyphenol 
subgroup 
 
Compound 
 
g/100g Soluble 
solids (SS) 
Dihydrochalcone Aspalathin 18.73 
 Nothofagin 1.45 
Flavone C-
glycoside 
Isoorientin 1.45 
 Orientin 0.81 
 Vitexin 0.30 
 Isovitexin 0.39 
Flavonol Rutin+Isoquercitrin+Quercetin-
3-robinobioside 
2.10 
 Quercetin Traces 
 Hyperoside 0.29 
Flavone Luteolin 0.06 
 Chrysoeriol 0.02 
 Luteolin-7-glucoside 0.04 
Cyclopia spp. (Honeybush) 
 
Polyphenol 
subgroup 
 
Compound 
C. genistoides 
g/100g SS 
C. subternata 
g/100g SS 
Xanthones Mangiferin 9.29 3.79 
 Isomangiferin 3.29 1.30 
Flavanones Hesperidin 0.83 0.99 
 Eriocitrin nd 1.1 
 Naringenin 0.01 0.01 
 Eriodictyol-glycoside 0.03 0.23 
Flavone Luteolin 0.09 0.06 
 Scolymoside nd 1.29 
HPLC analysis was done by Dr D de Beer, ARC Infruitec-Nietvoorbij, Stellenbosch. 
All values are expressed as a percentage of the soluble solids (g/100g SS). 
Values are means of duplicate analysis.  
nd- not detected.  
Rutin, isoquercrtrin and quercetin-3-robinobioside co-eluted under the HPLC separation conditions. 
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iso-orientin: R1 =  H, R2 = R4 =OH, R3 = C-β-D-glucosyl    rutin: R = O-β-D-rutinosyl 
vitexin: R1 = C-β-D-glucosyl, R2 = OH, R3 = R4 = H    isoquercitrin: R = O-β-D-glucosyl 
isovitexin: R1 = R4 = H, R2 = OH, R3 = C-β-D-glucosyl 
luteolin: R1 = R3 = H, R2 = R4 = OH 
chrysoeriol: R1 = R3 = H, R2 = OH, R4 = OCH3 
scolymoside: R1 = R3 = H, R2 = O-β-D-rutinosyl, R4 = OH 
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Xanthones                                     Flavanones 
mangiferin: R1 = C-glucosyl; R2 = H                                  hesperidin: R1 = O-β-D-rutinosyl; R2 = CH3; R3 = OH 
mangiferin: R1 = H; R2 = C-glucosy;          eriocitrin: R1 = O-β-D-rutinosyl; R2 = H; R3 = OH 
                                      naringenin: R1, R2 = OH; R3 = H  
 
 
Figure 1 Chemical structures of the polyphenolic constituents of A. linearis, C. genistoides 
and C. subternata.
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Table 3 Feed intake of the rats and a representation of the extract and total 
polyphenol intake per 100 g body weight. 
Treatment 
TP 
(g gallic acid/ 
100 g extract) 
Feed intake 
(g feed/100 g 
bw) 
Extract intake 
(g extract/100 g 
bw) 
TP intake 
(mg GAE/ 
100 g bw) 
Control - 9.73 ± 0.42a - - 
A. linearis 39.22 ± 1.10a 9.65 ± 0.39a 0.19 ± 0.01a 75.66 ± 3.04a 
C. genistoides 21.88 ± 0.59c 9.97 ± 0.49a 0.25 ± 0.01b 54.55 ± 2.70b 
C. subternata 24.83 ± 0.82b 10.35 ± 0.45a 0.26 ± 0.01b 64.27 ± 2.77c 
Data form part of J.D. van der Merwe PhD thesis.  
Values are means ± standard deviation (n = 10), except for C. genistoides (n = 9).  
Rooibos and honeybush enriched extracts were incorporated at a 2 and 2.5% level in the diets, 
respectively.  
TP- Total polyphenols. GAE – Gallic acid equivalents, bw - body weight. 
 
Individual polyphenol intake  
In the rooibos group, intake of aspalathin was the highest (Table 4), followed by the 
flavonols. Equal levels of nothofagin and isoorientin were ingested followed by orientin. 
The intake of the nothofagin oxidation products, vitexin and isovitexin, and the 
flavonol, hyperoside, was similar, followed by the minor flavones, the aglycones, 
chrysoeriol and luteolin. The rats that received the C. genistoides extract ingested 
more than twice the amount of the xanthones, mangiferin and isomangiferin, compared 
to the group that received the C. subternata extracts. However, the intakes of the 
flavanones, eriocitrin, hesperidin and eriodictyol-glycoside, and the flavone 
scolymoside, were significantly (P≤0.05) higher in the C. subternata treated rats, 
whereas the C. genistoides treated rats  had a higher (P≤0.05) luteolin intake.  
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Table 4 Daily rat intakes of individual rooibos and honeybush monomeric 
polyphenols.  
Polyphenols A. linearis (mg per 100 g rat BW) 
 
Aspalathin 
Nothofagin 
Orientin 
Isoorientin 
Vitexin 
Isovitexin 
Rutin/isoquercitrin 
Luteolin 
Chrysoeriol 
Hyperoside 
36.13 ± 1.45 
2.8 ± 0.11 
1.56 ± 0.06 
2.8 ± 0.11 
0.58 ± 0.02 
0.75 ± 0.03 
4.05 ± 0.23 
0.12 ± 0.01 
0.39 ± 0.02 
0.56 ± 0.02 
 
Honeybush C. genistoides (mg per 100 g rat BW) 
C. subternata 
(mg per 100 g rat BW 
Mangiferin 
Isomangiferin 
Hesperidin 
Luteolin 
Eriocitrin 
Naringenin 
23.16 ± 1.15a 
8.20 ± 0,41a 
2.07 ± 0.10a 
0.22 ± 0.01a 
- 
0.02 ± 0.001a 
9.81 ± 0.42b 
3.37 ± 0.15b 
2.56 ± 0.11b 
0.12 ± 0.01b 
2.85 ± 0.12 
0.03 ± 0.001a 
Eriodictyol-glycoside 0.07 ± 0.004a 0.60 ± 0.03b 
Scolymoside - 3.34 ± 0.14 
 Data form part of Debora van der Merwe’s PhD thesis.  
Means followed by the same letter do not differ significantly, if letter differs then P≤0.05.  
Values represent the average daily polyphenol intake (n=10). 
 
 
Body weight and serum clinical biochemistry parameters  
There were no significant changes in the body weight gain and relative liver and 
kidney weights between the different treatment and control rats (Table 5).  Of the 
serum clinical biochemical parameters only the total bilirubin was significantly 
increased (P≤0.05) by C. subternata, while a marginal (P<0.1) effect was noticed for 
C. genistoides.  Cyclopia subternata significantly (P≤0.05) reduced the level of alanine 
aminotransferase (AST), while a marginal reduction was noticed for C. genistoides. 
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Gene expression analyses 
qPCR array analysis of xenobiotic metabolising enzymes in the liver  
Of the 84 genes analysed, only 11 were significantly (P≤0.05) affected in the liver 
(Table 6). The genes, Ald1a1, Cyp19a1 and glucose phosphate isomerase (Gpi), were 
up-regulated by the polyphenol-enriched rooibos herbal extract, whereas Hsd17β2 
was down-regulated. Cyclopia genistoides up-regulated the genes of alcohol 
dehydrogenase (Adh4), Ald1a1 and Gpi, however, it down-regulated the genes of both 
Hsd17β1 and Hsd17β2. Cyclopia subternata up-regulated the genes Ald1a1, carboxyl 
esterases 1 and 2 (Ces1 and 2), Cyp2e1 and Gpi, but down-regulated Cyp2b6, 
Cyp2c13 and Hsd17β2.  
The major CYPs, Cyp3A and 1a1/1a2, nuclear receptors, ABC transporters and phase 
II transferases, glutathione-S-transferase (Gst), sulfotransferase (Sult), UDP-
glucuronyltransferase (Ugt) and N-acetyltransferase (Nat) were not significantly 
affected by the extracts (Table 6, Addendum II). 
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Table 5 Body weight gain, relative liver and kidney weight, and serum clinical biochemical parameters of rats fed 
the polyphenol-enriched herbal tea extracts for 28 days.  
Data form part of J.D. van der Merwe’s PhD thesis.  
Values are means ± STD (in parenthesis) of n = 10 rats (with the exception of C. genistoides, n = 9).   
Means in a column followed by the same letter are not significantly different P≥0.05).  
Abbr: Cholesterol (Chol), Alkaline phosphate (ALP), Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), Total bilirubin (TBili), 
Direct/unconjugated bilirubin (DBili), Creatine (Creat), body weight (BW). 
Treatment BW gain (g) 
Relative 
liver 
weight 
(%/bw) 
Relative 
kidney 
weight 
(%/bw) 
Chol 
(mmol/
L) 
Iron 
(µmol/L) 
ALP 
(U/L) 
ALT 
(U/L) 
AST 
(µmol/L) 
TBili 
(µmol/L) 
DBili 
(µmol/
L) 
Creat 
(µmol/L) 
Control 94.50a (10.20) 
3.57a 
(0.18) 
0.65a 
(0.03) 
1.17a 
(0.18) 
11.04a  
(1.06) 
126.80a 
(11.36) 
44.20a 
(9.90) 
104.90a 
(21.93)a 
8.26a 
(1.75) 
0.99a 
(0.41) 
46.19a 
(4.54) 
A. linearis 89.50a (12.94) 
3.70a 
(0.18) 
0.63a 
(0.03) 
1.15 a 
(0.09) 
11.34a 
(1.27) 
136.90a 
(6.43) 
42.40a 
(5.04) 
105.40a 
(12.96)a 
7.78a 
(1.21) 
0.84 a 
(0.21) 
46.09a 
(2.72) 
C. genistoides 92.00a (9.70) 
3.81a 
(0.25) 
0.67a 
(0.03) 
1.18 a 
(0.07) 
11.74a 
(2.12) 
135.11a 
(10.92) 
43.67a 
(5.87) 
89.33ab 
(6.73)ab 
8.60ab 
(2.55 
1.05a 
(0.57) 
45.34a 
(1.22) 
C. subternata 93.50a (12.83) 
3.57a 
(0.19) 
0.66a 
(0.03) 
1.19a 
(0.13) 
11.41a 
(1.30) 
128.00a 
(7.31) 
41.90a 
(4.41) 
88.30bc 
(5.10) 
10.51bc 
(1.38) 
1.24a 
(0.33) 
45.66a 
(2.92) 
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Table 6 qPCR array analysis of liver tissue after exposure to polyphenol-enriched herbal teas for 28 
days. 
Gene A. linearis C. genistoides C. subternata 
 
Fold 
difference P-value 
Fold 
difference P-value 
Fold 
difference P-value 
Adh4 
  1.33 0.0429   
Ald1a1 2.39 0.0488 1.672 0.0283 2.47 0.0278 
Ces1 
    1.32 0.0396 
Ces2 
    1.61 0.0016 
Cyp19a1 1.98 0.0272     
Cyp2b6 
    -1.29 0.0332 
Cyp2c13 
    -1.33 0.0349 
Cyp2e1 
    1.23 0.0345 
Gpi 2.48 0.0068 2.17 0.0053 1.92 0.0131 
Hsd17β1 
  -1.72 0.041   
Hsd17β2 -2.42 0.0078 -3.41 0.0138 -2.09 0.0421 
 P≤0.05 designated as significant. 
 - indicates down-regulation; + indicates up-regulation.  
Alcohol dehydrogenase 4 (Adh4), aldehyde dehydrogenase 1a1 (Ald1a1), carboxyl esterase (Ces1&2), 
cytochrome P450 19a1 (Cyp19a1), cytochrome P450 2b6 (Cyp2b6), cytochrome P450 2c13 (Cyp2c13), 
cytochrome P450 2e1 (Cyp2e1), glucose phosphate isomerase (Gpi), 17β- hydroxysteroid dehydrogenase 1&2 
(Hsd17β1&2). 
 
 
Quantitative real-time PCR (qPCR) of liver samples 
The mRNA of the selected genes was normalised against the reference gene Hprt1. 
Compared to the control, rooibos showed the same level of Cyp2e1 mRNA, whereas C. 
genistoides and C. subternata slightly decreased its quantity. Whilst no significant 
change in mRNA quantity was observed for Comt, all three herbal tea extracts 
decreased Hsd17β2 transcription. 
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Some inconsistencies were observed in the qPCR results, which could be due to poor 
primer design or very little mRNA present in the liver tissue for Ald1a1, Cyp1a1 and 
Sult1e1 and were therefore omitted.  
 
qPCR array analysis of xenobiotic metabolising enzymes in the kidneys 
Of the 84 xenobiotic metabolism-associated genes analysed in the kidneys, only 20 
were significantly (P≤0.05) affected (Table 6). The genes encoding Gstm1 and 
microsomal Gst1 were significantly up-regulated by rooibos, whereas Abcb1, Cyp4b1, 
gamma glutamyltransferase 1 (Ggt1) and Nat1 were down-regulated. Cyclopia 
genistoides up-regulated the Cyp19a1, Cyp1a1 and Hsd17β3 encoded genes, while 
down-regulating the genes of Gstm3 and Gstm5 and hexokinase 2 (Hk2). Similar to 
what was observed in the liver, C. subternata affected the expression of most genes. 
The herbal tea extract up-regulated the gene encoding of arachidonate 15-lipoxygenase 
(Alox15), aryl hydrocarbon receptor nuclear translocator (Arnt), Cyp1b1, fatty acid 
amide hydrolase (Faah), Gstm1 and Gstm4, Mgst2 and myeloperoxidase (Mpo), but up-
regulated the esterase 22 (Es22), Gstm5 and Hk2 encoded genes. 
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Table 7 Gene expression profile of xenobiotic metabolising enzymes in kidney tissue after 
exposure to polyphenol-enriched herbal tea extracts for 28 days. 
The values indicate fold differences.  
P≤0.05 designated as significant; 
 - indicates down-regulation; + indicates up-regulation.  
ATP binding cassette beta 1 (Abcb1), arachidonate 15-lipoxygenase (Alox15), aryl hydrocarbon receptor 
nuclear translocator (Arnt), cytochrome P450 19a1 (Cyp19a1), cytochrome P450 4b1 (Cyp4b1), 
cytochrome P450 1b1 (Cyp1b1) esterase 22 (Es22), gamma glutamyltransferase 1 (Ggt1), glutathione-S-
tranferase mu (Gstm), hexokinase 2 (Hk2), 17β- hydroxysteroid dehydrogenase 3 (Hsd17β3), microsomal 
glutathione-S-tranferase (Mgst), myeloperoxidase (Mpo), N-acetyltransferase 1 (Nat1). 
 
Gene A. linearis C. genistoides C. subternata 
Abcb1 -1.85 (P= 0.01)     
Alox15 
  1.71 (P= 0.05) 
Arnt 
  1.30 (P= 0.03) 
Cyp19a1  2.99 (P= 0.07)  
Cyp1a1 
 3.74 (P= 0.06)  
Cyp4b1 -2.19 (P= 0.05)    
Cyp1b1 
  5.66 (P= 0.01) 
Es22 
  -1.23 (P= 0.04) 
Faah 
  1.90 (P= 0.01) 
Ggt1 -1.69 (P= 0.02)    
Gstm1 1.57 (P= 0.05)  1.69 (P= 0.05) 
Gstm3 
 -1.60 (P= 0.04)  
Gstm4 
  1.74 (P= 0.04) 
Gstm5 
 -1.61 (P= 0.02) -1.69 (P= 0.01) 
Hk2 
 -2.12 (P= 0.02) -2.18 (P= 0.01) 
Hsd17β3 
 4.42 (P= 0.06)  
Mgst2 
  2.62 (P= 0.04) 
Mgst1 1.29 (P= 0.01)    
Mpo 
  18.60 (P= 0.05) 
Nat1 -1.22 (P= 0.02)    
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DISCUSSION 
Many plant constituents are known to affect xenobiotic metabolising enzymes 
experimentally (Budzinski et al., 2000). Grapefruit juice inhibits the enzymatic activity of 
CYP3A4 and therefore decreases the first pass effect of the immunosuppressant, 
cyclosporine, leading to increased levels of the drug in the blood (Hollander et al., 
1995). On the other hand, the herbal antidepressant, St John’s wort, induces CYP450 
activity and can seriously decrease cyclosporin levels (Breidenbach et al., 2000). In the 
past few decades South African herbal teas, rooibos (A. linearis), and honeybush (C. 
genistoides and C. subternata), have become increasingly popular as beverages 
worldwide (Joubert et al., 2008). Rooibos and honeybush (C. intermedia) herbal teas 
have various effects on antioxidant capacity, immune responses, gastrointestinal 
actions, cancer, amongst others as reviewed by Joubert et al. (2008).  
 
However, at present very little is known on the effects of these herbal teas on xenobiotic 
metabolism, especially when utilising polyphenol-enriched extracts.  Marnewick et al. 
(2003) reported enhanced activity of glutathione-S-transferase and UDP- 
glucuronosyltransferase (UGT) in rat liver after intake of unfermented rooibos and C. 
intermedia. Even though no significant difference was found in total hepatic CYP 
content, Matsuda et al. (2007) showed that rooibos inhibits CYP3A-mediated MDZ-4OH 
activity by 80% compared to the control group in rat liver microsomes, but increased 
activity by 25% in vivo and by 50% in intestinal microsomes. These studies suggest that 
rooibos interferes with xenobiotic metabolism, presumably by interfering with the 
formation of the substrate enzyme complex. The present study represents the first 
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investigation of the in vivo effects of polyphenol-enriched extracts of rooibos and two 
honeybush spp, C. genistoides and C. subternata on the expression of genes encoding 
xenobiotic metabolising enzymes in rat liver and kidneys.  
 
Cytochrome P450 enzymes play a pivotal role in xenobiotic as well as endobiotic 
metabolism in all organisms (Nebert, 1991). Approximately 75% of known drugs are 
metabolised by CYP450 enzymes, which are found predominantly in the endoplasmic 
reticulum and in greatest abundance in the liver, but are also found in extrahepatic 
tissues such as the kidneys, brain and intestines (Pavek and Dvorak, 2008). In the 
present study, the Cyp2b6 gene was down-regulated in the liver by C. subternata. This 
enzyme is responsible for the metabolism of 4% of the top 200 drugs which includes 
HIV treatment drugs, efavirenz and nevirapine, and anticancer drugs, 
cyclophosphamide and ifosphamide (Xie et al., 2003; Saitoh et al., 2007ab). In the 
kidneys, the gene expressions of Cyp1a1 and Cyp1b1 were significantly up-regulated 
by C. genistoides and C. subternata, respectively, whereas Cyp4b1 was down-regulated 
by rooibos. These enzymes are not only responsible for the metabolism of an 
abundance of drugs and other xenobiotics, but they also metabolise carcinogens such 
as aflatoxin B1 and polyaromatic hydrocarbons such as benzo(α)pyrene (Gonzalez, 
1990; Okey, 1990; Nebert and McKinnon, 1994; Hankinson, 1995; Beedanagari et al., 
2010). The Cyp1 genes are regulated by the AhR/ARNT complex (Pavek and Dvorak, 
2008). Activation of the aryl hydrocarbon receptor (AhR) upon binding with its ligand 
causes translocation of the activated complex to the nucleus. In the nucleus, HSP90 
dissociate from the activated AhR which subsequently heterodimerizes with a nuclear 
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transcription factor protein, the aryl hydrocarbon receptor nuclear translocator (ARNT) 
(Whitelaw et al., 1995). The AhR/ARNT complex then binds to a specific DNA 
recognition sequence, GCGTG, within the xenobiotic responsive element (XRE), located 
in the promoter region of a number of receptor regulated genes, including the CYP1A1 
(Denison et al., 1989; Nebert et al., 2004). Since C. subternata also up-regulated the 
gene Arnt in the kidneys, it is apparent that procarcinogen metabolism may be favoured 
in the kidneys after exposure to the herbal tea.   
 
The effect of these herbal teas on the expression of genes regulating steroidogenesis is 
of interest (Figure 2).  Steroidogenic enzymes are responsible for the biosynthesis of 
various steroid hormones, including glucocorticoids, mineralcorticoids, progestins, and 
sex hormones, and consist of various specific CYPs, and several hydroxysteroid 
dehydrogenases and reductases (Miller, 1988). Androstenedione, a product of 
cholesterol catabolism, can be reversibly converted to testosterone by HSD17β3 or to 
estrone by Cyp19a1 (aromatase). Estrone and testosterone can be converted to 
estradiol by HSD17β1 and Cyp19a1, respectively (Sanderson and van den Berg, 2003) 
(Figure 2).  
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Figure 2    Schematic diagram of the enzymes involved in steroidogenesis.     
↓Indicates down-regulation, ↑ indicates up-regulation, Rb- rooibos, Cgen-      
C. genistoides, Csub- C. subternata. Red highlight indicates an effect in the 
kidneys. 
 
 
The balance of steroid hormones can be affected if aromatase is targeted by 
xenobiotics (You, 2004). These environmental compounds can inhibit or induce 
aromatase gene expression or enzyme activity. A study tested aromatase activity in 
JAR cells (a choriocarcinoma cell line) in response to dietary polyphenols and found 
that green and black teas significantly decreased aromatase activity, and polyphenols 
inhibited estrogen production, however, no effect on aromatase expression was 
detected after 24 hour treatment with flavonoids (Monteiro et al., 2006).  The flavone, 
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apigenin, was shown to exhibit anti-aromatase and anti-17β-hydroxysteroid 
dehydrogenase activity (Le Bail et al., 1998), however in the present study the 
aromatase gene expression was up-regulated by rooibos and C. genistoides in the liver 
and kidneys, respectively. Of interest is that the rooibos flavones vitexin and isovitexin, 
are glycosides of apigenin, however it is not known whether they will affect aromatase 
activity.  The present findings seem to imply that the herbal tea extracts may favour the 
production of estradiol. This active form of estrogen is desirable in normal cells since it 
promotes proliferation after cell damage, however, it is not desirable in cancer cells 
where it would promote tumour growth (Francavilla et al., 1989a; Barone et al., 2006). 
Additionally, men with advanced liver diseases can develop a feminization syndrome 
with increased estradiol and decreased androgen levels. Similar effects are seen 
acutely after major liver resection (Francavilla et al., 1989b and 1990; Villa et al., 1988). 
 
The Hsd17β gene expression was also altered by the herbal tea extracts; Hsd17β1, 
which catalyses the conversion of estrone to estradiol (Tremblay et al., 1989), was 
down-regulated by C. genistoides in the liver; Hsd17β2, which converts estradiol, 
testosterone and 5α-dihydrotestosterone to their respective less active forms, estrone, 
androstenedione and 5α-androstenedione (Wu et al., 1993), was down-regulated by 
rooibos, C. subternata and C. genistoides in the liver.  Hsd17β3, which is essential for 
testosterone biosynthesis (Geissler et al., 1994), was significantly up-regulated by C. 
genistoides in the kidneys.  The gene expression of Cyp2c13, a major cytochrome in 
male rat liver microsomes (Eguchi et al., 1991), was down-regulated by C. subternata. 
The enzyme converts testosterone to a 6β-hydroxyl metabolite (Wang et al., 2009). 
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These results indicate that polyphenol-enriched rooibos and Cyclopia spp. regulate the 
gene expression of steroidogenic enzymes by favouring estradiol anabolism in the liver 
and testosterone accumulation in the kidneys of rats. 
 
Cyclopia genistoides and C. subternata also interfered with alcohol metabolism by 
favouring acetaldehyde formation in the liver, by up-regulating the genes, Adh4 and 
Cyp2e1, respectively. However, all three herbal tea extracts significantly up-regulated 
aldehyde dehydrogenase (Aldh), which in the presence of NAD as a cofactor, converts 
the toxic acetaldehyde to less toxic acetate (Pawan, 1972; Hunt, 1996). The suggestion 
of an improvement to the discomfort from excessive alcohol consumption by drinking 
tea (Camellia sinensis) has been recorded by Eisai-Zenshi in the Kamakura era in 
Japan (Kakuda et al., 1996). Green tea (C. sinensis) extracts were shown to promote 
alcohol metabolism in ICR mice and to prevent the changes observed after ethanol 
intoxication (Skrzydlewska et al., 2002). This coincides with our results which indicate 
that rooibos and Cyclopia spp. may regulate ethanol toxicity at the gene expression 
level. However, Cyp2e1 also changes many toxicologically important substrates, 
including carbon tetrachloride, N-nitrosodimethylamine and acetaminophen, to more 
toxic products (Guengerich et al., 1991; Koop, 1992). The analgesic acetaminophen can 
be metabolically activated by Cyp2e1 to a reactive metabolite, N-acetyl-p-benzoquinone 
imine (NAPQI), which depletes glutathione and covalently binds to proteins, causing a 
potentially fatal hepatic centrilobular necrosis (James et al., 2003). 
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Aqueous extracts of rooibos and the Cyclopia spp. also may have an effect on the 
glycolytic pathway affecting energy production. The gene expression of glucose 
phosphate isomerase (Gpi), the enzyme that catalyses the conversion of glucose-6-
phosphate to fructose-6-phosphate in the second step of glycolysis, was significantly 
up-regulated in the liver by all three herbal teas which will entail a positive effect on 
glucose breakdown. On the other hand, the gene expression of hexokinase 2 (Hk2), an 
enzyme that phosphorylates glucose into glucose-6-phosphate, was down-regulated by 
both C. subternata and C. genistoides in the kidneys which could affect the glycolytic 
breakdown of glucose negatively.  
 
The gene expressions of hepatic Ces1 and Ces2 were up-regulated by C. subternata in 
the liver. Carboxyl esterases are responsible for the hydrolysis of ester- and amide-
bond-containing drugs (Staudinger et al., 2010) such as angiotensin-converting enzyme 
inhibitors (temocapril and cilazapril) (Takai et al., 1997), anti-tumor drugs (CPT-II and 
capecitabin) and narcotics (cocaine, heroin and meperidine) (Pindel et al., 1997). 
Cyclopia subternata may therefore facilitate the deactivation of these drugs. In the 
kidneys, the esterase gene known as egasyn (Es22) was down-regulated by C. 
subternata. The enzyme specifically hydrolyses retinyl esters to form retinol (Mentlein 
and Heymann, 1987), which is the most active form of animal derived vitamin A. Vitamin 
A is essential for vision, bone growth and immune responses amongst others 
(D’Ambrosio et al., 2011). Therefore an inhibition of Es22 attenuates an accumulation of 
retinol esters (van Berkel, 2009), thus providing a precursor for vitamin A synthesis.    
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Cyclopia subternata up-regulated the arachidonate 15-lipoxygenase (Alox15) gene in 
the kidneys. Alox15 is responsible for the synthesis of 15S-hydroperoxyeicosatetraenoic 
(15-HETE) acid by region-selectively adding oxygen to arachidonic acid. 15-HETE 
decreases renal blood flow and glomerular filtration (Imig, 2000) and it has anti-
proliferative and pro-apoptotic functions (Kumar et al., 2009). Cyclopia subternata may 
therefore impede on the elimination of drugs, but also protect against cancer 
development. 
 
Fatty acid amide hydrolase (Faah) gene was up-regulated by C. subternata in the 
kidneys.   This gene encodes a protein that is responsible for the hydrolysis of a number 
of primary and secondary fatty acid amides, including neuromodulatory compounds, 
anandamide (Devane et al., 1992) and oleamide (Cravatt et al., 1995), thereby serving 
to eliminate the signaling functions of the molecules. Inactivation of Faah has been 
linked to sleep enhancement (Huitron-Resendiz et al., 2004) due to the lack of 
anandamide degradation (Murillo-Rodriguez et al., 2007), anti-depressant (Cravatt et 
al., 2004) and anti-inflammatory (Lichtman et al., 2004; Cravatt et al., 2004; Holt et al., 
2005) effects due to elevated endogenous levels of fatty acid amides. Cyclopia 
subternata may therefore restrain sleep, and induce depression and pain caused by 
inflammation. 
 
The significant up-regulation of the myeloperoxidase Mpo gene in the kidneys by C. 
subternata is of interest. Mpo, a member of the haem peroxidase-cyclooxygenase 
family, is abundantly expressed in neutrophils and to lesser extent in monocytes and 
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certain types of macrophages. During inflammation Mpo is released from cytoplasmic 
granules of neutrophils by a degranulation process, where it reacts with hydrogen 
peroxide (H2O2) to form a complex that can oxidise a large variety of substances 
(Klebanoff, 2005). Mpo-H2O2 can react with chloride leading to the formation of reactive 
oxidants (hypochlorous acid) which is important in the innate immune defenses.  
However, if released outside the cell, it may induce damage to adjacent tissues (Malle 
et al., 2007). It has been suggested that renal glomerular damage may be caused by 
the Mpo system. Mpo has also been associated with pyelonephritis, membrane 
proliferative glomerular nephritis and membranous glomerular nephritis (Odobasic et al., 
2007). It has been shown that Mpo metabolises the anticonvulsant carbamazepine to 
reactive intermediates that could be responsible for the adverse reactions (such as 
agranulocytosis and lupus) associated with the drug (Furst and Uetrecht, 1993).  
 
The gene expression of phase II enzymes, specifically the glutathione tranferases and 
N-acetyltransferase, were altered in the kidneys after exposure to all the herbal teas. 
Marnewick et al. (2003) found that unfermented rooibos and C. intermedia significantly 
enhanced the activity of cytosolic glutathione S-transferase alpha in the rat liver, 
however, in the present study no effect on the gene expression of the enzyme in the 
liver was noticed. In addition, the gene encoding gamma glutamyltransferase (Ggt1), an 
enzyme involved in the degradation of glutathione, was down-regulated by rooibos in 
the kidneys. Glutathione degradation occurs in the proximal tubule at both the luminal 
(Hahn et al., 1978) and basolateral membrane (Abbot et al., 1984) a process that is 
modulated by rooibos presumably due to changes in GSH metabolism in the body.  
 
 
 
 
112 
 
 
 
Finally, of the phase III drug transporters, the ATP-binding cassette (ABC) transporters 
constitute a ubiquitous superfamily of integral membrane proteins that are responsible 
for the translocation of many substances across membranes.  Rooibos down-regulated 
the Abcb1 gene in the kidneys, which could be advantageous in the treatment of cancer 
during chemotherapy, however the protection of normal cells against toxic compounds 
may be impaired. This also indicates that rooibos polyphenols may prevent their own 
transport out of the kidney cells. 
 
Differences in the polyphenol intake between the herbal teas may explain the differential 
expression of the genes in the liver and kidneys. At present very little information is 
available on the effect of polyphenols on the expression of xenobiotics metabolising 
enzymes in the liver and kidney. The highest polyphenol intake was obtained in the rats 
receiving the rooibos extract with the dihydrochalcone aspalathin as the major 
polyphenol.  Of the honeybush herbal teas, rats receiving the C. subternata extract had 
the highest polyphenol intake despite the fact that the mangiferin content was up to two 
fold lower than C. genistoides. However, the exposure to the flavanones, hesperidin, 
eriocitrin eriodictyol glycoside and the flavones, specifically scolymoside was 
significantly higher when compared to the rats receiving the C. genistoides extract. In 
the liver only three genes were affected by all three herbal teas with the flavone, luteolin 
the only common flavonoid present.  It is not known at present whether luteolin will 
modulate the expression of Ald1a1, Gpi and Hsd17β2. In the kidney, however the 
expression of very few genes is simultaneously altered by the herbal teas which could 
be related to the presence of different metabolic and/or conjugated forms of the 
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polyphenols.  Of interest is the Cyclopia subternata affected more of the genes 
compared to C. genistoides and rooibos in both the liver and kidneys while it also 
significantly enhanced the total bilirubin serum levels. This coincided with a higher total 
polyphenol intake when compared to C. genistoides although it was significantly lower 
than the rooibos polyphenol intake. It would appear that specific or different 
combinations of polyphenols and/or non-polyphenolic constituents and their respective 
metabolites could be involved in the differential expression of the xenobiotic 
metabolising enzymes in the body.  
 
The current investigation indicated herbal teas differentially altered the gene expression 
of xenobiotic metabolising enzymes in the liver and kidneys of male Fischer rats, 
suggesting that rooibos and honeybush herbal teas can restrain and/or enhance the 
metabolism of both foreign and endogenous compounds. Investigation of the effect of 
rooibos and Cyclopia spp. polyphenols on the protein expression levels of the altered 
genes and enzyme interactions may provide insight into the downstream effects.   
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CHAPTER 4 
 
Validation of the rat primary hepatocyte model to predict in vivo 
effects of polyphenol-enriched herbal tea extracts and the major 
polyphenols, aspalathin and mangiferin, on the gene expression of 
selected xenobiotic metabolising enzymes 
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ABSTRACT 
 
In vivo studies are often expensive and labour intensive, therefore scientists are 
exploring other methods that can mimic the effects observed in vivo. The current study 
investigated whether or not rat primary hepatocytes may serve as a tool to predict the 
effects of polyphenol-enriched extracts on the gene expression of xenobiotic 
metabolising enzymes in the liver. Isolated rat primary hepatocytes were exposed to 
non-toxic concentrations of extracts of aspalathin-enriched rooibos and mangiferin-
enriched C. subternata and C. genistoides, and their major polyphenolic constituents, 
aspalathin and mangiferin, respectively for 24 hours. The gene expression of selected 
xenobiotic metabolising enzymes were analysed by quantitative real-time PCR.  
Cyclopia subternata significantly (P≤0.05) down-regulated the Comt gene with 
mangiferin down-regulating both Comt and the Hsd17β2 genes. Aspalathin up-regulated 
the Comt and marginally (P<0.1) the Cyp2e1 genes, and down-regulated the Hsd17β2 
gene. Cyclopia genistoides markedly decreased the expression of all three genes while 
rooibos slightly reduced the expression of Comt. However, the changes were not 
statistically significant. The results differ from the in vivo study in that the Comt gene 
was affected by C. subternata while the other herbal teas markedly reduced the gene 
expression of Cyp2e1 and Hsd17β2. Primary hepatocytes seems to be an appropriate 
model to mimic changes in the expression of Hsd17β2 gene by the herbal teas with 
aspalathin and mangiferin to be the likely candidates to play a role.  However, 
differences exist depending on the specific gene under study when considering the 
effect of a pure polyphenol and the complex enriched polyphenol extracts.  Additional 
studies, investigating the effect of different doses of the herbal teas, combination of 
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different polyphenolic constituents and a longer exposure period is recommended to 
further validate the in vitro rat primary hepatocytes as a model to predict changes 
observed in vivo. 
 
Keywords:  Aspalathin, mangiferin, rat primary hepatocytes, xenobiotic metabolising 
enzymes. 
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INTRODUCTION 
Living organisms, with their extremely complex functional systems and cell interactions, 
are difficult to study in vivo. Thousands of genes, protein molecules, nucleic acids and 
other components are spatially organised by membranes or organ systems, which 
creates a barrier for the identification of individual components and the exploration of 
their basic biological functions. In vitro studies allow scientists to overcome these 
barriers by isolating components from their biological context to permit a more detailed 
and convenient applicable analyses that could otherwise not have been conducted 
utilising the whole organisms (Chenery et al., 1987; Le Bigot et al., 1987; O’Brien et al., 
2004). 
 
Seventy to  80% of the liver’s mass consist of hepatocytes that are involved in various 
biological processes such as protein synthesis and storage, transformation of 
carbohydrates, synthesis of cholesterol, bile salts and phospholipids, but of more 
importance is its role in the detoxification, modification and excretion of exogenous 
(xenobiotic) substances (Orzechowski et al., 1995; Bort et al., 1999). Intestinal venous 
blood and xenobiotics drained into the liver are detoxified by enzymes to maintain 
homeostasis and to protect the organism against the adverse effects of ingested toxins. 
The xenobiotic metabolising enzymes modify the xenobiotics in order to facilitate their 
excretion by either adding or unveiling a polar functional group. Primary rat hepatocytes 
retain the activity of the majority of these xenobiotic metabolising enzymes and 
therefore provide an excellent model to investigate xenobiotic metabolism in vitro 
(Paillard et al., 1999).  
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In the previous chapter, an in vivo study indicated that polyphenol-enriched extracts of 
rooibos and two honeybush species, C. subternata and C. genistoides, altered the gene 
expression of several xenobiotic metabolising enzymes in the liver and kidneys of male 
Fischer 344 rats after exposure for 28 days.  The current study investigated the effect of 
the same polyphenol-enriched extracts, as well as the major polyphenol constituents of 
rooibos and honeybush, aspalathin and mangiferin, respectively on the gene expression 
of selected genes coding for xenobiotic metabolising enzymes in rat primary 
hepatocytes. The genes selected were based on the findings that the three herbal tea 
extracts significantly down-regulated the hydroxysteroid dehydrogenase (Hsd17β2) 
gene, but did not significantly alter the cathechol-O-methyltransferase (Comt) gene 
while the cytochrome P450 (Cyp2e1) gene was only slightly but significantly up-
regulated by C. subternata. A comparison of the results to that obtained in vivo will be 
conducted to validate whether the in vitro findings, utilising the rat primary hepatocyte 
model, can be extrapolated to the effects observed in vivo.  
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MATERIALS AND METHODS 
 
 
Chemicals 
 
Aspalathin-enriched green rooibos (18.7% aspalathin), mangiferin-enriched green C. 
subternata (3.8% mangiferin) and C. genistoides (9.3% mangiferin) extracts were 
supplied by the RAPS Foundation (Germany). Aspalathin was purified from 
unfermented rooibos at the PROMEC Unit of the Medical Research Council, Tygerberg, 
South Africa to a purity of >95% and mangiferin was obtained from Sigma-Aldrich (Cape 
Town, South Africa). 
 
The Williams’ E medium (WE), Hanks buffer salt solution (HBSS), 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), rat tail collagen type 1, collagenase type 4, 
insulin, sodium-pyruvic acid, L-glutamine, L-proline, ethylene glycol tetraacetic acid 
(EGTA), dimethyl-sulfoxide (DMSO) and Eagle’s minimal essential medium (EMEM) 
were purchased from Sigma-Aldrich (Cape Town, South Africa) as was the molecular 
biology grade β-mercaptoethanol (β-ME). Fetal bovine serum (FBS) was obtained from 
Invitrogen (Carlsbad, CA). Penicillin, streptomycin, fungizone (Amphotericin B), trypan 
blue and MEM non-essential amino acid solution were obtained from 
BioWhittaker/Lonza (Switzerland). Analytical grade methanol, ethanol and hydrochloric 
acid, were purchased from Merck Chemicals (Johannesburg, South Africa).   
 
Chemical analysis of herbal tea samples  
The determination of the total and individual polyphenol content of the enriched herbal 
tea extracts, by HPLC is described in Chapter 3.  
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Animals 
The study was approved by the Ethics Committee for Research on Animals (ECRA) of 
the Medical Research Council (MRC). Male Fischer 344 rats, 7-8 weeks old and 
weighing between 150-200g, were obtained from the Primate Unit of the Medical 
Research Council of South Africa. The animals were housed in stainless steel wire-
bottomed cages in a room illumination of 12 hr photoperiods at 50% humidity and a 
constant room temperature of 24-25°C. Rats had free access to food (Epol Ltd, South 
Africa) and water. Prior to termination, rats were anaesthetised by injecting 0.22 mg per 
100g body weight sodium pentobarbital intraperitoneally.   
 
Preparation of rat primary hepatocyte cultures 
 
Primary hepatocytes were isolated from male Fischer 344 rats according to the 
collagenase perfusion technique as described by Hayes et al. (1984) (See addendum III 
for detailed protocol). Briefly, in a sterile environment, the abdomen of the rat was 
opened through a midline incision and the liver was exposed after dissecting the 
surrounding structures.  A cannula was then placed in the portal vein and the liver was 
perfused with 10% HBSS (containing 1 % EGTA) at 37°C, at a flow rate of 15 ml per 
minute for 10 min. Subsequently, a collagenase solution (37°C) was circulated through 
the liver at a flow rate of 4-5 ml/min for approximately 13 min. The liver was removed 
and placed into a petri dish filled with collagenase solution. Modified WE medium, 
containing 10% FBS was immediately added to inactivate the enzyme. The liver capsule 
was removed and the cells were harvested in the medium. The resulting cell suspension 
was filtered through a sterile single layer cheesecloth and washed with WE containing 
10% FBS at 450 rpm for 10 minutes. After removing the supernatant, WE containing 
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10% FBS was added to the pellet and the cell suspension filtered through double 
layered cheesecloth. Prior to plating, the percentage cell viability was determined using 
trypan blue stain and a haemocytometer. Only isolates yielding a viability of 80% and 
greater were used for future experiments. Cells were plated at a density of 3×106 viable 
cells in collagen-coated culture dishes (60 mm) for RNA extractions or 2×104 viable 
cells in collagen-coated 96-well opaque-walled plates for cell viability assays and 
incubated in WE medium containing 10% FBS, insulin (20 U/L), L- glutamine (2 mM), 
HEPES (10 mM), penicillin (100 U/ml) and streptomycin (100 µg/ml) for 3 hrs at 37°C to 
allow cell attachment. The cells were then washed twice with HBSS and supplemented 
with modified WE medium (200 µl in 96-well plates or 2 ml in 60 mm plates) containing 
0.5% FBS, L- proline (2 mM) and sodium pyruvate (10 mM), in addition to the other 
components described above, and incubated for 24 hrs at 37°C in air/carbon dioxide 
(95:5). 
 
Cell viability assay to determine IC50’s 
 DMSO solubility of herbal tea extracts, aspalathin and mangiferin  
 
The herbal tea extracts and polyphenols were first dissolved in 10% and 100% DMSO, 
respectively (Table 1), to yield a stock solution, and then diluted in culture medium 
(modified WE) to create a 1% DMSO concentration in each dilution to be  used in the 
cell culture studies. 
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Table 1 Solubility of herbal tea extracts, aspalathin and mangiferin in various 
concentrations of DMSO. 
Extract/ compound DMSO percentiles 
Pure/ 
100% 
10% 5% 1% 0.5% 
Rooibos N.A Soluble Soluble Insoluble Insoluble 
C. genistoides N.A Soluble Soluble Insoluble Insoluble 
C. subternata N.A Soluble Soluble Insoluble Insoluble 
Aspalathin 
(dihydrochalcone) 
Soluble Insoluble Insoluble Insoluble Insoluble 
 
     
Mangiferin 
(xanthone) 
Soluble Insoluble Insoluble Insoluble Insoluble 
N.A (not applicable) indicates that it has not been analysed. 
 
Treatment with extracts, aspalathin and mangiferin  
Following incubation of the hepatocytes, the medium was removed and the cells 
washed with HBSS. Different concentrations of the polyphenol-enriched extracts or 
polyphenol (100 µl) was added to the respective wells and the 96-well opaque-walled 
microtitre plate incubated for 24 hrs at 37°C in air/carbon dioxide (95:5). The dilutions 
used for the rooibos extracts were 0.2, 0.1, 0.05, 0.025 mg/ml and 2.0, 1.5, 1.0, 0.5 
mg/ml for C. subternata and C. genistoides. Different dilutions for aspalathin (2.0, 1.25, 
0.63, 0.31, 0.16 µM) and mangiferin (1.25, 1.00, 0.63, 0.31 µM) were prepared in 
DMSO (1%).  A 1% DMSO solution in culture medium was used as a control sample.  
 
Cell viability assay 
The number of viable cells was determined based on the assessment of ATP production 
as a measure of metabolically active cells, using the CellTitre-Glo® assay (Promega, 
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Wisconsin, USA). The plates and the assay kit components were kept at room 
temperature prior to performing the assay. The assay was conducted at room 
temperature according to the manufacturer’s protocol. Briefly, the CellTitre-Glo® 
reagent (100 µl) was added to each well containing the test compounds and controls 
and the contents mixed on a shaker for 2 min and incubated for 10 min. The 
luminescence was recorded using a VeritasTM Microplate Luminometer (Promega, 
Wisconsin, USA). The percentage ATP inhibition was determined and the respective 
IC50 values (concentration of test compound required to inhibit 50% ATP production in 
the cell) were calculated using the PRISM® 5 programme. The assay was repeated five 
times to obtain an average IC50 value for each extract and/or pure compound. 
 
Gene expression experiments 
Incubation conditions 
Cells in the 60 mm culture dishes were exposed to IC50 levels (Table 3) and at non-toxic 
levels (≥80% viability) of rooibos (0.025 mg/ml), C. genistoides (0.5 mg/ml), C. 
subternata (0.5 mg/ml), aspalathin (0.31 µM) and mangiferin (1.25 µM) for 24 hrs at 
37°C in air/carbon dioxide (95:5). Each treatment and control were repeated four times 
in a total volume of 2 ml per tissue culture dish 
 
Cell disruption 
The hepatocyte cultures were washed with ice cold phosphate buffered saline (pH=7.4), 
scraped in RLT buffer* (350 µl/dish), containing guanidine isothiocyanate and β-
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mercaptoethanol, pooled (total of 4 dishes) into clean nuclease-free tubes and then 
disrupted in liquid nitrogen.  
*The description, concentration and pH of the buffer are not defined in the RNA extraction kit 
user manual.  
 
 
Total RNA isolation, quality assessment and reverse transcription   
Total RNA was isolated from the hepatocyte cultures, the quality was assessed and the 
RNA was reversed transcribed into cDNA, as previously described in Chapter 3.  
 
Primer design and optimisation 
The gene expression of three xenobiotic metabolising genes were analysed by qRT-
PCR. The hypoxanthine guanine phosphoribosyltrasferase (Hprt1) gene was used as 
an endogenous control. Gene- specific qPCR primers (Table 2) were designed using 
the Primer Express® software v2.5 (Applied biosystems, South Africa) and synthesized 
by Integrated DNA technologies (IDT, Whitehead scientific, South Africa).  
 
Table 2 Primer sequences of selected genes for qPCR analyses. 
Gene Genebank Sense Antisense 
5’→3’ 5’→3’ 
Hsd17β2 NM_024391 CGCAGAGAAGATACAAGACAA
AGG 
AAAGTGCAAGACCCCAGCA
T 
Comt NM_012531 CCATGGAGATGAACCCTGACT
AC 
TAGGCCTGCAAAGTTCAGC
ATT 
Cyp2e1 NM_031543 TTGGCCGACCTGTTCTTTG TTTCTGGGTATTTCATGAG
GATCA 
Hprt1 NM_012583 TCAAGCAGTACAGCCCCAAAA
T 
CAACACTTCGAGAGGTCCT
TTTC 
 
Hsd17β2- 17β-Hydroxysteroid dehydrogenase 2, Comt- Catechol-O-methyltransferase, Cyp2e1- 
Cytochrome P450 2e1, Hprt- Hypoxanthine guanine phosphoribosyl transferase. 
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Quantitative real-time PCR (qPCR)  
The qPCR and statistical analyses are described in Chapter 3. 
 
RESULTS  
Dose response effects 
Herbal tea extracts 
Typical dose response effects were observed on cell viability for each of the herbal tea 
extracts (Figure 1).  Compared to the rooibos extract, up to ten times the concentration 
of the honeybush extracts was needed for obtaining dose response effects.  
 
Comparative effects of Cyclopia extracts 
A comparison of the dose response effects of the Cyclopia extracts revealed that C. 
subternata inhibited ATP production at a significantly lower concentration than C. 
genistoides (Figure 2). 
 
Individual polyphenols 
Typical dose response effects were observed for aspalathin, whereas the dose 
response for mangiferin could not be obtained at the concentrations used. This was due 
to insolubility of mangiferin in the cell culture medium at higher concentrations (Figure 
3).  
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IC50 value of extracts, aspalathin and mangiferin 
The IC50 for cytotoxicity for rooibos was significantly (P<0.05) lower when compared to 
that of the honeybush herbal teas (Table 3). Of the honeybush herbal teas C. 
subternata exhibited a higher cytotoxic effect despite the fact that the TP content was 
lower. Aspalathin exhbited an IC50 of 1.91 µM while no value could be obtained for 
mangiferin due to its insolubility at high concentrations. 
Table 3 Concentration of rooibos, C. genistoides, C. subternata, aspalathin and 
mangiferin required to inhibit 50% ATP production in rat primary hepatocytes. 
Extract IC50 TP equivalents 
A. linearis 0.12 ± 0.01mg/mla 47.1 
C. genistoides 1.52± 0.17mg/mlb 332.6 
C. subternata 1.12 ± 0.09mg/mlc 278.1 
Pure polyphenols   
Aspalathin 1.91 ± 0.05µM  
Mangiferin >1.25 µM*   
Means ± std of two experiments.  Means followed by the same letter do not differ significantly, if letter 
differs then P<0.05). *Insoluble at higher concentrations.TP- total polyphenols. IC50 - inhibition of 50% of 
ATP production. 
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Figure 1 Dose response effects of A. linearis, C. genistoides and C. subternata on 
ATP production in rat primary hepatocytes. Values are means ± Std 
(values in parenthesis) of at least two experiments. Different symbols on 
the bars indicate significant differences (P≤0.05). 
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Figure 2 Comparison of the dose response effects of Cyclopia spp. on ATP 
production in rat primary hepatocytes. Values are means ± Std (values in 
parenthesis) of at least two experiments. *indicate significant difference 
(P≤0.05). 
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Figure 3 Dose response effects of aspalathin and mangiferin on ATP production in 
rat primary hepatocytes. Values are means ± Std (values in parenthesis) 
of at least two experiments. Different symbols on the bars indicate 
significant differences (P≤0.05). 
 
 
 
Concentration of TPP and monomeric flavonoids utilised for gene expression 
analyses 
 
Rooibos  herbal tea (A. linearis) 
The dihydrochalcone aspalathin was the major flavonoid in the rooibos extract that was 
added to the hepatocytes followed by rutin+Isoquercitrin+Quercetin-3-robinobioside, 
nothofagin, isoorientin and orientin (Table 4). Only small amounts of vitexin, isovitexin, 
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hyperoside, luteolin-7-glucoside, luteolin, chrysoeriol were recorded as well as traces of 
quercetin.  The TPP level of rooibos used was similar to that of C. genistoides.  
 
Honeybush herbal teas (Cyclopia spp.) 
Of the honeybush polyphenolic constituents added to the hepatocytes, the xanthones 
mangiferin and isomangiferin were found to be the most abundant (Table 4). Cyclopia 
genistoides had a higher xanthone content, whereas C. subternata contained a higher 
flavanone content due to the presence of eriocitrin.  The level of hesperidin, naringenin 
and eriodictyol and the flavone, luteolin were similar while scolymoside was higher in C. 
subternata (Table 4).  When considering the TP content, the hepatocytes were exposed 
to a higher level when using the C. subternata extract. 
 
Gene expression analysis by qRT-PCR 
Athough test samples at IC50 level were initially included in the experiment, it generated 
too little RNA due to the low number of the cells resulted from cytotoxic effects, and 
therefore only the results of the non-toxic levels are reported.  
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Table 4 Monomeric rooibos and honeybush polyphenolic constituents of the 
enriched extracts exposed to the cells in the culture dishes. 
Aspalathus linearis (Rooibos) 
 
Polyphenol  
content 
 
Compound 
 
µg/0.025 mg extract* 
TP - 98.1 
 
Dihydrochalcone 
 
Aspalathin 
 
4.70 
 Nothofagin 0.36 
Flavone C-
glycoside 
Isoorientin 
Orientin 
0.36 
0.20 
 Vitexin 0.075 
 Isovitexin 
 
0.098 
Flavonol Rutin+Isoquercitrin+Quercetin-
3-robinobioside 
0.53 
 Quercetin Traces 
 Hyperoside 0.073 
Flavone Luteolin 0.02 
 Chrysoeriol 0.005 
 Luteolin-7-glucoside 0.01 
Cyclopia spp. (Honeybush) 
 
Polyphenol  
content 
 
Compound 
C. genistoides 
µg/0.5 mg 
extract* 
C. subternata 
µg/0.5 mg extract* 
TP 
 
- 109.4 124.2 
Xanthones Mangiferin 46.5 19.0 
 Isomangiferin 16.5  6.5 
Flavanones Hesperidin 4.15 4.95  
 Eriocitrin nd 5.50 
 Naringenin 0.05 0.05 
 Eriodictyol-glucoside 0.15 1.15 
Flavone Luteolin 0.45 0.3 
 Scolymoside nd 6.45 
The data represents the amount of monomeric polyphenols exposed to cells in the culture dish and is 
based on the HPLC data summarised in Chapter 3, Table 2. nd- not detected. *concentration of extract 
associated with ≥80% cell viability after 24 hrs. TP – total polyphenols. 
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Rooibos and C. genistoides did not significantly alter the gene expression of the 
analysed genes, while C. subternata significantly down-regulated the Comt gene, (Table 
5).  However, rooibos markedly reduced the expression of COMT, while C. genistoides 
reduced the expression of Hsd17β2 and Cyp2e1, although changes were not 
significant.  Aspalathin significantly (P≤0.05) increased the expression of Comt and 
down-regulated the HSD17β2 gene while mangiferin down-regulated both the Comt and 
Hsd17β2 genes by 50%.  Aspalathin also marginally increased the expression of 
Cyp2e1. 
 
Table 5 Gene expression induction/inhibition of xenobiotic metabolising enzymes 
after exposure to various test samples at non-toxic levels. 
Treatment Comt Hsd17β2 Cyp2e1 
 Fold P value Fold P value Fold P value 
A. linearis 0.83 0.15 1.18 0.62 1.10 0.21 
C. genistoides 0.67 0.36 0.64 0.64 0.77 0.52 
C. subternata 0.76 0.05 0.77 0.46 0.83 0.39 
Aspalathin 2.05 0.04 0.68 0.05 1.65 0.07 
Mangiferin 0.55 0.002 0.54 0.05 0.98 0.15 
Data normalised against the Hprt1 reference gene. Control (untreated) group set as fold=1. Comt= 
catechol-o-methyltransferase, Cyp2e1= cytochrome P450 2e1, Hsd17β2= 17-beta hydroxysteroid 
dehydrogenase type 2. Shaded areas – significant changes (P≤0.05); Lightly shaded areas – marginal 
(P<0.1)/marked reduction. Concentration of herbal tea extract per culture dish:  A linearis (0.25 mg/ml) 
Cyclopia spp (0.5 mg/ml); Aspalathin (0.31 µM) and mangiferin (125 µM).    
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DISCUSSION 
The liver plays an essential role in the biotransformation of endogenous molecules as 
well as xenobiotics, including pharmaceutical drugs, plant polyphenols and 
procarcinogens (Pineiro-Carrero and Pineiro, 2004). Since metabolic enzymes occur in 
abundance in the liver, it is the primary organ used in pharmacological and toxicological 
studies (Wilkening et al., 2003). Although in vivo models provide a fairly accurate 
indication of the effects of chemical compounds on a whole animal, experiments are 
usually time- consuming, labour intensive and expensive. In vitro cell models are 
therefore employed not only to minimise cost and time, but also to elucidate specific 
mechanisms of action. Because of the predominance of hepatocytes, in terms of 
abundance and functional contribution to the liver, primary hepatocyte cultures, have 
been utilised as a prominent tool for in vitro studies (Brandon et al., 2003). It is a well-
known model for investigating drug metabolism, induction of drug metabolising enzymes 
and cytotoxicity studies of chemicals (Wang et al., 2002). Both cultured hepatocytes and 
suspensions of primary hepatocytes have been repeatedly proven to be powerful tools 
to analyse the specific metabolic profile of a variety of drugs with good in vitro-in vivo 
correlations (Le Bigot et al., 1987; Chenery et al., 1987; Berry et al., 1992; Cross et al., 
1995; Bayliss et al., 1999; O’Brien et al., 2004). The disadvantages of using primary 
hepatocytes are, however, that proliferation does not occur, cells only remain viable for 
up to 4 weeks in culture (Brandon et al., 2003; Wilkening et al., 2003) and they are 
subjected to a gradual loss of liver-specific functions, with special reference to a 
decreased cytochrome P450 expression (George et al., 1997).  It also lacks non-
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hepatocyte cells such as Kupffer cells that may be necessary for cofactor supply 
(Brandon et al., 2003). 
The current study used rat primary hepatocytes as an in vitro cell model to investigate 
differences in the gene expression of three selected xenobiotic metabolising enzymes in 
rat liver by exposing the cells to polyphenol-enriched extracts rooibos and honeybush 
and their major polyphenols, aspalathin and mangiferin, respectively. Although the Comt 
gene, whose enzyme is known to metabolise tea polyphenols having a catechol moiety, 
was not significantly affected by the herbal tea extracts in the in vivo study, it was  
significantly down-regulated by C. subternata and mangiferin, and up-regulated by 
aspalathin in the primary hepatocytes. Studies reported that catechol-containing tea 
polyphenols are rapidly O-methylated by the COMT enzyme (Morand et al., 1998; Zhu 
et al., 1994) and other studies suggest that the biological action of tea polyphenols may 
be attributed to its methylated products (Zhu et al., 2000; Huffman et al., 2003). 
Polyphenols also inhibits COMT-mediated O-methylation of catechol estrogens (Zhu et 
al., 2009), due to its higher affinity for the enzyme (Manach et al., 2004). Polyphenols 
are known to mimic the effects of catechol estrogens by competing for the estrogen 
receptor β binding sites (Mfenyana et al., 2008; Martin et al., 1996; Loukovaara et al., 
1995; Makela et al., 1995; Keung, 1995; Hu et al., 2010).  
 
Hsd17β2, the gene that codes the enzyme responsible for the catabolism of 
testosterone and the anabolism of estradiol (E2), was significantly down-regulated by all 
three herbal tea extracts in the in vivo study.  In primary hepatocytes aspalathin and 
mangiferin significantly down-regulated the gene, while both the honeybush herbal teas 
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markedly reduced the level of expression. The Cyp2e1 gene was not significantly 
altered by the herbal tea extracts although the expression was markedly reduced by 
both Cyclopia spp. This also contradicts the in vivo findings where C. subternata 
significantly up-regulated the gene by 1.23 fold. In the current study aspalathin 
significant up-regulated the expression of Cyp2e1 while no effect was noticed with the 
rooibos extract.   
 
This study showed a good in vitro and in vivo comparison with respect to the Hsd17β2 
gene, however the Comt and Cyp2e1 genes did not correspond with the in vivo findings. 
Therefore, caution should be observed when using rat primary hepatocytes to validate 
genes in vivo. When conducting in vitro studies for toxicity or metabolism evaluation, 
especially when using primary hepatocytes, it should be noted that the concentration of 
the extracts/pure compound used are relatively low and exposure occur over a far 
shorter period of time than what would normally occur in in vivo studies. An example of 
this is that, in the previous in vivo study (Chapter 3), animals were exposed to a rooibos 
extract containing 36 mg aspalathin per 100 g rat bodyweight per day for 28 days, while 
in the present in vitro study, cells (3×106) were exposed to the rooibos extract (0.025 
mg/ml), containing 4.7 µg aspalathin, for 24 hours.  The in vivo exposure to rooibos TP 
was significantly higher when compared to the honeybush herbal teas. In the primary 
hepatocyte model, however, the TP exposure to the cells using the rooibos and 
honeybush extracts were similar, except for C. subternata which was slightly higher. 
Therefore, cognisance of the different exposure regimens has to be taken when 
comparing the effect on the gene expression between the two models.  This could 
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explain why differences were observed in the expression of the xenobiotics 
metabolising genes between the in vivo and in vitro models.  
Additionally, in vivo effects could be due to metabolic conjugates, formed during 
metabolism in other organ systems such as the intestines, rather than the parent 
polyphenol (Kroon et al., 2004). It is imperative to note that polyphenols are 
substantially modified during first-pass metabolism and are therefore molecularly 
different from those present in foods, when reaching the target tissues (Day et al., 2001; 
Day and Williamson, 2001; Graefe et al., 2001; Natsume et al., 2003; Setchell et al., 
2003; Zhang et al., 2003). The resulting metabolites formed in the intestines are 
typically glucuronate and sulfate conjugates, with or without methylation across the 
catechol functional group (Kroon et al., 2004). The hepatocytes are exposed to the 
conjugates via the blood in the hepatic portal vein and may further metabolise them via 
phase II metabolism. The conjugates are chemically distinct from their parent 
compounds, differing in size, polarity, and ionic form. Consequently, their physiological 
behaviour is likely to be different. In contrast, when conducting in vitro studies, the 
cultured hepatocytes are exposed to polyphenols that have not been subjected to 
metabolism.  In vivo effects of polyphenols could therefore be masked when conducting 
in vitro studies to predict in vivo scenarios. It is thus necessary to identify their 
metabolites and test their own biological activity (Scalbert et al., 2002).  
 
Another explanation for the variation in in vivo and in vitro effects is that differences 
exist when cells are exposed to a single substance and/or polyphenol or towards a 
complex mixture containing polyphenolic and non-polyphenolic constituents as was 
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conducted in the current experiment. When considering aspalathin, the hepatocyte 
cultures were exposed to 0.28 µg (0.31 µM) of the pure dihydrochalcone while a 16 fold 
higher level was achieved when using the polyphenol-enriched rooibos extract.  A 
similar effect was noticed with mangiferin (1.06 µg) where a 20 to 40 fold higher 
concentration was achieved when using the enriched extracts of C. subternata (19.0 µg) 
and C. genistoides (46.5 µg), respectively.  It would appear that the effects in primary 
hepatocytes of the pure polyphenols were masked when utilising the polyphenol-
enriched extracts. In this regard it was shown that when utilising a rat uterotrophic assay 
individual estrogens gave an opposite effect as compared to when tested as a mixture 
(Tinwell and Ashby, 2004). However, additive effects of single and combinations of 
compounds could also occur depending on the specific model used. In caco-2 colon cell 
monolayers, individual polyphenols increased the apical transport of a pro carcinogen 
while a complex mixture of different polyphenols increased the absorption (Schutte et 
al., 2008). In the current study both aspalathin and mangiferin significantly down-
regulated the expression of Hsd17β2 in primary hepatocytes while only marked effects 
were noticed with the polyphenol-enriched extracts.  It could be argued that different 
polyphenols may have opposite effects on the expression of the gene in vitro while 
other parameters, such as bioavailability and metabolism could modulate the effect of 
the herbal teas on the expression of the gene differently. It would therefore be of 
interest to monitor the effect of aspalathin on the expression of Hsd17β2 in vivo.   
However, the current study implies that both aspalathin and mangiferin may play an 
important role in the down-regulation of steroid catabolism in vivo which should be 
further investigated.   
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CONCLUSIONS 
Differences as well as similarities were observed between the in vivo and in vitro 
studies. This could be due to variation in the period of exposure, which was longer in 
the former (28 days) than the latter (exposure of only 24 hours), as well as first-pass 
metabolism of polyphenols before it reached the hepatocytes. Additional studies should 
be employed to investigate other genes, relevant polyphenol conjugates, duration and 
doses of exposure before primary hepatocytes can be used as a substitute for in vivo 
studies, with reference to xenobiotic metabolism.  Differences also exist when using 
pure polyphenols as compared to enriched extracts containing high levels of the 
respective polyphenols.  However, the change in the expression of Hsd17β2 by the 
herbal teas is consistent under the current experimental conditions and primary 
hepatocytes can be utilised to investigate this aspect in more detail on a protein level. 
 
 
 
 
 
149 
 
REFERENCES 
 
Bayliss M.K, Bell J.A, Jenner W.N, Park G.R, Wilson K. Utility of hepatocytes to model 
species in the metabolism of loxtidine and to predict pharmacokinetic parameters in rat, 
dog and man, Xenobiotica, 1999; 29, 253-268. 
 
Berry M.N, Halls H.J, Grivell M.B. Techniques for pharmacological and toxicological 
studies with isolated hepatocyte suspensions, Life Sci, 1992; 51, 1-16. 
Bort R, Ponsoda X, Jover R, Gómez-Lechón M.J, Castell J.V. Diclofenac toxicity to 
hepatocytes: A role for drug metabolism in cell toxicity, J Pharmacol Exp Ther, 1999; 
288, 65–72. 
Brandon E.F.A, Raap C.D, Meijerman I, Beijnen J.H, Schellens J.H.M. An update on in 
vitro test methods in human hepatic drug biotransformation research: pros and cons, 
Toxicol Appl Pharmacol, 2003; 189, 233-246.   
 
Chenery R.J, Ayrton A, Oldham H.G, Standring P, Norman S.J, Seddon T, Kirby R. 
Diazepam metabolism in cultured hepatocytes from rat, rabbit, dog, guinea pig, and 
man, Drug Metab Disp, 1987; 15, 312-317.  
 
Cross D.M, Bell J.A, Wilson K. Kinetics of ranitidine metabolism in dog and rat isolated 
hepatocytes, Xenobiotica, 1995; 25, 367-375. 
 
Day A.J, Mellon F. A, Barron D, Sarrazin G, Morgan M.R, Williamson G. Human 
metabolism of flavonoids: identification of plasma metabolites of quercetin, Free Radic 
Res, 2001; 35, 941-952. 
 
Day A.J, Williamson G. Biomarkers of exposure to dietary flavonoids a review of the 
current evidence for identification of quercetin glycosides in plasma, Br J Nutr, 2001; 
86, 105-110.  
 
 
 
 
 
150 
 
George J, Goodwin B, Liddle C, Tapner M, Farrel G.C. Time-dependent expression of 
cytochrome P450 genes in primary cultures of well-differentiated human hepatocytes, J 
Lab Clin Med, 1997; 129, 638-648. 
 
Graefe E.U, Wittig J, Mueller S, Riethling A.K, Uehleke B, Drewelow B, Pforte H, 
Jacobasch G, Derendorf H, Veit M. Pharmacokinetics and bioavailability of quercetin 
glycosides in humans, J Clin Pharmacol, 2001; 41, 492-499. 
 
Hu G.X, Zhao B.H, Chu Y.H, Zhou H.Y, Akingbemi B.T, Zheng Z.Q, Ge R.S. Effects of 
genistein and equol on human and rat testicular 3β-hydroxysteroid dehydrogenase and 
17β-hydroxysteroid dehydrogenase 3 activities, Asian J Androl, 2010; 12, 519-526.  
 
Huffman M.A. Animal self-medication and ethno-medicine: exploration and exploitation 
of the medicinal properties of plants, Proc Nutr Soc, 2003; 62, 371-81. 
 
 
Keung W.M. Dietary estrogenic isoflavones are potent inhibitors of β-hydroxysteroid 
dehydrogenase of P. testosteronii, Biochem Biophys Res Commun, 1995; 215, 1137-
1144. 
 
Kroon P.A, Clifford M.N, Crozier A, Day A.J, Donovan J.L, Manach C. How should we 
assess the effects of exposure to dietary polyphenols in vitro?, Am J Clin Nutr, 2004; 
80, 15-21. 
 
Le Bigot J.F, Begue J.M, Kiechel J.R, Guillouzo A. Species differences in metabolism of 
ketotifen in rat, rabbit and man: demonstration of similar pathways in vivo and in 
cultured hepatocytes, Life Sci, 1987; 40, 883-890. 
 
Loukovaara M, Carson M, Palotie A, Adlercreutz H. Regulation of sex hormone-binding 
globulin production by isoflavonoids and patterns of isoflavonoid conjugation in HepG2 
cell cultures, Steroids, 1995; 60, 656-661. 
 
 
 
 
 
151 
 
Makela  S, Poutanen M, Lehtimaki J, Kostian M.L, Santii R, Vihko R. Estrogen-specific 
17 β-hydroxysteroid oxidoreductase type 1 (E.C. 1.1.1.62) as a possible target for the 
action of phytoestrogens, Proc Soc Exper Biol Med, 1995; 208, 51-59. 
 
Manach C, Scalbert A, Morand C, Rémésy C, Jiménez L. Polyphenols: food sources 
and bioavailabiliy, Am J Clin Nutr, 2004; 79, 727-747. 
 
Martin M.E, Haourigui M, Pelissero C, Benassayag C, Nunez E.A. Interactions between 
phytoestrogens and human sex steroid binding protein, Life Sci, 1996; 58, 429-436. 
 
Mfenyana C, DeBeer D, Joubert E, Louw A. Selective extraction of Cyclopia for 
enhanced in vitro phytoestrogenicity and benchmarking against commercial 
phytoestrogen extracts, J Steroid Biochem Mol Biol, 2008; 112, 74-86. 
 
Morand C, Crespy V, Manach C, Besson C, Demigné C, Rémésy C. Plasma 
metabolites of quercetin and their antioxidant properties, Amer J Physiol, 1998; 
275, 212-219. 
 
Natsume M, Osakabe N, Oyama M, Sasaki M, Baba S, Nakamura Y, Osawa T, Terao J. 
Structures of (-)-epicatechin glucuronide identified from plasma and urine after oral 
ingestion of (-)-epicatechin: differences between human and rat, Free Radic Biol Med, 
2003; 34, 840-849. 
 
O’Brien P.J, Chan K, Silber P.M. Human and animal hepatocytes in vitro with 
extrapolation in vivo, Chem Biol Interact, 2004; 150, 97-114.   
 
Orzechowski A, Schwarz L.R, Schwegler U, Boak W, Synder R, Schrenk D. Benzene 
metabolism in rodent hepatocytes: role of sulphate conjugation, Xenobiotica, 1995; 25, 
1093-1102. 
 
 
 
 
 
152 
 
Paillard F, Finot F, Mouche I, Prenez A, Vericat J.A. Use of primary cultures of rat 
hepatocytes to predict toxicity in the early development of new chemical entities, Toxicol 
In Vitro, 1999; 13, 693-700. 
 
Pineiro-Carrero V.M, Pineiro E.O. Liver, Pediatrics, 2004; 113, 1097-1106. 
 
Setchell K.D, Faughnan M, Avades T, Zimmer-Nechemias L, Brown NM, Wolfe BE, 
Brashear WT, Desai P, Oldfield MF, Botting NP, Cassidy A. Comparing the 
pharmacokinetics of daidzein and genistein with the use of 13C-labeled tracers in 
premenopausal women, Am J Clin Nutr, 2003; 77, 411-419. 
 
Scalbert A, Morand C, Manach C, Rémésy C, Absorption and metabolism of 
polyphenols in the gut and impact on health, Biomed Pharmacother, 2002; 56, 276-282. 
 
Schutte M.E, Boersma M.G, Verhallen D.A.M, Groten J.P, Rietjens I.M.C.M. Effects of 
flavonoid mixtures on the transport of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine 
(PhIP) through caco-2 monolayers: An in vitro and kinetic modelling approach to predict 
the combined effects on transporter inhibition, Food Chem Toxicol, 2008; 46, 557-566. 
 
Tinwell H, Ashby J. Sensitivity of the immature rat uterotrophic assay to mixtures of 
estrogens, Environ Health Pers, 2004; 112, 575-582. 
 
Wang C, Makela T, Hase T, Adlercreutz H, Kurzer M.S. Lignans and flavonoids inhibits 
aromatase enzyme in human preadipocytes, J Steroid Biochem Mol Biol, 1994; 50, 205-
212. 
 
Wilkening S, Stahl F, Bader A. Comparison of primary human hepatocytes and 
hepatoma cell line hepG2 with regard to their biotransformation properties, Drug Metab 
Disp, 2003; 31, 1035-1042. 
 
 
 
 
 
153 
 
Zhang Y, Hendrich S, Murphy P.A, Glucuronides are the main isoflavone metabolites in 
women, J Nutr, 2003; 133, 399-404. 
 
Zhu B.T, Ezell E.L, Liehr J.G. Catechol-O-methyltransferase-catalysed rapid O-
methylation of mutagenic flavonoids. Metabolic inactivation as a possible reason for 
their lack of carcinogenicity in vivo, J Biol Chem, 1994; 269, 292-299. 
 
Zhu B.T, Patel U.K, Cai M.X, Conney A.H. Metabolic O-methylation of tea polyphenols 
catalysed by human placental cytosolic catechol-O-methyltransferase, Drug Metab 
Disp, 2000; 28, 1024–1030. 
 
Zhu B.T, Wang P, Nagai M, Wen Y, Bai H.W. Inhibition of human catechol-O-
methyltransferase (COMT)-mediated O-methylation of catechol estrogens by major 
polyphenolic compounds present in coffee, J Steroid Biochem Mol Biol, 2009; 113, 65-
74.  
 
 
 
 
  
 
 
 
 
 
 
CHAPTER 5 
GENERAL DISCUSSION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
155 
 
The consumption of the herbal teas rooibos (Aspalathus linearis) and honeybush 
(Cyclopia spp.) is increasing worldwide (Snyman, 2000; De Villiers, 2004) due to 
the promotion of their health benefits by pharmaceutical and nutraceutical 
companies. These benefits include anecdotal evidence of alleviation of headaches, 
fever, asthma, insomnia, colic in infants and skin disorders (Morton, 1983; Joubert 
and Ferreira, 1996). It has also been shown to have anti-oxidant, anti-mutagenic 
and anti-cancer properties (Marnewick et al., 2000; Standley et al., 2001; Richards, 
2002). These herbal teas contain a complex mixture of polyphenolic compounds 
(Rabeet al., 1994; Ferreira et al., 1995; Ferreira et al., 1998; Marias et al., 1998; 
Marais et al., 2000; Kamara et al., 2003; Kamara et al., 2004; Shimamura et al., 
2006; Iswaldi et al., 2011), and have been utilised by the nutraceutical industry to 
formulate various combinations of polyphenol-enriched extracts in an attempt to 
explore their health benefits.  Most of the biological properties are attributed to the 
polyphenolic composition of the herbal teas. Studies have shown that polyphenols 
also interact with xenobiotic metabolising enzymes (Mandlekar et al., 2006; Murray, 
2006; Rodeiro et al., 2008; Sergent et al., 2009), causing it to enhance or inhibit the 
activity of certain pharmaceutical drugs. The potential risk associated with the 
chronic use of polyphenol-enriched extracts is not clearly understood and needs 
clarification.  
 
The present study was the first to investigate the effect of polyphenol-enriched 
extracts of green rooibos and honeybush (C. genistoides and C. subternata) on the 
gene expression of a battery (eighty four) of xenobiotic metabolising enzymes in 
male Fischer 344 rat liver and kidneys in vivo. In a subsequent study the 
modulation of certain phase I and II enzymes was validated in rat primary 
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hepatocytes utilising the same herbal tea extracts as well as the respective major 
polyphenolic constituents of rooibos and honeybush, aspalathin and mangiferin. 
The study was conducted to validate the use of the in vitro cell model to predict 
effects of the herbal tea in vivo and to further elucidate the underlying mechanisms 
regarding changes in gene expression of the xenobiotics metabolising enzymes. 
 
Xenobiotics can undergo three fates upon entering an organism, namely, 
metabolism by enzymes, spontaneous change into other substances under 
optimum pH conditions, or be excreted unchanged (Williams, 1972). Following 
ingestion, xenobiotics pass through the gastrointestinal tract to the liver where the 
majority of xenobiotic metabolism reactions are carried out by phase I and phase II 
enzymes in the hepatic cells (Gillette, 1966).  The conjugated xenobiotics are then 
excreted via urinary and/or biliary pathways. In the kidney, certain cells in the 
proximal convoluted tubuli express immunologically similar xenobiotic metabolising 
enzymes to hepatocytes (Lock and Reed, 1998; Lash et al., 2008) and are 
therefore capable of actively metabolising many drugs, hormones and other 
xenobiotics (Anders, 1980; Cummings et al., 2000). The conjugated metabolite can 
either be de-conjugated to its original form or it can be actively reabsorbed into the 
blood stream (Aleksunes et al., 2008; Klaassen and Lu, 2008) by retrograde 
transporters on the basolateral face of the plasma membrane, such as multidrug 
resistance-associated proteins. Uptake of chemicals across the basolateral 
membranes into the kidneys is mediated by secondary active transport systems 
such as P-glycoprotein, a protein product of the multidrug resistance proteins. The 
elucidation of renal excretory mechanisms is therefore important in understanding 
the pharmacologic efficacy and duration of action of xenobiotics (Grantham and 
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Chonko, 1991; Grundemann et al., 1994; Krishna and Klotz, 1994). Functional 
differences exist between the liver and kidneys with respect to their role in 
xenobiotic metabolism and excretion. 
 
Quantitative real time polymerase chain reaction (qRT-PCR) and qPCR array 
analysis showed that the polyphenol-enriched extracts of rooibos and honeybush 
differentially altered the gene expression of several genes in the liver and kidneys. 
In the present study, the up-regulation of the glucose phosphate isomerise (Gpi) 
gene by all three herbal teas in the liver indicates that the extracts may increase the 
energy demand in the cells, therefore the glycolytic gene is switched on to maintain 
homeostasis regarding ATP production. However, with respect to cancer 
development, this may enhance cancer cell survival and proliferation thereby 
promoting cancer progression. Normal cells exhibit metabolic flexibility and are 
capable of regulating their dependence on glycolysis relative to mitochondrial 
respiration. This allows cells to cope with the prevailing nutrient availability or 
energy demands (Gohil et al., 2010). Favouring anaerobic glycolytic metabolism 
appears to be a natural adaptation to reduced oxygen availability (Ramirez et al., 
2007). However, redirecting energy metabolism toward glycolysis can reduce 
oxidative damage and suppresses apoptosis (Jeong et al., 2004; Hunter et al., 
2007; Vaughn and Deshmukh, 2008). Many cancer cells therefore rely on 
glycolysis, which is known as the Warburg effect (Warburg, 1956), whereas normal 
cells utilise the oxidative phosphorylation in the tricarboxylic acid cycle in the 
mitochondria for the production of ATP (Kondoh, 2008; Denko, 2008; Ortega et al., 
2009; Buchakjian and Kornbluth, 2010; Cairns et al., 2011). Malignant cells 
increase their expression of glycolytic enzymes such as Gpi and hexokinase 2 
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(Hk2), and glucose uptake which leads to the production of ATP and synthesis of 
nucleic acids and lipids essential for cell survival and division (Kondoh, 2008; 
Buchakjian and Kornbluth, 2010; Cairns et al., 2011). 
 
The aspalathin-enriched rooibos extract suppressed the expression of the Abcb1 
gene, while the two mangiferin-enriched Cyclopia extracts down-regulated the Hk2 
gene in the kidneys. Cancer cells are known to increase the expression of ATP-
dependent efflux pumps, the ATP-binding cassette (ABC) transporters including P-
glycoprotein (ABCB1), which attributes to its drug resistance (Dean, 2009; Allen et 
al., 2000). Therefore, ABC transporters are widely considered to be one of the most 
critical targets in the treatment of cancers, especially those with drug resistance. 
Inhibition of glycolysis is able to inactivate all types of ABC transporters in cancer 
cells, since their dependence on ATP generation is mainly through enhanced 
glycolysis.  Certain isoforms of enzymes such as HK2 have been reported to be up-
regulated and responsible for the enhancement of glycolysis exclusively in cancer 
cells (Ko et al., 2001; Mathupala et al., 2009; Wolf et al., 2011). It would appear that 
rooibos and honeybush could selectively alter these pathways and may therefore 
be used to sensitise the cancer cell’s susceptibility to anti-cancer drugs in the 
kidneys.  
 
The liver and kidneys are equipped with the relevant enzymes to metabolise 
various forms of xenobiotics including procarcinogens, pharmaceutical drugs and 
dietary polyphenols. The metabolism of chemical procarcinogenic compounds by 
the two cytochrome (CYP) P450 enzymes, CYP1A1 and CYP1B1, often lead to the 
formation of reactive carcinogenic intermediates (Sutter et al., 1994; Crofts et al., 
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1997; Shimada et al., 1997; Heidel et al., 2000; Shimada et al., 2002). CYP1B1 is 
also over expressed in various cancers, but not in normal hepatic tissues (Murray 
et al., 1997; McFadyen et al., 1999), thus studies have reported using the enzyme 
as a target for anti-cancer drugs (Rochat et al., 2001; McFadyen et al., 2001). The 
isoform also biotransforms 17β-estradiol to its 4-hydroxy-metabolites (Hayes et al., 
1996). CYP1 isoforms are transcriptionally regulated by the aryl hydrocarbon 
receptor (AhR) (Ramadoss et al., 2004) upon activation by AhR ligands such as 
polyaromatic hydrocarbons. Studies have also shown that polyphenols weakly 
activate the AhR and can also act as AhR antagonists (Ciolino et al., 1999; Casper 
et al., 1999; Quadri et al., 2000; Ramadoss et al., 2004). The activated AhR 
translocates to the nucleus and then dissociates from its chaperone proteins and 
associates with the aryl hydrocarbon nuclear translocator (ARNT) protein. The 
heterodimer can then bind dioxin response elements (Reyes et al., 1992), and 
regulate the transcription of target genes (CYP1 isoforms). Since the Arnt and the 
Cyp1b1 genes were up-regulated by C. subternata, and the Cyp1a1 gene by C. 
genistoides, in the kidneys, it would appear that the mangiferin-enriched Cyclopia 
extracts could regulate gene expression of enzymes that bioactivate 
procarcinogens and therefore favour genotoxic DNA damage and cancer initiation. 
Conversely another carcinogen-associated cytochrome, Cyp4b1, was down-
regulated by the rooibos extract in the kidneys, thus may protect against the 
development of carcinogen-induced DNA lesions. This is supported by the up-
regulation of the phase II enzymes, glutathione-S-transferase mu (Gstm1) and 
microsomal Gst (Mgst1), and the down-regulation of the glutathione-depletion 
enzyme, gamma glutathione transferase (Ggt1), by rooibos, indicating that the 
extract could protect the cell against carcinogens when utilising the glutathione 
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conjugation deactivation pathway. The C. subternata extract, also up-regulated the 
genes of two phase II enzymes, Gstm4 and Mgst2. In contrast the C. genistoides 
extract down-regulated the Gstm3 and Gstm5 genes, thereby impairing the 
clearance of carcinogenic substances by glutathione conjugation.  
 
The expression of genes encoding enzymes that are involved in the metabolism of 
pharmaceutical drugs and xenobiotics have been differentially altered by C. 
subternata extract in the liver and kidneys. The liver Cyp2b6 and Cyp2c13 as well 
as the kidney esterase 22 (Es22) were down-regulated. Cyp2e1, carboxyl 
esterases (Ces) 1 and 2 were up-regulated in the liver while the expression of 
arachidonate 15-lipoxygenase (Alox15) and fatty acid amide hydrolase (Faah) were 
up-regulated in the kidney. These findings indicate that the extract may selectively 
enhance or inhibit the phase I metabolism of drugs and other xenobiotics. It should 
also be noted that the C. genistoides and rooibos extracts did not alter the gene 
expression of phase I enzymes and may therefore not transcriptionally interfere 
with phase I metabolism.  
 
All three herbal tea extracts are likely to affect alcohol metabolism in the liver. The 
alcohol dehydrogenase (Adh4) gene, which codes for the enzyme responsible for 
the conversion of alcohol to the toxic acetaldehyde, was up-regulated by C. 
genistoides. Aldehyde dehydrogenase (Ald1a1), responsible for the catalysis of 
acetaldehyde to its less toxic form acetate, was up-regulated by all three extracts, 
indicating that concurrent ingestion of these extracts and alcohol could be 
beneficial in the prevention of the “hang-over” effect observed after excessive 
alcohol consumption. This is in agreement with studies indicating that extracts of 
 
 
 
 
161 
 
green tea (Camellia sinensis) promote alcohol metabolism (Skrzydlewska et al., 
2002). 
 
Polyphenols have been shown to play a role in steroid metabolism (Yang et al., 
2001). In the current study, Cyp19a1, which codes the aromatase enzyme 
responsible for the conversion of testosterone to estradiol and androstenedione to 
estrone, was up-regulated by the rooibos and C. genistoides extracts in the liver 
and kidneys, respectively. However, it does not coincide with the study by Wang et 
al. (1994), which demonstrated an inhibitory effect on aromatase by flavonoids and 
suggested that flavonoid-rich foods may contribute to the reduction of estrogen-
dependent disease, such as breast cancer. The specific flavonoids, however, may 
play a role.  The herbal tea extracts also regulated the gene expression of three 
isoforms of the 17-beta hydroxysteroid dehydrogenases, Hsd17β1, 2 and 3, the 
former two was down-regulated by the extracts in the liver, whereas the latter was 
up-regulated by C. genistoides in the kidneys. The liver and kidneys are known to 
be the major organs involved in steroid metabolism and clearance, especially in the 
degradation thereby regulating their levels in the blood (West and Samuels, 1951; 
Kley et al., 1979). The 17-beta hydroxysteroid dehydrogenases mainly catalyses 
the steps of sex steroid degradation by converting biologically active forms to 
inactive metabolites (Wu et al., 1993; Casey et al., 1994). The herbal tea extracts 
seem to disrupt this balance by the impairment of estradiol and testosterone 
breakdown in the liver and kidneys. Recent studies indicated that C. subternata and 
C. genistoides exhibited phytoestrogen activity in breast cancer cells (Mfenyana et 
al., 2008).  This would imply that these phytoestrogens will be antagonists for the 
estrogen receptor presumably resulting in estradiol accumulation. However, the 
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present study suggests the impairment of estrogen degradation by the mangiferin-
enriched honeybush extracts which tend to contradict the phytoestrogenic 
properties of honeybush shown under in vitro conditions. It would appear that 
differences exist when considering the effect of the herbal teas on steroid 
metabolism under in vivo conditions which do not necessarily reflect in vitro 
conditions. This is also in agreement with the current study where the expression of 
specific xenobiotic metabolising enzymes by the herbal tea extracts differs under in 
vivo and in vitro conditions.   
 
Of interest is the up-regulation of the myeloperoxidase gene (18.60 fold) by C. 
subternata extract in the kidneys. The enzyme is involved in inflammatory 
responses which can be beneficial in terms of infection (Klebanoff, 2005), but 
harmful when leached out of the cell, where it can cause cellular damage (Malle et 
al., 2007) as in the case of pyelonephritis and glomerular nephritis (Odobasic et al., 
2007). The herbal tea extract may therefore expose the kidney cells to reactive 
oxidants that can be unfavourable. 
 
Modulation of the expression of the xenobiotic metabolising enzyme observed 
could be attributed to differences in the polyphenolic content of the aspalathin-
enriched rooibos extract and mangiferin-enriched extracts of C. genistoides and C. 
subternata. However, of the honeybush herbal teas, the C. subternata extract 
demonstrated a higher response regarding the modulation of the expression of 
different xenobiotic metabolism enzymes in the liver and kidneys, despite it having 
lower mangiferin content. This indicates that other polyphenols in the extract and/or 
non-polyphenolic constituents may have caused the effects observed. Of note is 
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the high eriocitrin (1.1 g/100 g extract) and scolymoside (1.29 g/100 g extract) 
contents of C. subternata extract which were absent in the C. genistoides extract. 
The hesperidin and eriodictyol-glucoside contents were also slightly higher in the C. 
subternata extract. It should also be noted that the total polyphenol content of the 
C. subternata extract as well as the total polyphenol intake of the rats was 
significantly higher when compared to the C. genistoides treated rats. This could 
also be related to the increase of the serum parameter total bilirubin which suggest 
that the biliary system was adversely affected by C. subternata.    
 
Differences were observed between liver and kidney in terms of the effect of the 
herbal tea extracts on gene expression. The genes affected in the liver and kidneys 
were aligned with their main function. In the liver the genes involved in alcohol, 
energy, steroid and phase I metabolism were altered. The lack of changes to the 
phase II genes in the liver could be ascribed to its high capacity to metabolise 
polyphenols which masked their adverse effects. In the kidneys, however mostly 
phase II genes, transporters and only certain phase I genes were altered. This is 
due to the kidney being the main organ for excretion although it retains capacity to 
metabolise xenobiotics, which is far less effective when compared to the liver.  
 
Since the herbal tea extracts displayed differential gene expression in the liver, a 
primary hepatocyte model was used to validate changes to selected genes in vitro. 
The results indicated variable effects regarding the expression of the selected 
genes. It seems that rat primary hepatocytes can be used to predict in vivo effects 
of the herbal tea extracts on Hsd17β2, however, care should be taken when 
considering effects on Cyp2e1 and Comt. In this particular study, the polyphenols, 
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aspalathin and mangiferin, were also included to investigate the differences 
between complex mixtures and single compounds. Aspalathin up-regulated the 
Comt gene and down-regulated the Hsd17β2 gene, whereas the aspalathin-
enriched rooibos extract did not significantly alter the genes. Mangiferin also 
differed from the mangiferin-enriched Cyclopia extracts by significantly down-
regulating both genes. It is known that complex mixtures versus single compounds 
do have varying effects when monitoring a specific biological event in a cell.  Active 
transport of a food borne carcinogen into Caco-2 mono layers was less effective in 
the presence of a single flavonoid as compared to the effect of a combination of 
flavonoids (Schutte et al., 2008).  In contrast, when utilising a rat uterothropic assay 
a mixture of estrogens showed an intermediate or reduced effect compared to a 
moderate stimulating effect by a single estrogen (Tinwell and Ashby, 2004).  Of 
interest is that the expression of the Hsd17β2 and Comt genes was significantly 
reduced by aspalathin and mangiferin while the enriched extracts showed an 
intermediate effect. It would appear that the gene modulating effects of a single 
polyphenol may be masked in the presence of complex mixtures containing other 
polyphenolic and non-polyphenolic constituents such as the polyphenol-enriched 
herbal tea extracts utilised in the present study. 
 
In conclusion, although human intervention studies are yet to be conducted with 
regards to the polyphenol-enriched extracts of rooibos and honeybush herbal teas, 
the present findings showed that the genes of xenobiotic metabolising enzymes are 
differentially altered by the herbal teas. Caution should therefore be taken when 
using the herbal tea extracts in combination with pharmaceutical drugs and/or 
xenobiotics and a moderate consumption is advised. Future studies will therefore 
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include the effects of the herbal tea extracts, their polyphenols and metabolites on 
enzyme interactions in terms of xenobiotic metabolism. 
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Table 1       Commonly prescribed cytochrome P450 inducers (Sandson,     
                   2004). 
 
 
 
 
  
1A2 2B6 2C8 2C9 2C19 2D6 2E1 3A4, 5, 7 
broccoli 
brussel 
sprouts 
char-grilled 
meat 
insulin 
methylchol
anthrene 
modafinil 
nafcillin 
beta-
naphthoflav
one 
omeprazole 
tobacco 
phenobarbital 
rifampin 
rifampin rifampin 
secobarbital 
carbamazepine 
norethindrone 
NOT 
pentobarbital 
prednisone 
rifampin 
dexamethasone 
rifampin 
ethanol 
isoniazid 
HIV Antivirals: 
efavirenz 
nevirapine 
barbiturates 
carbamazepine 
efavirenz 
glucocorticoids 
modafinil 
nevirapine 
oxcarbazepine 
phenobarbital 
phenytoin 
pioglitazone 
rifabutin 
rifampin 
St. John's wort 
troglitazone 
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Table 2         Commonly prescribed cytochrome P450 inhibitors (Sandson, 2004). 
 
 
1A2 2B6 2C8 2C9 2C19 2D6 2E1 3A4, 5, 7 
fluvoxamine 
ciprofloxacin 
cimetidine 
amiodarone 
fluoroquinolones 
furafylline 
interferon 
methoxsalen 
mibefradil 
thiotepa 
ticlopidine 
gemfibrozil 
trimethoprim 
glitazones 
montelukast 
quercetin 
fluconazole 
amiodarone 
fenofibrate 
fluvastatin 
fluvoxamine 
isoniazid 
lovastatin 
phenylbutazone 
probenicid 
sertraline 
sulfamethoxazol
e 
sulfaphenazole 
teniposide 
voriconazole 
zafirlukast 
PPIs: 
 
lansoprazole 
omeprazole 
pantoprazole 
rabeprazole 
chloramphenicol 
cimetidine 
felbamate 
fluoxetine 
fluvoxamine 
indomethacin 
ketoconazole 
modafinil 
oxcarbazepine 
probenicid 
ticlopidine 
topiramate 
 diethyldithioc
arbamate 
disulfiram 
HIV Antivirals: 
 
indinavir 
nelfinavir 
ritonavir 
clarithromycin 
itraconazole 
ketoconazole 
nefazodone 
saquinavir 
telithromycin 
aprepitant 
erythromycin 
fluconazole 
grapefruit juice 
verapamil 
diltiazem 
cimetidine 
amiodarone 
NOT 
azithromycin 
chloramphenicol 
ciprofloxacin 
delaviridine 
diethyldithiocarba
mate 
fluvoxamine 
gestodene 
imatinib 
mibefradil 
mifepristone 
norfloxacin 
norfluoxetine 
star fruit 
voriconazole 
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Table       Substrates of the major isoforms of cytochrome P450 (Sandson,  
                2004). 
 
1A2 2B6 2C8 2C9 2C19 2D6 2E1 3A4, 5, 7 
amitriptyline 
caffeine 
clomipramine 
clozapine 
cyclobenzaprin
e 
estradiol 
fluvoxamine 
haloperidol 
imioramine N-
DeMe 
mexilletine 
naproxen 
olanzapine 
ondansetron 
phenacetin_ 
acetaminophen            
NAPQI 
propranolol 
riluzole 
ropivacaine 
tacrine 
theophylline 
tizanidine 
verapamil 
(R)warfarin 
Zileuton 
zolmitriptan 
 
bupropion 
cyclophosphami
de 
efavirenz 
ifosfamide 
methadone 
 
 
paclitaxel 
torsemide 
amodiaquine 
cerivastatin 
repaglinide 
NSAIDs: 
diclofenac 
ibuprofen 
lornoxicam 
meloxicam 
S-naproxen –Nor 
piroxicam 
Suprofen 
Oral 
Hypoglycemic 
Agents: 
tolbutamide 
glipizide 
Angiotensin II 
Blockers: 
losartan 
irbesartan 
Sulfonylureas: 
glyburide 
glibenclamide 
glipizide 
glimepiride 
tolbutamide 
amitriptyline 
celecoxib 
fluoxetine 
fluvastatin 
glyburide 
nateglinide 
phenytoin-4-OH2 
rosiglitazone 
tamoxifen 
torsemide 
S-warfarin 
 
Proton Pump 
Inhibitors: 
 
lansoprazole 
omeprazole 
pantoprazole 
rabeprazole 
Anti-epileptics: 
diazepam_Nor 
phenytoin(O) 
S-mephenytoin 
phenobarbitone 
amitriptyline 
carisoprodol 
citalopram 
chloramphenico
l 
clomipramine 
cyclophospham
ide 
hexobarbital 
imipramine N-
DeME 
indomethacin 
R-
mephobarbital 
moclobemide 
nelfinavir 
nilutamide 
primidone 
progesterone 
proguanil 
propranolol 
teniposide 
R-warfarin_8-
OH 
 Anesthetics
: 
 
enflurane 
halothane 
isoflurane 
methoxyflur
ane 
sevoflurane 
acetaminop
hen_ 
NAPQI 
aniline2 
benzene 
chlorzoxaz
one 
ethanol 
N,N-
dimethyl 
formamide 
theophyllin
e_ 
8-OH 
 
Macrolide 
antibiotics: 
 
clarithromycin 
erythromycin (not 
3A5) 
NOT azithromycin 
telithromycin 
 
Anti-arrhythmics: 
 
quinidine_3OH 
(not 
3A5) 
 
Benzodiazepines: 
 
alprazolam 
diazepam_3OH 
midazolam 
triazolam 
Immune  
Modulators: 
cyclosporine 
tacrolimus 
(FK506) 
HIV Antivirals: 
indinavir 
nelfinavir 
ritonavir 
saquinavir 
Prokinetic: 
cisapride 
 
Antihistamines: 
astemizole 
chlorpheniramine 
terfenadine 
 
 
 
Calcium Channel 
Blockers: 
 
amlodipine 
diltiazem 
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felodipine 
lercanidipine 
nifedipine2 
nisoldipine 
nitrendipine 
verapamil 
HMG CoA  
 
Reductase 
Inhibitors: 
atorvastatin 
cerivastatin 
lovastatin 
NOT pravastatin 
simvastatin 
 
Steroid 6beta-OH: 
estradiol 
hydrocortisone 
progesterone 
testosterone 
 
Miscellaneous: 
alfentanyl 
aprepitant 
aripiprazole 
buspirone 
cafergot 
caffeine_TMU 
cilostazol 
cocaine 
codeine- 
Ndemethylation 
dapsone 
dexamethasone 
dextromethorphan 
docetaxel 
domperidone 
eplerenone 
fentanyl 
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finasteride 
gleevec 
haloperidol 
irinotecan 
LAAM 
lidocaine 
methadone 
nateglinide 
ondansetron 
pimozide 
propranolol 
quetiapine 
quinine 
risperidone 
NOT rosuvastatin 
salmeterol 
sildenafil 
sirolimus 
tamoxifen 
taxol 
terfenadine 
trazodone 
vincristine 
zaleplon 
ziprasidone 
zolpidem 
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Table 1 The feed intake of individual animals calculated as g feed/100 g 
bodyweight of male Fisher rats fed with aspalathin-enriched rooibos and 
mangiferin-enriched honeybush extracts for a period of 30 days.   
Animal No. Control (Neg) Rooibos C. genistoides C. subternata 
  g feed/100g BW g feed/100g BW g feed/100g BW g feed/100g BW 
1 8.93 9.80 9.97 9.91 
2 10.38 10.36 9.55 10.52 
3 9.95 9.60 9.63 10.32 
4 9.60 9.60 10.11 10.03 
5 9.69 9.07 10.89 10.15 
6 9.87 9.42 10.10 9.83 
7 9.94 9.49 10.18 10.71 
8 9.91 10.21  11.35 
9 9.17 9.50 9.14 10.49 
10 9.87 9.39 10.18 10.24 
AVE 9.73 9.65 9.97 10.35 
STD 1.66 1.42 1.56 1.66 
 
* The concentrations of the extracts were 2.0 g rooibos extract/kg diet and 2.5 g honeybush extract 
/kg diet. 
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Table 2 Individual bodyweight gain and relative liver and kidney weight of 
male Fisher rats fed with aspalathin-enriched rooibos and mangiferin-
enriched honeybush extracts for a period of 30 days.   
 
Group No. Bodyweight gain Relative liver weight Relative kidney weight 
 
 (g) (%) (%) 
 
1.
 
Co
n
tr
o
l (N
eg
) 
 1 87 3.75 0.68 
2 100 3.25 0.62 
3 78 3.44 0.64 
4 87 3.60 0.64 
5 103 3.62 0.70 
6 90 3.60 0.67 
7 87 3.45 0.63 
8 97 3.46 0.61 
9 109 3.60 0.63 
10 107 3.90 0.64 
AVE   94.50 3.57 0.65 
STD   10.20 0.18 0.03 
2.
 
R
o
o
ib
o
s
 
1 69 3.74 0.62 
2 75 3.68 0.65 
3 93 3.81 0.59 
4 105 3.99 0.62 
5 80 3.57 0.63 
6 95 3.94 0.67 
7 95 3.42 0.62 
8 107 3.67 0.59 
9 79 3.61 0.62 
10 97 3.57 0.68 
AVE   89.50 3.70 0.63 
STD   12.94 0.18 0.03 
3.
 
C.
 
ge
n
is
to
id
es
 
1 102 3.88 0.66 
2 96 4.18 0.65 
3 101 3.65 0.64 
4 91 3.76 0.70 
5 88 3.55 0.66 
6 99 3.70 0.63 
7 90 3.71 0.64 
9 70 3.60 0.70 
10 91 4.26 0.70 
AVE 
 
92.00 3.81 0.67 
STD 
 
9.70 0.25 0.03 
4.
 
C.
 
su
bt
er
n
at
a
 
1 86 3.36 0.63 
2 110 3.65 0.65 
3 104 3.42 0.62 
4 87 3.32 0.71 
5 78 3.52 0.62 
6 95 3.74 0.69 
7 80 3.52 0.64 
8 108 3.96 0.70 
9 80 3.66 0.64 
10 107 3.56 0.68 
AVE 
  
93.50 3.57 0.66 
STD 
  
12.83 0.19 0.03 
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Table 3 GeneBank codes of genes encoding xenobiotic metabolising enzymes 
and transporters. 
                     Gene Table  
Position Unigene GeneBank Symbol Description Gene Name 
A01  Rn.144554 NM_012623 Abcb1b ATP-binding cassette, sub-
family B (MDR/TAP), 
member 1B 
Abcb1/Mdr1 
A02  Rn.154810 NM_133401 Abcb1a ATP-binding cassette, sub-
family B (MDR/TAP), 
member 1A 
Mdr1a 
A03  N/A NM_012690  Abcb4 ATP-binding cassette, sub-
family B (MDR/TAP), 
member 4 
Mdr2/Pgy3 
A04  Rn.10495 NM_022281 Abcc1 ATP-binding cassette, sub-
family C (CFTR/MRP), 
member 1 
Abcc1a/Avcc1a 
A05  Rn.54493 NM_022935 Abp1 Amiloride binding protein 1 
(amine oxidase, copper-
containing) 
Abp 
A06  Rn.40222 NM_019286 Adh1 Alcohol dehydrogenase 1 
(class I) 
Adh/Adh1a 
A07  Rn.98159 NM_017270 Adh4 Alcohol dehydrogenase 4 
(class II), pi polypeptide 
ADH-1/Ac1002 
A08  Rn.91370 NM_013149 Ahr Aryl hydrocarbon receptor Ahr 
A09  Rn.3941 NM_012899 Alad Aminolevulinate, delta-, 
dehydratase 
ALADR/aminolevulinatedelta-
dehydratase 
A10  Rn.6132 NM_022407 Aldh1a1 Aldehyde dehydrogenase 
family 1, member A1 
AHD2/Aldh1 
A11  Rn.11318 NM_031010 Alox15 Arachidonate 15-
lipoxygenase 
12-LOX/Alox12 
A12  Rn.9662 NM_012822 Alox5 Arachidonate 5-
lipoxygenase 
LOX5A 
B01  Rn.32351 NM_138828 Apoe Apolipoprotein E APOEA 
B02  Rn.10520 NM_012780 Arnt Aryl hydrocarbon receptor 
nuclear translocator 
Arnt1 
B03  Rn.7354 XM_213848 Asna1 ArsA arsenite transporter, 
ATP-binding, homolog 1 
(bacterial) 
N/A 
B04  Rn.9865 NM_053850 Blvra Biliverdin reductase A Blvra 
B05  Rn.161812 XM_214823 Blvrb_predicted Biliverdin reductase B 
(flavin reductase (NADPH)) 
(predicted) 
LOC292737 
B06  Rn.161717 NM_031565 Ces1 Carboxylesterase 1 MGC156521 
B07  Rn.14535 NM_133586 Ces2 Carboxylesterase 2 
(intestine, liver) 
CES RL4/rCES2 
B08  Rn.16695 NM_001011955 Chst1 Carbohydrate (keratan 
sulfate Gal-6) 
LOC295934 
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sulfotransferase 1 
B09  Rn.220 NM_012531 Comt Catechol-O-
methyltransferase 
Comt 
B10  Rn.35994 NM_138877 Cyb5r3 Cytochrome b5 reductase 3 Dia1/Nadhcb5 
B11  Rn.10172 NM_012753 Cyp17a1 Cytochrome P450, family 
17, subfamily a, 
polypeptide 1 
Cyp17 
B12  Rn.21402 NM_017085 Cyp19a1 Cytochrome P450, family 
19, subfamily a, 
polypeptide 1 
Aromatase/Cyp19 
C01  Rn.10352 NM_012540 Cyp1a1 Cytochrome P450, family 
1, subfamily a, polypeptide 
1 
AHH/AHRR 
C02  Rn.5563 NM_012541 Cyp1a2 Cytochrome P450, family 
1, subfamily a, polypeptide 
2 
CYPD45/P-450d 
C03  Rn.10125 NM_012940 Cyp1b1 Cytochrome P450, family 
1, subfamily b, polypeptide 
1 
Cyp1b1 
C04  Rn.10847 NM_053763 Cyp27b1 Cytochrome P450, family 
27, subfamily b, 
polypeptide 1 
Cyp40 
C05  Rn.144570 NM_017156 Cyp2b15 Cytochrome P450, family 
2, subfamily b, polypeptide 
15 
Cyp2b15 
C06  Rn.127147 M19973 Cyp2b6 Cytochrome P450, 
subfamily IIB 
(phenobarbital-inducible), 
polypeptide 6 
Cyp2b6 
C07  Rn.82715 NM_138514 Cyp2c13 Cytochrome P450 2c13 Cyp2c38 
C08  Rn.91122 XM_001066767 Cyp2c6_predicted Cytochrome P450, 
subfamily IIC6 (predicted) 
Cyp2c6/PB1 
C09  Rn.1247 NM_017158 Cyp2c7 Cytochrome P450, family 
2, subfamily c, polypeptide 
7 
Cyp2c39 
C10  Rn.1372 NM_031543 Cyp2e1 Cytochrome P450, family 
2, subfamily e, polypeptide 
1 
Cyp2e 
C11  Rn.91120 NM_013105 Cyp3a23/3a1 Cytochrome P450, family 
3, subfamily a, polypeptide 
23/polypeptide 1 
CYP/Cyp3a1 
C12  Rn.86651 NM_016999 Cyp4b1 Cytochrome P450, family 
4, subfamily b, polypeptide 
1 
Cyp4b1 
D01  Rn.3603 NM_012844 Ephx1 Epoxide hydrolase 1, 
microsomal 
MEH8 
D02  Rn.89119 NM_024132 Faah Fatty acid amide hydrolase Faah 
D03  Rn.33703 NM_012558 Fbp1 Fructose-1,6- 
biphosphatase 1 
Fdp 
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D04  Rn.91245 NM_017007 Gad1 Glutamic acid 
decarboxylase 1 
Gad67 
D05  Rn.29951 NM_012563 Gad2 Glutamic acid 
decarboxylase 2 
gad65 
D06  Rn.7863 NM_013120 Gckr Glucokinase regulatory 
protein 
GLRE 
D07  Rn.10010 NM_053840 Ggt1 Gamma-
glutamyltransferase 1 
GGLUT/Ggt 
D08  Rn.84435 NM_207592 Gpi Glucose phosphate 
isomerase 
Amf/Gpi1 
D09  Rn.11323 NM_030826 Gpx1 Glutathione peroxidase 1 GSHPx/GSHPx-1 
D10  Rn.3503 NM_183403 Gpx2 Glutathione peroxidase 2 GPX-GI/GSHPx-2 
D11  Rn.108074 NM_022525 Gpx3 Glutathione peroxidase 3 GSHPx-3/GSHPx-P 
D12  Rn.3647 NM_017165 Gpx4 Glutathione peroxidase 4 Phgpx/gpx-4 
E01  Rn.218434XM_001059839 Gpx5 Glutathione peroxidase 5 Gpx5 
E02  Rn.19721 NM_053906 Gsr Glutathione reductase Gsr 
E03  Rn.10460 NM_031509 Gsta3 Glutathione S-transferase 
A3 
Gsta1/Gsta5 
E04  Rn.57528 XM_217195 Gsta4 Glutathione S-transferase, 
alpha 4 
LOC300850 
E05  Rn.202944 NM_017014 Gstm1 Glutathione S-transferase, 
mu 1 
GSTA3 
E06  Rn.625 NM_177426 Gstm2 Glutathione S-transferase, 
mu 2 
GSTA4 
E07  Rn.6036 NM_031154 Gstm3 Glutathione S-transferase, 
mu type 3 
Gstm3 
E08  Rn.209043 NM_020540 Gstm4 Glutathione S-transferase 
M4 
GstYb4 
E09  Rn.9158 NM_172038 Gstm5 Glutathione S-transferase, 
mu 5 
Gstm5 
E10  Rn.87063 NM_138974 Gstp1 Glutathione-S-transferase, 
pi 1 
GST-P/Gst3 
E11  Rn.11122 NM_053293 Gstt1 Glutathione S-transferase 
theta 1 
GSTYRS 
E12  Rn.91375 NM_012735 Hk2 Hexokinase 2 Hk2 
F01  Rn.10594 NM_012851 Hsd17b1 Hydroxysteroid (17-beta) 
dehydrogenase 1 
17BHD1 
F02  Rn.10515 NM_024391 Hsd17b2 Hydroxysteroid (17-beta) 
dehydrogenase 2 
Hsd17b2 
F03  Rn.10895 NM_054007 Hsd17b3 Hydroxysteroid (17-beta) 
dehydrogenase 3 
Hsd17b3 
F04  Rn.60583 XM_220831 Lpo_predicted Lactoperoxidase 
(predicted) 
N/A 
F05  Rn.9560 XM_215403 Marcks Myristoylated alanine rich 
protein kinase C substrate 
KINC/Macs 
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F06  Rn.2580 NM_134349 Mgst1 Microsomal glutathione S-
transferase 1 
MGC72699 
F07  Rn.7854 XM_215562 Mgst2_predicted Microsomal glutathione S-
transferase 2 (predicted) 
LOC295037 
F08  Rn.1916 XM_213943 Mgst3_predicted Microsomal glutathione S-
transferase 3 (predicted) 
LOC289197 
F09  Rn.47782 XM_220830 Mpo Myeloperoxidase Mpo 
F10  Rn.11325 NM_053968 Mt3 Metallothionein 3 GIF/Mt-3 
F11  Rn.10494 XM_342975 Mthfr_predicted 5,10-
methylenetetrahydrofolate 
reductase (NADPH) 
(predicted) 
Mthfr 
F12  Rn.37420 NM_001037315 Nat1 N-acetyltransferase 1 
(arylamine N-
acetyltransferase) 
Nat2 
G01  Rn.10400 NM_012611 Nos2 Nitric oxide synthase 2, 
inducible 
Nos2a/iNos 
G02  Rn.44265 NM_021838 Nos3 Nitric oxide synthase 3, 
endothelial cell 
eNos 
G03  Rn.11234 NM_017000 Nqo1 NAD(P)H dehydrogenase, 
quinone 1 
Dia4 
G04  Rn.48821 NM_012624 Pklr Pyruvate kinase, liver and 
red blood cell 
PK1/PKL 
G05  Rn.1556 NM_053297 Pkm2 Pyruvate kinase, muscle PKM12/Pk3 
G06  Rn.20732 NM_032077 Pon1 Paraoxonase 1 Pon1 
G07  Rn.1100 NM_001013082 Pon2 Paraoxonase 2 N/A 
G08  Rn.16469 NM_001004086 Pon3 Paraoxonase 3 MGC95026 
G09  Rn.34679 XM_237241 Smarcal1_predicted Swi/SNF related matrix 
associated, actin 
dependent regulator of 
chromatin, subfamily a-like 
1 (predicted) 
N/A 
G10  Rn.6147 NM_001034083 Snn Stannin Snn 
G11  Rn.4620 NM_017070 Srd5a1 Steroid 5 alpha-reductase 
1 
MGC156498 
G12  Rn.202951 NM_017154 Xdh Xanthine dehydrogenase XOR 
H01  Rn.973 NM_001007604 Rplp1 Ribosomal protein, large, 
P1 
MGC72935 
H02  Rn.47 NM_012583 Hprt Hypoxanthine guanine 
phosphoribosyl transferase 
Hgprtase/Hprt1 
H03  Rn.92211 NM_173340 Rpl13a Ribosomal protein L13A Rpl13a 
H04  Rn.107896 NM_017025 Ldha Lactate dehydrogenase A Ldh1 
H05  Rn.94978 NM_031144 Actb Actin, beta Actx 
H06  N/A U26919 RGDC Rat Genomic DNA 
Contamination 
RGDC 
H07  N/A SA_00104 RTC Reverse Transcription RTC 
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Control 
H08  N/A SA_00104 RTC Reverse Transcription 
Control 
RTC 
H09  N/A SA_00104 RTC Reverse Transcription 
Control 
RTC 
H10  N/A SA_00103 PPC Positive PCR Control PPC 
H11  N/A SA_00103 PPC Positive PCR Control PPC 
H12  N/A SA_00103 PPC Positive PCR Control PPC 
 
 
 
Table 4 Ratios indicating the integrity of the RNA isolated from liver and kidney 
tissue after exposure to polyphenol-enriched herbal tea extracts. 
SAMPLE LIVER KIDNEY 
  260/280a 260/230b 260/280a 260/230b 
C1 1.99 1.76 2.00 1.60 
C4 1.99 1.60 2.00 1.70 
C9 1.97 1.40 2.10 1.80 
R7 1.98 1.57 2.10 1.40 
R8 1.98 1.54 2.10 1.80 
R9 1.98 1.51 2.00 1.20 
S7 2.00 1.43 2.10 1.60 
S8 1.98 1.49 2.10 1.40 
S9 2.00 1.49 2.10 1.30 
G5 1.98 1.68 2.10 1.70 
G7 1.99 1.52 2.10 1.60 
G9 1.99 1.39 2.10 1.60 
a Indicates protein and/or DNA contamination (Where ≥2 indicates pure RNA) bIndicates salt 
contamination (Where ≥1.5 indicates pure RNA). C= Control group; R= Aspalathin-enriched rooibos; 
S= Mangiferin- enriched C. subternata; G= Mangiferin- enriched C. genistoides.  
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Table 5 Efficiency of the reverse transcription reaction and the genomic DNA contamination 
controls of treated and untreated liver samples.  
  Control/untreated Rooibos C. subternata C. genistoides 
Replicates 1 2 3 1 2 3 1 2 3 1 2 3 
∆Ct (Ave 
RTC-Ave 
PPC) 0.61 0.63 1.06 1.06 1.30 1.21 1.04 0.96 0.64 0.81 1.36 0.53 
RT 
efficiency 
Pas
s 
Pas
s Pass 
Pas
s 
Pas
s Pass 
Pas
s Pass Pass 
Pas
s 
Pas
s Pass 
  Control/untreated Rooibos C. subternata C. genistoides 
Replicates 1 2 3 1 2 3 1 2 3 1 2 3 
Ct (GDC) 35 35 35 35 35 32.74 35 
34.4
1 33.46 35 35 35 
Genomic 
DNA 
Pas
s 
Pas
s Pass 
Pas
s 
Pas
s Fail 
Pas
s Fail Fail 
Pas
s 
Pas
s Pass 
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Table 6 Gene profile of xenobiotic metabolising enzymes in the liver after exposure 
to enriched extracts of rooibos and honeybush herbal teas. 
Gene symbol p value 
Test 
/Control p value 
Test 
/Control p value 
Test 
/Control  
  
Rooibos C. genistoides     C. subternata 
Abcb1b 0.860 -1.073 0.095 1.834 0.138 1.551 
Abcb1a 0.112 -1.345 0.697 -1.084 0.161 -1.272 
Abcb4 0.177 -1.495 0.333 -1.355 0.253 -1.361 
Abcc1 0.535 -1.264 0.376 -1.406 0.674 -1.178 
Abp1 0.637 1.766 0.600 1.674 0.500 2.175 
Adh1 0.673 -1.152 0.331 1.337 0.610 1.088 
Adh4 0.286 1.232 0.043 1.333 0.081 1.409 
Ahr 0.523 -1.451 0.680 -1.283 0.551 -1.417 
Alad 0.581 1.047 0.294 1.127 0.668 1.064 
Aldh1a1 0.049 2.393 0.028 1.673 0.028 2.472 
Alox15 0.098 -1.227 0.151 -1.750 0.052 -1.551 
Alox5 0.643 -1.915 0.493 -2.132 0.650 -1.895 
Apoe 0.342 1.166 0.742 -1.040 0.947 1.016 
Arnt 0.520 -1.074 0.131 1.347 0.833 1.031 
Asna1 0.660 1.143 0.864 1.041 0.927 1.022 
Blvra 0.184 1.312 0.539 1.141 0.669 1.112 
Blvrb_predicted 0.291 -2.399 0.342 -2.188 0.350 -2.144 
Ces1 0.083 1.287 0.089 1.262 0.040 1.319 
Ces2 0.308 1.267 0.070 1.392 0.002 1.606 
Chst1 0.808 1.083 0.152 1.832 0.869 1.075 
Comt 0.783 1.051 0.356 1.314 0.645 1.129 
Cyb5r3 0.253 1.179 0.054 1.499 0.362 1.135 
Cyp17a1 0.247 -1.390 0.959 1.017 0.345 1.296 
Cyp19a1 0.027 1.980 0.337 -1.298 0.874 1.102 
Cyp1a1 0.790 -1.114 0.919 1.036 0.934 -1.046 
Cyp1a2 0.929 -1.010 0.213 1.246 0.455 1.130 
Cyp1b1 0.732 -1.242 0.520 -1.372 0.626 1.695 
Cyp27b1 0.458 -2.032 0.490 -1.804 0.726 -1.351 
Cyp2b15 0.264 2.145 0.608 -1.508 0.809 -1.239 
Cyp2b6 0.162 -1.418 0.824 -1.102 0.033 -1.287 
Cyp2c13 0.120 -1.394 0.753 -1.087 0.035 -1.334 
Cyp2c6_predicted 0.352 1.198 0.099 1.236 0.204 1.182 
Cyp2c7 0.142 1.247 0.680 1.114 0.235 1.298 
Cyp2e1 0.112 1.265 0.065 1.279 0.034 1.230 
Cyp3a23/3a1 0.523 1.272 0.418 1.324 0.566 1.204 
Cyp4b1 0.104 -1.972 0.662 1.107 0.484 -1.356 
Ephx1 0.792 1.040 0.496 -1.138 0.438 1.121 
Faah 0.906 -1.051 0.567 -1.270 0.501 -1.382 
Fbp1 0.338 1.067 0.337 1.160 0.587 1.046 
Gad1 0.213 -3.134 0.703 -1.125 0.555 -1.182 
Gad2 0.947 1.034 0.709 1.268 0.575 1.460 
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Gene symbol p value 
Test 
/Control p value 
Test 
/Control p value 
Test 
/Control  
  
Rooibos C. genistoides      C. subternata 
Gckr 0.492 -1.511 0.838 -1.120 0.371 -1.578 
Ggt1 0.480 -1.682 0.769 -1.193 0.474 -1.780 
Gpi 0.007 2.475 0.005 2.175 0.013 1.919 
Gpx1 0.840 1.053 0.729 -1.086 0.536 1.130 
Gpx2 0.700 1.179 0.270 -1.575 0.486 -1.317 
Gpx3 0.141 1.377 0.453 1.149 0.880 -1.050 
Gpx4 0.163 1.131 0.256 1.121 0.597 1.057 
Gpx5 0.964 1.038 0.880 -1.055 0.722 -1.189 
Gsr 0.120 1.269 0.691 1.051 0.224 1.201 
Gsta3 0.196 1.462 0.256 1.377 0.196 1.427 
Gsta4 0.320 -1.300 0.965 1.013 0.349 -1.413 
Gstm1 0.940 1.020 0.956 1.013 0.946 -1.018 
Gstm2 0.296 1.313 0.564 1.156 0.776 1.100 
Gstm3 0.557 1.079 0.129 1.298 0.926 -1.016 
Gstm4 0.715 -1.054 0.065 -1.217 0.692 -1.070 
Gstm5 0.705 -1.206 0.843 -1.103 0.761 -1.152 
Gstp1 0.605 -1.155 0.562 1.160 0.374 -1.370 
Gstt1 0.863 -1.036 0.940 -1.016 0.992 -1.002 
Hk2 0.922 1.042 0.167 -2.088 0.285 -1.264 
Hsd17b1 0.157 -1.814 0.041 -1.716 0.173 -1.781 
Hsd17b2 0.008 -2.416 0.014 -3.410 0.042 -2.085 
Hsd17b3 0.972 1.027 0.713 1.204 0.496 -1.593 
Lpo_predicted 0.584 -1.837 0.948 -1.076 0.602 -1.871 
Marcks 0.596 -1.194 0.640 -1.144 0.261 -1.183 
Mgst1 0.101 1.153 0.321 1.136 0.459 1.105 
Mgst2_predicted 0.210 -1.405 0.724 -1.090 0.197 -1.383 
Mgst3_predicted 0.755 1.026 0.285 1.123 0.847 1.009 
Mpo 0.109 -1.818 0.511 1.169 0.247 -1.897 
Mt3 0.299 2.281 0.443 1.740 0.239 2.624 
Mthfr_predicted 0.408 -1.331 0.089 -1.349 0.234 -1.232 
Nat1 0.508 -1.426 0.910 1.049 0.858 -1.104 
Nos2 0.928 1.078 0.924 1.070 0.315 -2.977 
Nos3 0.113 -1.546 0.569 1.420 0.186 -1.526 
Nqo1 0.239 1.269 0.112 1.616 0.246 3.619 
Pklr 0.700 -1.077 0.242 1.340 0.882 1.027 
Pkm2 0.468 1.172 0.071 1.518 0.274 1.300 
Pon1 0.808 1.058 0.320 1.351 0.362 1.214 
Pon2 0.943 1.012 0.644 -1.079 0.693 -1.097 
Pon3 0.931 1.019 0.958 1.009 0.479 1.135 
Smarcal1_predicted 0.072 -1.655 0.418 -1.268 0.712 -1.093 
Snn 0.233 -9.741 0.762 1.051 0.703 -1.107 
Srd5a1 0.964 -1.020 0.737 1.155 0.672 1.156 
Xdh 0.500 -1.130 0.990 1.002 0.338 1.123 
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Gene symbol p value 
Test 
/Control p value 
Test 
/Control p value 
Test 
/Control  
  
Rooibos C. genistoides     C. subternata 
Rplp1 0.539 -1.051 0.541 1.073 0.549 1.078 
Hprt 0.981 -1.003 0.154 1.299 0.419 1.132 
Rpl13a 0.324 -1.243 0.251 -1.508 0.321 -1.319 
Ldha 0.753 1.073 0.938 -1.020 0.782 -1.061 
Actb 0.085 1.222 0.550 1.103 0.170 1.146 
 
Table 7 Gene profile of xenobiotic metabolising enzymes and transporters in the 
kidneys after exposure to enriched extracts of rooibos and honeybush 
herbal teas. 
 
Gene symbol p value 
Test 
/Control p value 
Test 
/Control p value 
Test 
/Control  
  
Rooibos C. genistoides     C. subternata 
Abcb1b 0.735 -1.069 0.645 -1.100 0.239 -1.401 
Abcb1a 0.007 -1.851 0.580 -1.315 0.205 -1.889 
Abcb4 0.293 -1.665 0.869 1.066 0.584 -1.170 
Abcc1 0.159 1.318 0.809 1.108 0.268 1.393 
Abp1 0.971 -1.074 0.311 5.299 0.419 3.515 
Adh1 0.407 -1.361 0.549 1.325 0.400 1.424 
Adh4 0.790 1.222 0.538 1.529 0.461 1.667 
Ahr 0.370 1.168 0.967 -1.011 0.683 1.125 
Alad 0.626 1.060 0.997 -1.001 0.139 1.291 
Aldh1a1 0.668 1.075 0.550 -1.081 0.856 1.043 
Alox15 0.227 1.439 0.974 1.010 0.049 1.710 
Alox5 0.749 -1.527 0.749 1.562 0.717 1.428 
Apoe 0.954 -1.025 0.814 1.127 0.972 -1.021 
Arnt 0.661 1.066 0.967 -1.010 0.030 1.303 
Asna1 0.339 -1.192 0.906 -1.027 0.901 1.032 
Blvra 0.837 1.027 0.418 -1.220 0.156 -1.397 
Blvrb_predicted 0.751 -1.052 0.691 -1.099 0.965 -1.005 
Ces1 0.792 -1.042 0.846 -1.084 0.045 -1.230 
Ces2 0.167 -1.238 0.501 -1.147 0.084 -1.297 
Chst1 0.339 1.296 0.755 1.082 0.682 -1.204 
Comt 0.723 1.102 0.971 -1.015 0.051 1.444 
Cyb5r3 0.938 1.009 0.787 1.068 0.172 1.204 
Cyp17a1 0.541 1.986 0.318 3.212 0.212 4.614 
Cyp19a1 0.505 1.735 0.067 2.989 0.335 2.075 
Cyp1a1 0.181 2.359 0.060 3.737 0.749 1.286 
Cyp1a2 0.329 -4.691 0.323 -3.263 0.996 1.009 
Cyp1b1 0.648 1.756 0.074 6.975 0.011 5.663 
Cyp27b1 0.293 -3.666 0.541 -1.508 0.464 1.549 
Cyp2b15 0.274 5.744 0.667 2.222 0.941 -1.123 
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Gene symbol p value 
Test 
/Control p value 
Test 
/Control p value 
Test 
/Control  
  
Rooibos C. genistoides     C. subternata 
Cyp2b6 0.066 -5.651 0.131 -8.302 0.729 1.350 
Cyp2c13 0.846 -1.197 0.092 6.678 0.062 3.886 
Cyp2c6_predicted 0.548 -1.858 0.953 -1.075 0.179 5.547 
Cyp2c7 0.553 1.218 0.189 1.581 0.099 1.641 
Cyp2e1 0.507 -1.074 0.452 1.037 0.230 1.162 
Cyp3a23/3a1 0.647 -2.027 0.764 -1.455 0.145 5.669 
Cyp4b1 0.051 -2.193 0.070 1.882 0.183 1.519 
Ephx1 0.088 -1.507 0.866 1.035 0.742 1.059 
Faah 0.160 1.404 0.059 2.407 0.010 1.902 
Fbp1 0.431 -1.144 0.871 1.032 0.689 1.072 
Gad1 0.118 -9.511 0.338 -4.768 0.097 3.269 
Gad2 0.857 1.202 0.251 3.111 0.655 1.383 
Gckr 0.888 -1.190 0.286 2.462 0.092 3.727 
Ggt1 0.024 -1.691 0.901 -1.031 0.169 -1.748 
Gpi 0.258 1.250 0.846 -1.059 0.387 1.178 
Gpx1 0.780 -1.051 0.415 1.195 0.182 1.327 
Gpx2 0.791 -1.033 0.980 -1.007 0.790 1.040 
Gpx3 0.462 1.167 0.998 -1.001 0.169 1.689 
Gpx4 0.361 -1.073 0.748 -1.031 0.897 1.009 
Gpx5 0.953 -1.121 0.772 -1.491 0.943 -1.102 
Gsr 0.619 1.079 0.498 -1.142 0.753 -1.048 
Gsta3 0.580 -1.090 0.437 -1.183 0.657 -1.063 
Gsta4 0.320 -1.306 0.888 -1.053 0.498 -1.165 
Gstm1 0.047 1.572 0.971 -1.008 0.049 1.693 
Gstm2 0.223 1.225 0.712 1.105 0.150 1.337 
Gstm3 0.278 1.092 0.037 -1.601 0.237 -1.273 
Gstm4 0.629 -1.384 0.886 1.031 0.041 1.742 
Gstm5 0.181 -1.226 0.021 -1.614 0.008 -1.691 
Gstp1 0.329 1.194 0.361 -1.187 0.838 -1.067 
Gstt1 0.412 -1.134 0.326 -1.163 0.200 -1.348 
Hk2 0.121 -1.827 0.017 -2.119 0.013 -2.184 
Hsd17b1 0.916 -1.028 0.661 1.079 0.356 -1.215 
Hsd17b2 0.671 -1.195 0.825 1.105 0.577 1.260 
Hsd17b3 0.267 134.314 0.057 4.424 0.760 1.359 
Lpo_predicted 0.442 4.027 0.277 -7.487 0.179 11.307 
Marcks 0.887 1.024 0.640 1.084 0.517 1.178 
Mgst1 0.013 1.286 0.135 1.228 0.108 1.191 
Mgst2_predicted 0.776 -1.094 0.347 1.658 0.039 2.615 
Mgst3_predicted 0.128 -1.330 0.793 -1.070 0.905 1.017 
Mpo 0.624 2.279 0.743 -1.539 0.055 18.598 
Mt3 0.323 -2.258 0.350 -1.474 0.193 -2.023 
Mthfr_predicted 0.380 -1.252 0.436 1.183 0.567 1.340 
Nat1 0.015 -1.225 0.894 1.064 0.296 -1.074 
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Gene symbol p value 
Test 
/Control p value 
Test 
/Control p value 
Test 
/Control  
  
Rooibos C. genistoides     C. subternata 
Nos2 0.731 1.450 0.791 1.730 0.651 1.426 
Nos3 0.586 -1.119 0.272 1.286 0.196 1.500 
Nqo1 0.215 1.122 0.071 1.680 0.219 1.248 
Pklr 0.895 -1.018 0.272 -1.148 0.399 -1.114 
Pkm2 0.088 1.217 0.652 1.097 0.232 1.116 
Pon1 0.432 -3.979 0.196 -12.812 0.896 1.126 
Pon2 0.773 -1.066 0.440 -1.086 0.157 1.185 
Pon3 0.783 -1.028 0.324 1.260 0.485 -7.110 
Smarcal1_predicted 0.140 -1.530 0.698 -1.171 0.509 1.155 
Snn 0.065 -1.424 0.309 -1.327 0.089 -1.253 
Srd5a1 0.782 1.034 0.108 1.386 0.095 1.215 
Xdh 0.833 -1.091 0.713 1.167 0.396 1.489 
Rplp1 0.844 -1.020 0.744 -1.032 0.863 1.013 
Hprt 0.979 1.005 0.880 -1.028 0.687 -1.076 
Rpl13a 0.139 -1.369 0.897 1.025 0.803 -1.058 
Ldha 0.796 1.031 0.091 -1.217 0.746 -1.044 
Actb 0.073 1.347 0.272 1.260 0.287 1.173 
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Figure 1 Distinct bands of the 28S and 18S ribosomal units. 
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Figure 2 Distinct peaks of the 18S and 28S ribosomal units and RNA integrity 
numbers (RINs). 
 
 
 
 
  
 
 
  
 
 
 
 
ADDENDUM III 
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PREPARATION OF PRIMARY RAT HEPATOCYTES 
 
 
Only use autoclaved ddH20, autoclaved glassware and sterile equipment!  
 
PERFUSION REAGENTS (STORED AT 4°C): 
 
L-Gluthamine:     
0.2 M (200 mM) in WE 
1 M  = 146.1 g/1000 mL 
2 M  = 292.2 g/1000 mL 
0.2 M = 29.22 g/1000 mL 
 = 2.92 g/100 mL WE or 1.46 g/50 mL WE 
 
L-Proline:    
0.2 M (200 mM) in WE 
1 M  = 115.1 g/1000 mL 
2 M  = 230.2 g/1000 mL 
0.2 M = 23.02 g/1000 mL 
 = 2.30 g/100 mL WE or 1.15 g/50 mL WE 
 
Pyruvate (Na):     
1 M in WE 
1 M = 110.0 g/1000 mL 
 =  11.0 g/ 1000 mL 
=   5.5 g/1000 mL 
 
Insulin: 
Dilute from liquid stock: 
20 U/L in 6 mM HCl 
25.6 U/mg 
In 0.1 g (100 mg) = 2560 U…0.1g (100mg) contains 2560 U 
   2560 U in 25.6 mL [6 mM] HCl 
   ≈ 100 U in 1.0 mL 
Dilute stock with x 5 in WE when used in medium 
 
EGTA: 
0.05 M in HBSS 
1.902 g in 100 mL HBSS + 3 NaOH pellets 
pH = 7.4 
 
 
Collagen:       
3 mg/mL powder stock: 25 mg bottle + 8.333 mL HCL [0.012 M] 
Place in water bath at 37°C to dissolve 
For plating: dilute stock 1:4 with autoclaved ddH2O 
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Or use liquid stock (dilute 1:4 with autoclaved ddH2O) 
Williams’ Medium E:  
1 bottle of WE   
Add 2.2 g of NaHCO3 
Make up to 1 L with autoclaved ddH2O in a volumetric flask.  
pH 7.2 (with HCl) 
Add 5 mL Pen/Strep/Fungizone to this bottle (work sterile) 
 
Hank’s Balanced Salts: 
1 bottle of HBSS 
Set pH to 7.2 (with NaOH) 
Add autoclaved ddH2O up to 100 mL in a volumetric flask 
 
Hank’s wash: 
Total volume  250 mL  500 mL 
25 mL HBSS  50 mL HBSS 
2.5 mL HEPES 5 mL HEPES 
222.5 mL ddH2O 445 mL ddH2O 
Hank’s perfusion: 
Total volume  250 mL 500 mL 
 25 mL HBSS 50 mL HBSS 
 2.5 mL HEPES 5 mL HEPES 
 2.5 mL EGTA 5 mL EGTA 
 220 mL ddH2O 440 ddH2O 
 
WE for perfusion: 
Total volume ±250 mL 
  250 mL WE 
  2.5 mL HEPES 
 
WE + 10% FBS: 
Total volume  250 mL   500 mL 
   25 mL FBS   50 mL FBS 
   2.5 mL HEPES  5 mL HEPES 
   *2.5 mL Gluthamine *5 mL Gluthamine 
   **0.25 mL Insulin  **0.5 mL Insulin 
   217.25 mL WE  434.5 mL WE 
 
 
WEX with 0.5% FBS: 
Total volume: 250 mL    500 mL 
   2.5 mL HEPES   5 mL HEPES 
   1.25 mL FBS    2.5 mL FBS 
   *2.5 mL Gluthamine   *5 mL Gluthamine 
   2.5 mL Pyruvate   5 mL Pyruvate 
   2.5 mL Proline   5 mL Proline  
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   **0.25 mL Insulin   **0.5 mL Insulin 
   237.25 mL WE   474.5 mL WE 
 
Filter reagents in the following order:  “Hanks’ Wash”, “Hanks’ Perfusion”, 
“WE for perfusion”, “WEX” and “WE + 10% FBS”. Use a 1 L Corning filter 
system.   
 
 
PRIMARY RAT HEPATOCYTE PERFUSION TECHNIQUE 
 
• Autoclave a glass petri dish or take a sterile plastic petri dish to Room 330, 
this is used to transport the perfused live to the Culture Room 
• Coat the petri dishes 
• Make sure there are sterile cheese cloth filters (single layer and double layer). 
Make sure there a plastic bags and hand towels available for the perfusion  
• Make sure there are a spray bottle with 70% ETOH available  
 
Perfusion pump and tubing: 
 
• ALWAYS leave the tubing in 70% ETOH 
• Make sure there are autoclaved ddH2O water to rinse the tubing 
• Once you have changed the setting of the tubing on the pump you need to 
calibrate the pump flow to 15mL/min 
• Check pump flow before you do a perfusion use a measuring cylinder  
 
 
Filter reagents in the following order:  “Hanks’ Wash”, “Hanks’ Perfusion”, 
“WE for perfusion”, “WEX” and “WE + 10% FBS”.  Use a 1 L Corning filter 
system.   
 
• 125 mg Collagenase (weigh out separately in glass bijous or blue 15 mL 
falcon tube):  Keep on ice:  
• 118 mg CaCL2⋅2H2O (weigh out separately in glass bijous or blue 15 mL falcon 
tube):  Keep on ice:  
• Rinse perfusion pump well with 70% ETOH  
• Rinse perfusion pump with ddH2O  
• Switch on all the water baths (37°C)  
• Sterilise all working areas  
• Place All the reagents in a water bath (at 37°C)  
• Wash the petri dishes x 1 with Hank’s wash 
• Sterilise all the instruments  
• After perfusion pump is thoroughly cleaned: Start pumping Hank’s perfusion 
solution. 
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Use rats between 150 and 300 g 
Anaesthetise rats:  (0.22 pentobarbital /100g body weight). 
 
1. Check temperature of all water baths continuously during the perfusion 
2. Reduce pump speed (0.15) 
3. Spray rat with 70% ETOH 
4. Cut 2X catgut lengths (± 10 cm)  
5. Remove skin from a big area 
6. Make sure hair will not come into contact with the insides of the rat 
7. Rinse all instruments to remove hair 
8. Cut open muscle up to the diaphragm – carefully, do not puncture diaphragm 
9. Move intestines with gauss swaps, wipe to the right – be gentle 
10. Expose portal and aorta veins  
11. Do not touch liver with hands use the swaps 
12. Carefully pull catgut around each vein and bind loosely  
13. Insert perfusion needle into portal vein 
14. Tie catgut around the needlepoint – rather tightly 
15. Increase pump flow to a set mark to ensure a flow of 15 mL/min  
16. Tie off aorta catgut string 
17. Open the thorax and puncture the heart 
18. Liver should loose color immediately  
19. Discoloration (blood removal) should be visible over all the liver lobes 
20. Place muscle top layer over the perfused liver 
21. Perfuse for 10 min 
22. After 5 min add the Collegenase and CaCL2 to the WE for perfusion  
23. Mix well until all the Collagnenase has dissolved 
24. Stop the pump and put pump tube into the WE for perfusion  
25. Start the pump and wait until a darker pink are observed in tubes before 
starting the timer 
26. Digest for ± 13 min at speed between 5.00 and 4.00 
27.  Remove top muscle layer and expose liver 
28. Carefully and lightly stroke liver without using your hands 
29. If a bubble is observed try to perfuse as long as possible don’t wait until it 
bursts 
30. Check liver closely, stop perfusion if liver cell separation under the capsule is 
visible 
31. After digestion stop pump and remove needle 
32.  Hold liver over a big petri dish and cut loose 
33. Pour some WE for perfusion onto the liver 
34. Proceed to the sterile laminar cabinet immediately 
35. Add WE + FBS 10% immediately to inactivate the enzyme 
 
 Wash pump with autoclaved ddH2O followed by 70 % ETOH, leave it in the 70 
% ETOH 
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Cell harvesting and growth: 
 
1. Remove liver capsule with tweezers 
2. Gently free the cells from the capsule 
3. Filter through a sterile single layer cheesecloth into a 50 mL blue cap Falcon 
tube. 
4. Rinse with WE + 10% FBS. 
5. Centrifuge for 10 min at 450 rpm. 
6. Remove top supernatant. 
7. Fill tube with WE + 10% FBS: 20 mL for a 5 mL pellet. 
8. Gently “dissolve” cells in this solution. 
9. ALTERNITIVE METHOD: use a shaking water bath set at 37°C to dissolve 
cells (± 20 min) in the blue–top falcon tube.  Wrap the cap in parafilm to 
ensure no water leaks in. 
10. Filter through the double cheesecloth layer into another 50 mL tube – Do not 
rinse! 
11. This solution is used for the viability determinations. 
 
 
Viability determinations: 
 
0.5 mL cell (gently mix cells suspended in the WE + 10% FBS solution to 
homogenate) 
4.5 mL WE 
1 mL Trypan blue 
(Ensuring you have a 12X dilution) 
 
Wait 5 min. 
 
Place in heamocytometer.     
Count cells in each of the 4 squares and calculate the mean. 
Count live cells: colorless with a distinct outline.  
⇒Single cells or strings indicate the perfusion was a success. 
⇒Clumps of cells indicate a bad perfusion. 
Count the dead cells: cells will be blue in color with a blue nucleus. 
 
% Viability:  dead cells/ Total cell count (living +dead cells) x 100 
  = (100 – answer) 
  = % viable 
Value above 90% is very good and preferable 
Plate according to the no living/viable cells 
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Determining the dilution needed for plating the cells: 
 
Example: 
 
Use 60 mm petri-dishes 
Need 40 dishes 
6 mL “WE + 10% FBS” needed per 60 mm petri-dish 
Plate 6 x 105 cells/ 6 mL “WE + 10% FBS” (one petri-dish) 
After counting viable cells work out the cells in suspension (cells/mL) =  
Mean (of 4 squares) = 35 
   35 cells / mm2 
• cells/mL  = 350 / mm3  (depth of heamocytometer = 0.1 mm) 
= 35 x 104 x 12 
   = 420 x 104 
   = 4.2 x 106 
For 40 dishes: 
     240 x 105 cell needed 
    =  24 x 106 cells 
∴4.2 cells/mL  = 24 x 106 cells/X 
X  = 24 x 106/4.2 x 106  
X  = 5.7 mL 
Aliquot 5.7 mL of cell suspension and add to 240 mL “WE + 10% FBS” (40 x 6mL 
media) 
 
Coating of Petri dishes: 
 
Collagen should be room temperature. 
Place in water bath at 37°C! 
Dilute the collagen 1:4 = 1 part collagen and 4 parts autoclaved ddH2O 
2 mL diluted collagen solution can be used to coat 20 small (35 mm) petri dishes. 
Place 1 mL (2 mL) diluted solution in small (60 mm) dishes and leave for 1 min   
Remove and place in next dish.    
Place in Incubator overnight 
Wash x 1 next morning with Hank’s wash: 1 mL for small and 2 mL for big. 
 
96 well microtitre plates: 
 
Use same diluted collagen solution. 
Only use 100 µL for each well.   Also transport from one (or one row with the aid 
of a multi-pipette) to the next.  Wait 30-60 sec. 
 
Plating of cells: 
 
Place the petri dishes in a incubator for a minimum of 2 hours. 
Remove the WE + 10% FBS by washing the plates 2x with Hank’s wash. 
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(FBS may mask any toxic effect of other reagents added – not good when 
investigating cytotoxicity of compounds) 
Add 2mL or 3mL WEX receptively to the 35 mm and 60 mm plates.   
 
While plating and washing, continuously monitor the cell adhesion to the 
collagen. No use in doing the experiment if you lost all the cells while removing 
media or washing. 
 
 
 
Rat liver perfusion stock reagents 
Reagent Stock 
Storage 
Working Stock Storage Specifications Company 
WE 2-8 °C Fridge 
Culture room 
N/A - L-Glutamine; 
- H(CO3)2 
Sigma: W4125 
10 x 1 L 
WE plus GlutaMAX 2-8 °C Fridge 
Culture room 
N/A + L-Glutamine; 
+H(CO3)2 
Invitrogen/Gibco 
32551 – 020 for 500 
mL 
32551-087 10x500 
mL 
HBSS 2-8 °C Fridge 
Culture room 
N/A - Ca, Mg, Phenol 
red, Na(CO3)2 
500 mL 
Sigma: H2387 
10 x 1L 
HEPES 2-8 °C Fridge 
Culture room 
2-8 °C Fridge 
Culture room 
1M 
100 mL 
Invitrogen/Gibco 
15630 
FBS -20 °C  
Culture room 
N/A Heat inactivation 
required 
Aliquot in 50 mL 
INV/GIBCO 
10106 
Collagen Powder: 
-20 °C  
Liquid: 
Fridge 
Culture room 
After Diluted: 
2-8 °C Fridge 
Culture room 
Type 1 from rat tail Powder: 
Sigma: C7661 
 
Liquid: 
Sigma: C3867-1VL 
Collagenase -20°C 
Culture room 
N/A Type IV Sigma: 
C5138 
Pen/Strep/Fungizone 
(Amphotericin B) 
-20 °C  
Culture room 
N/A Aliquot in 5 mL BioWhittaker/Lonza 
17-745E 
Insulin -20 °C  
Culture room 
2-8 °C Fridge 
Culture room 
From Bovine 
Pancreas 
100mg 
Sigma: I1882 
Sodium-pyruvic acid Powder: 
Room temp 
Lab 312 
Liquid: 
-20 °C 
Culture room  
2-8 °C Fridge 
Culture room 
Powder: 1 M  
Liquid: 100 mM 
(100 mL) 
 
Powder: 
Sigma: P5280 
 
Liquid: 
BioWhittaker/Lonza:  
13-115E 
L-Glutamine Powder: 
Room 312 
Liquid: 
-20 °C, 
Culture room 
2-8 °C Fridge 
Culture room 
200 mM 
100 mL 
Powder: 
Sigma: G8540  
Liquid: 
BioWhittaker/Lonza 
17-605E 
L-Proline Room 312 2-8 °C Fridge 
Culture room 
 Powder 
Sigma: P5607 
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MEM Non-essential 
Amino Acid Solution  
Culture Room -20°C Freezer 
Culture Room 
Used instead of L-
proline 
BioWhittaker/Lonza 
13-114E 
EGTA Room 312 2-8 °C Fridge 
Culture room 
 Sigma: E3889 
NaHCO3 Room 312 N/A  Sigma: S5761 
CaCl22H2O Room 312 N/A  ICN: 193818 
Corning filter system  Culture Room N/A 1 L 
0.22 µm PES 
Sigma: 
CLS431098 
Perfusion needle 
Canula with injection 
valve PTVE  
Room 312 Room 229 G: 18 
Ø: 1.3 mm 
L 45 mm 
Flow: 90 mL/min 
 
Rob Dyer:  
Neotec Medical 
Industries 
Ref: NM-218 
Surgical Catgut 
Chromic  
Room 229  Sterile 
3.5 m 
150 cm each 
Rob Dyer: 
SCIMITAR Surgical 
Sutures 
Ref CG 290 Ligature/ 
CG20-150 
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